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Abstract 
 
 
The prevention and pathogenesis of retinal detachment 
 
Retinal detachment contributes to nearly 500 new blind registrations in the United 
Kingdom each year. In contrast to other retinal blinding disorders, blindness from 
retinal detachment is potentially avoidable with a better understanding of the 
mechanisms defining sub-groups at risk of the event. 
 
The majority of retinal detachments are rhegmatogenous, resulting from retinal tears 
that occur during the process of posterior vitreous detachment. Posterior vitreous 
detachment is generally considered to be a common, age-related synchitic and 
syneretic degeneration of the vitreous gel. However, this current understanding fails 
to explain the significant number of elderly individuals who never undergo posterior 
vitreous detachment, or the number of young patients with co-existing intraocular 
pathology who do.  
 
Furthermore, the factors distinguishing the majority of patients who undergo 
‘physiological’ posterior vitreous detachment (with no associated retinal tears or 
detachment) from the minority of patients who suffer ‘pathological’ posterior vitreous 
detachment (associated with retinal tears and/or detachment), remain poorly 
understood.  
 
The objectives of this research project were two-fold: 
 
Firstly, to investigate the hypothesis that appropriate prophylactic intervention could 
reduce blindness from retinal detachment if a high-risk sub-group of individuals were 
defined. This clinical study retrospectively evaluated a group of molecularly 
confirmed type 1 Stickler syndrome patients, a homogenous cohort who have been 
identified to carry the greatest risk of inherited retinal detachment at the time of their 
posterior vitreous detachment. Multiple analyses comparing patients and eyes that 
received prophylactic intervention with appropriate controls, consistently 
demonstrated that the Cambridge Prophylactic Cryotherapy protocol is safe and 
markedly reduces the risk of retinal detachment in type 1 Stickler syndrome. 
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Secondly, to investigate the anatomical and cellular mechanisms of posterior 
vitreous detachment in the wider population. This laboratory study sought to isolate 
and immunohistochemically phenotype posterior hyaloid membranes and 
associated laminocytes from donor human globes that had undergone 
‘physiological’ posterior vitreous detachment. The isolated posterior hyaloid 
membranes were demonsatrated to be distinct basement membranes composed of 
type IV collagen and laminin, and morphologically correlated with posterior hyaloid 
membranes observed clinically in patietns presenting with posterior vitrous 
detachment. Furthermore, the laminocyte cell population adherent to the vitreal 
aspect of the posterior hyaloid membrane, was identified to express macrophage 
cell markers.  
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1 Introduction 
 
 
1.1 Retinal detachment 
 
The retina is a multi-layered, light-sensitive neural tissue lining the inner aspect of 
the posterior segment of the eye; rhegmatogenous retinal detachment refers to the 
disorder in which a break in the retina, commonly caused by the process of posterior 
vitreous detachment, permits fluid from the vitreous cavity to gain access to the 
potential subretinal space between the neural retina and the retinal pigment 
epithelium, and peels the retina off its underlying support tissue. 
 
In contrast to other ophthalmic disorders, such as cataract, until the turn of the 20th 
century retinal detachment was considered an untreatable blinding disorder. 
However, Joules Gonin, a Professor of Ophthalmology from the University of 
Lausanne, Switzerland, had the insight that retinal breaks were the cause and not 
the consequence of retinal detachment, challenging the Zeitgeist of the time 
(Wolfensberger, 2003); from 1902 to 1921, Gonin championed the doctrine that 
successful surgical management of retinal detachment had to comprise of the 
closure of causative retinal breaks at all costs (Gonin, 1904, 1931, 1934). 
 
For the first time it became possible to manage retinal detachments surgically. 
Gonin reported retinal reattachment rates of up to 40% using an ignipuncture 
technique (a thermocautery induced chorioretinal scar used to seal retinal breaks) 
(Gonin, 1923; Thilges and Gonin, 1970). Conceptual advances in the field of 
vitreoretinal surgery over the following century, such as intraocular air injection 
introduced by Bengt Rosengren (Rosengren, 1938), scleral buckling popularised by 
Ernst Custodis (Custodis, 1952, 1953, 1956) and closed vitrectomy techniques 
pioneered by Robert Machemer (Machemer et al., 1971), in addition to innumerable 
modifications of these surgical techniques, equipment and tamponades, have 
improved the rates of retinal reattachment surgery to approximately 90% (Chignell et 
al., 1973; Rachal and Burton, 1979; Tani et al., 1981; Sharma et al., 1994; Lincoff 
and Kreissig, 2000; Pastor et al., 2008). 
 
However, permanent functional damage to visual acuity is a recognised 
consequence in many patients suffering retinal detachment, despite the greatly 
improved postoperative anatomical success rates (Burton, 1982; Diederen et al., 
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2007; Hassan et al., 2002; Lewis et al., 2004; Machemer, 1968; Mervin et al., 1999; 
Mitry et al., 2013; Ozgür and Esgin, 2007; van de Put et al., 2014; Ross and Kozy, 
1998).  
 
Although unprecedented progress in vitreoretinal surgery has improved anatomical 
outcomes, in order to improve functional outcomes we need to develop a deeper 
understanding of the process of posterior vitreous detachment, the preceding event 
for the vast majority of rhegmatogenous retinal detachments. This could ultimately 
provide an insight into preventing this sight threatening event. 
 
In order to fully understand the aetiology of retinal detachment we should consider 
the prophetic words Gonin wrote for the fourth volume of the French Encyclopaedia 
of Ophthalmology in 1906:   
 
"…to effectively fight a pathological process, we must know its nature and 
anatomic conditions. Only the study of pathogenesis of spontaneous 
detachment, based on facts and not on hypotheses, will make it possible to 
find the treatment of this disease". (Gonin, 1906) 
 
 
1.2 Objectives 
 
The objectives of this research project were two-fold: 
 
Firstly, to undertake a retrospective clinical study in a group of type 1 Stickler 
syndrome patients, to investigate if an appropriately designed prophylactic 
intervention could reduce visual loss from retinal detachment in these individuals. 
Type 1 Stickler syndrome patients constitute a homogeneous cohort who have been 
identified to carry the greatest risk of inherited retinal detachment associated with 
posterior vitreous detachment.   
 
Secondly, to investigate the anatomical and cellular mechanisms of posterior 
vitreous detachment in a wider population. This laboratory study sought to isolate 
and immunohistochemically phenotype posterior hyaloid membranes and 
associated laminocytes from donor human globes that had undergone 
‘physiological’ posterior vitreous detachment.  
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2 Prevention: Retinal detachment prophylaxis in type 1 Stickler syndrome 
 
 
2.1 Background 
 
2.1.1 Non-syndromic retinal detachment prophylaxis 
 
The hypothesis that prophylactic retinopexy could prevent retinal detachment is an 
attractive concept for vitreoretinal practitioners and patients at risk of retinal 
detachment. To date however, no prospective randomised trial has been conducted 
into the prevention of retinal detachment (Ang et al., 2012; Wilkinson, 2012). 
 
Best current clinical practice guidelines regarding retinal detachment prophylaxis are 
founded on amalgamated historical cohort and case-control series (American 
Academy of Ophthalmology Retina Panel, 2008). These non-randomised studies 
are often incomplete and difficult to compare, with  assumptions often based on 
comparisons between heterogeneous patient groups with variable follow-up (Folk et 
al., 1989). Furthermore, known risk factors for retinal detachment, such as refractive 
error, type of retinal break, vitreous status, fellow eye retinal status, previous ocular 
surgery, lens status, family history of retinal detachment, extent of lattice 
degeneration and presenting symptoms are often lacking (Chauhan et al., 2006). 
Currently, no prospective or retrospective trial scrutinising prophylactic intervention 
has stratified study patients for the presence or absence of posterior vitreous 
detachment, despite good prospective evidence demonstrating posterior vitreous 
detachment increases the risk of retinal detachment tenfold in certain groups 
(Hovland, 1978). 
 
Symptomatic retinal breaks refer to the classic horseshoe retinal tears, typically 
found on fundal examination after patients present with new onset floaters and 
temporal photopsia at the time of posterior vitreous detachment; symptomatic retinal 
breaks are recognised as a significant precursor to retinal detachment. Prompt 
retinopexy, to create a chorioretinal adhesion around these breaks, reduces the risk 
of retinal detachment to less than 5% (Pollak and Oliver, 1981; Robertson and 
Norton, 1973; Smiddy et al., 1991), whereas at least half of untreated breaks will 
progress to retinal detachment (spontaneous reattachment is exceedingly 
uncommon)  (Colyear and Pishel, 1960; Davis, 1974; Shea et al., 1974). Treating 
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symptomatic breaks before a significant retinal detachment has occurred usually 
prevents progression, preserves vision, and is generally associated with few or no 
complications. It is accepted that there is sufficient published evidence and clinical 
experience to support an evidence-based recommendation to treat symptomatic 
retinal breaks (American Academy of Ophthalmology Retina Panel, 2008). 
 
However, asymptomatic retinal breaks, classified as operculated holes and atrophic 
round holes, very rarely progress to retinal detachment (Byer, 1998; Davis, 1974). 
Similarly, atrophic round holes associated with lattice degeneration only occasionally 
progress to retinal detachment; lattice-associated retinal detachment usually occurs 
when a horseshoe tear develops at the time of posterior vitreous detachment (Byer, 
1989). In addition, prophylactic treatment is recognised to prevent retinal tear 
formation within treated areas, but does not preclude, nor predict, tears occurring 
elsewhere in the retina (Chauhan et al., 2006). Evidence informing current clinical 
practice does not support treating asymptomatic retinal breaks or lattice 
degeneration (American Academy of Ophthalmology Retina Panel, 2008; Wilkinson, 
2012).  
 
Although the cited evidence which supports current clinical recommendations are 
not randomised controlled trials, they are the best and only available evidence and 
are considered to be sufficiently rigorous (American Academy of Ophthalmology 
Retina Panel, 2008). 
 
Review of the literature reiterates the clinical sentiment that no prophylactic 
intervention is suitable for all patients. Appropriate retinal detachment prophylaxis is 
difficult to achieve because of the heterogenous nature of non-syndromic 
rhegmatogenous retinal detachment group populations, in addition to the 
observation that aetiological breaks may occur in almost any fundal location 
(prohibiting precise preventative retinopexy application). In order to design a 
successful retinal detachment prophylaxis strategy, one would require a defined 
homogenous sub-group of individuals at high-risk of retinal detachment, who were 
predisposed to retinal breaks at a predictable fundal location. 
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2.1.2 Retinal detachment prophylaxis in Stickler syndrome 
 
The original Stickler family 
 
In June 1965, Gunnar Stickler, a paediatrician working at the Mayo Clinic in 
Rochester, Minnesota, USA, published the first description of hereditary progressive 
arthro-ophthalmopathy (Stickler et al., 1965). Eleven affected family members were 
traced through a five-generation family pedigree, after an initial examination of a 
visually impaired 12-year-old male proband with marked joint bony prominences, 
who attended the clinic with his blind mother in 1960.  
 
Reported ocular features of the family pedigree included congenital high myopia and 
total rhegmatogenous retinal detachment arising from “very large retinal 
disinsertions”. Retinal detachments tended to be bilateral and occurred in the first 
decade of life. Reported systemic features included premature degenerative 
arthropathy characterised by joint hypermobility and pain; there was destruction of 
articular cartilage surfaces, with wide joint spaces and broadening of metatarsal and 
metacarpal heads. The syndrome exhibited an autosomal dominant inheritance 
pattern. 
 
Two years later, a follow-up paper reported associated degenerative arthropathy of 
the thoracolumbar spine and sensorineural hearing loss in the proband and his 
mother (Stickler and Pugh, 1967). Although not mentioned in the original reports, 
published photographs demonstrated a patient with a facial profile that suggested a 
flattened malar region and a short nose with a depressed nasal bridge and 
anteverted nares (Snead, 1996) (Figure 2-1). 
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Figure 2-1 The original Stickler syndrome proband  
Photograph demonstrating the bony joint prominences and kyphoscoliosis in the 
original Stickler proband. Note classic facial features of Stickler syndrome not 
described in original reports.  
Reproduced with permission from Elsevier publishers (Stickler and Pugh, 1967). 
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Genetic classification of the Stickler syndromes 
 
Originally considered a single gene disorder, at least eight sub-groups of Stickler 
syndrome are now recognised according to genetic abnormalities of type II, IX and 
XI collagen (Figure 2-1),  suggesting the condition may be more precisely referred to 
as the Stickler syndromes (Snead et al., 2011). As the collagen structural proteins 
are principally and collectively expressed in the eye and in articular and hyaline 
cartilage, affected patients unsurprisingly present with premature arthropathy and 
classic orofacial, auditory and ocular features (Poulson et al., 2004; Snead and 
Yates, 1999; Stickler and Pugh, 1967; Stickler et al., 1965). 
 
The Stickler syndromes are one of the most frequently inherited connective tissue 
disorders (Herrmann et al., 1975), and are recognised as the most common cause 
of inherited and childhood retinal detachment (Carroll et al., 2011; Snead and Yates, 
1999). Although there are no available prevalence studies for the Stickler 
syndromes, an approximate incidence of 1:7500 live births has been estimated 
based on the known incidence of the disorder among neonates born with Pierre 
Robin sequence (Printzlau and Andersen, 2004). This equates to approximately 
eight and a half thousand affected individuals in the United Kingdom and nearly one 
million affected individuals worldwide. 
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Table 2-1 Molecular classification of Stickler syndrome 
 
Type 
 
Gene 
(Locus) 
 
 
Inheritance  
 
Ocular features 
 
Systemic features 
 
MIM No. 
 
Ref. 
 
Type 1 
 
COL2A1 
(12q13.11) 
 
Autosomal 
dominant 
 
• Congenital membranous type 
w1 vitreous anomaly  
• Congenital megalophthalmos 
• Congenital myopia 
• Retinal detachment 
• Paravascular lattice 
wdegeneration 
• Cataracts 
 
 
• Arthropathy 
• Hearing loss 
• Midline clefting 
• Facial dysmorphia 
 
 
#108300 
 
1-3 
Ocular 
only 
COL2A1 
(12q13.11) 
Autosomal 
dominant 
• Congenital membranous type 
w1 vitreous anomaly (majority) 
• Congenital megalophthalmos 
• Congenital myopia 
• Retinal detachment 
• Paravascular lattice 
wdegeneration 
• Cataracts 
 
• No systemic features 
 
#609508 4-8 
Type 2 COL11A1 
(1p21.1) 
Autosomal 
dominant 
• Congenital beaded type 2 
wvitreous anomaly  
• Congenital megalophthalmos 
• Congenital myopia 
• Retinal detachment 
• Paravascular lattice 
wdegeneration 
• Cataracts 
 
• Arthropathy 
• Midline clefting 
• Hearing loss 
• Facial dysmorphia 
 
#604841 9-13 
Type 2 COL11A1 
(1p21.1) 
Autosomal 
recessive 
• Congenital hypoplastic/ 
wbeaded type 2 vitreous 
wanomaly  
• Congenital megalophthalmos 
• Congenital myopia (majority) 
 
• Congenital profound 
asensorineural 
  deafness 
• Midline clefting 
Awaiting 14 
Type 3 COL11A2 
(6p21.32) 
Autosomal 
dominant 
• Normal vitreous phenotype 
• Normal ocular phenotype 
• Arthropathy 
• Midline clefting 
• Hearing loss 
• Facial dysmorphia 
 
#184840 15-18 
Type 4 COL9A1 
(6q13) 
Autosomal 
recessive 
• Syneretic empty vitreous  
• Myopia 
• Vitreoretinal degeneration 
 
• Epiphyseal dysplasia 
• Sensorineural 
whearing loss 
 
#614134 19 
Type 5 COL9A2 
(1p34.2) 
Autosomal 
recessive 
• Anomalous vitreous 
• Myopia 
• Vitreoretinal degeneration 
• Retinal detachment  
• Sensorineural 
whearing loss 
• Short stature 
• Facial dysmorphia 
 
#614284 20 
Other Unknown Autosomal 
dominant 
• Hypoplastic vitreous 
• Retinal detachment 
• Arthropathy 
• Midline clefting 
• Hearing loss 
 
 21-22 
 
1-3 (Ahmad et al., 1991; Snead and Yates, 1999; Williams et al., 1996) 
 
4-8 (Go et al., 2003; Körkkö et al., 1993; McAlinden et al., 2008; Richards et al., 2005, 2006) 
 
9-13 (Annunen et al., 1999; Majava et al., 2007; Martin et al., 1999; Poulson et al., 2004; Richards et al., 1996) 
 
14 (Richards et al., 2013) 
 
15-18 (Brunner et al., 1994; Sirko-Osadsa et al., 1998; Vikkula et al., 1995; Vuoristo et al., 2004) 
 
19 (Van Camp et al., 2006) 
 
20 (Baker et al., 2011) 
21-22 (Martin et al., 1999; Wilkin et al., 1998) 
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Clinical features of type 1 Stickler syndrome 
 
Over 80% of affected individuals have type 1 Stickler syndrome (OMIM#108300), a 
type II collagenopathy typically characterised by an autosomal dominant mutation in 
the COL2A1 gene (Ahmad et al., 1991); the majority are premature termination 
codon or frameshift mutations and result in haploinsufficiency of type II procollagen. 
 
On slit lamp biomicroscopic examination type 1 Stickler syndrome patients have a 
pathognomic vitreous phenotype with the appearance of a vestigial retrolenticular 
congenital membranous anomaly (Figure 2-2) (Snead et al., 1994a, 1996). 
 
Additional ocular features include megalophthalmos and high myopia that is typically 
congenital and non-progressive, congenital quadrantic lamellar cataract and early 
onset nuclear sclerosis (Scott, 1989; Seery et al., 1990), radial paravascular 
pigmented lattice degeneration (Parma et al., 2002; Vu et al., 2003) and a high risk 
of retinal detachment, the majority of which are bilateral, most frequently arising 
from giant retinal tears at the pars plana (Snead and Yates, 1999) (Figure 2-3). 
Developmental anterior chamber drainage angle abnormalities may predispose 
patients to glaucoma (Nielsen, 1981), but are relatively uncommon in patients who 
have not undergone previous intraocular surgery. 
 
The systemic features of type 1 Stickler syndrome include a characteristic orofacial 
phenotype (Temple, 1989), midline palatal clefting (Hoornaert et al., 2010; Snead 
and Yates, 1999) and spondyloepiphyseal dysplasia (Liberfarb and Hirose, 1982; 
Rai et al., 1994; Rose et al., 2001) (Figure 2-4, Figure 2-5 and Figure 2-6 
respectively). In addition, conductive and/or sensorineural hearing loss is a 
recognised systemic feature (Cho et al., 1991; Snead and Yates, 1999; Temple, 
1989); conductive hearing loss being associated with eustation tube dysfunction 
related to midline clefting and sensorineural hearing loss related to the observation 
of that type II collagen is expressed within the cochlea (Slepecky et al., 1992; 
Thalmann, 1993).  
 
Communication difficulties due to speech and language impairment resulting from 
palatal abnormalities, hearing impairment and blindness resulting from retinal 
detachment, coupled with mobility difficulties from premature arthropathy, can result 
in severe reduction in the quality of life in patients with Stickler syndrome. 
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Figure 2-2 The type 1 membranous anomaly  
Anterior segment colour photographs illustrating the pathognomonic retrolenticular 
congenital type 1 anomaly that appears clinically as a folded membrane over the 
posterior aspect of a vestigial secondary vitreous on slit-lamp biomicroscopy. 
Photographs courtesy of Mr Martin Snead. 
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Figure 2-3 The ocular features of Stickler syndrome  
Colour photographs demonstrating (a) congenital, non-progressive high myopia, (b) 
megalophalmos, (c) quadrantic lamellar and (d) nuclear sclerotic cataracts, (e) radial 
paravascular lattice degeneration, (f) oral giant retinal tear. 
Photographs courtesy of Mr Martin Snead. 
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Figure 2-4 The Stickler syndrome facial phenotype 
Please turn over for figure legend 
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Figure 2-4 The Stickler syndrome facial phenotype 
Colour photographs demonstrating the facial features associated with Stickler 
syndrome, these include micrognathia long philtrum, anteverte nares, depressed 
nasal bridge, low set ears, flattened malar regions and megalophthalmos. Note 
clinical observations suggest the facial phenotype in Stickler syndrome becomes 
less pronounced with age. A possible explaination of this observation may be that 
the majority of type II collagen mutations result in haploinsufficiency; this relative 
shortage in structural collagen may be most apparent during the rapid facial 
development that occurs during embryological development, resulting in a more 
pronounced facial phenotype in youth that gradually reduce as patients age. 
Photographs courtesy of Mr Martin Snead. 
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Figure 2-5 The spectrum of midline clefting in Stickler syndrome 
Colour photographs demonstrating (a) high-arched palate, (b) bifid uvula, (c) 
submucosal cleft of the soft and hard palate, (d) palatal cleft. 
Photographs courtesy of Mr Martin Snead. 
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Figure 2-6 Radiological features of Stickler syndrome arthropathy 
Please turn over for figure legend 
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Figure 2-6 Radiological features of Stickler syndrome arthropathy 
X-ray radiographs demonstrating (a) axial skeleton vertebral body flattening 
(platyspondyly), (b) L1 anterior vertebral body beaking in a three year old girl, (c) 
right widened and flattened femoral head deformity (initially incorrectly diagnosed as 
Perthes disease in this case) and left sclerotic hip joint with narrowed joint space, (d) 
right knee premature osteoarthropathy with lateral subchondral cystic degeneration 
and osteophyte formation, (e) left knee medial joint space narrowing. 
Radiographs courtesy of Mr Martin Snead. 
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Current prophylactic practice in Stickler syndrome 
 
Existing service provision, with regards to retinal detachment prophylaxis in Stickler 
syndrome populations, consists of either no treatment (with or without monitoring), 
laser retinopexy prophylaxis or retinal cryotherapy prophylaxis (Carroll et al., 2011); 
retinal laser and cryotherapy prophylaxis has been reported to be applied focally or 
circumferentially to the retina (at various positions anterior to the retinal equator), or 
specifically to areas of paravascular lattice (Haut et al., 1987; Leiba et al., 1996; 
Monin et al., 1994). There is widespread uncertainty regarding best practice and no 
agreed guidelines in the United Kingdom or elsewhere. The absence of robust and 
accepted evidence has divided opinion in vitreoretinal communities, and this 
disparity has created confusion and anxiety amongst patients, who often receive 
conflicting advice. 
 
In the United Kingdom, the lack of consensus prompted the Secretary of State for 
Health to commission the National Institute for Health Research to generate a 
Health Technology Assessment report into the clinical effectiveness and safety of 
prophylactic retinal interventions in reducing the risk of retinal detachment and 
subsequent visual loss in adults and children with Stickler syndrome. Under the 
terms of a commissioning contract, the School of Health and Related Research at 
the University of Sheffield published the findings of a systematic review in April 2011 
(Carroll et al., 2011). Of the 1444 unique citations identified by the literature search, 
two retrospective cohort studies with control groups satisfied the inclusion criteria as 
principal studies.  
 
The review established that both studies found a statistically significant reduction in 
the risk of retinal detachment after prophylaxis, however, the reported data did not 
permit a reliable estimate of the effect of cryotherapy or laser therapy compared to 
no prophylaxis. Due to the potential risk of bias in both studies, it was concluded that 
the efficacy of retinal prophylaxis remained uncertain in type 1 Stickler syndrome, 
and no recommendation regarding intervention could be supported. 
 
In the first principal study by Ang and colleagues (Ang et al., 2008), the efficacy of 
360° prophylactic cryotherapy to the post-oral retina was evaluated in a cohort of 
204 patients with type 1 Stickler syndrome. The rate of retinal detachment in 111 
control patients (who had received no prophylaxis) was compared to the rate of 
prophylaxis failure (defined as the development of retinal detachment or retinal tears 
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requiring further retinopexy) in 62 patients who underwent bilateral prophylactic 
cryotherapy and 31 patients who underwent unilateral prophylactic cryotherapy 
(after suffering a previous retinal detachment in their fellow eye). The results 
indicated a statistically significant benefit to 360° prophylactic cryotherapy, with the 
rate of unilateral retinal detachment in the control group being 73% (81/111) 
compared to 8% (5/62) in the bilateral and 10% (3/31) in the unilateral prophylactic 
cryotherapy groups. The rate of bilateral retinal detachment in the control group was 
48% (53/111) compared to no cases of bilateral prophylactic failure in the bilateral 
prophylactic cryotherapy group. 
 
However, the principal source of bias affecting the validity of these findings was 
deemed to be a discrepancy in the ages of the compared groups; the mean age of 
the control group was 49 years compared to a mean age of 21 years in the bilateral 
and 36 years in the unilateral prophylactic cryotherapy groups. As the risk of retinal 
detachment is known to be life-long in Stickler syndrome, the older controls were 
considered more likely to have experienced the primary outcome of retinal 
detachment. This lack of comparability between the groups introduced bias 
weighted in favour of prophylactic intervention (Aylward et al., 2008; Carroll et al., 
2011).  
 
In the second principal study by Leiba and colleagues (Leiba et al., 1996), the 
efficacy of focal and 360° prophylactic laser retinopexy was evaluated in a single 
family pedigree consisting of 22 members with type 1 Stickler syndrome. The 
incidence of retinal detachment was 44% (15/34) in the untreated eyes compared to 
10% (1/10) in those eyes that underwent laser retinal prophylaxis (four eyes 
received 360° circumferential laser retinopexy at the borders of extensive lattice 
degeneration, and six eyes received focal laser retinopexy).  
 
Although the results were reported as statistically significant, the study suffered from 
the same major potential confounding factor of discrepancy between control and 
treatment groups; mean age differences were not reported and the series was 
considered to be too small to generate a reliable estimate of efficacy (Carroll et al., 
2011). 
 
As evidence-based medicine becomes increasingly important to ensure 
contemporary practice delivers and maintains quality and consistency in the context 
of funding constraints, prophylactic therapies require robust scrutiny before being 
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accepted into clinical practice. However, the corollary to this approach has the 
potential to produce a contradictory situation, where the best available evidence 
may indicate a seemingly obvious benefit, but however likely, is ignored in favour of 
waiting for concrete evidence.  
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2.2  Hypothesis 
 
 
In order to evaluate the efficacy and safety of retinal prophylaxis in preventing retinal 
detachment, it is essential to identify a homogenous cohort of patients who are 
predisposed to a defined retinal detachment aetiology (recognising who is at risk 
and what it is they are at risk of). In addition, accurate assessment of intervention 
requires eliminating variables that may confound the results. 
 
Patients with type 1 Stickler syndrome are at an increased risk of retinal 
detachment, typically arising after a pathological anterior extension of a posterior 
vitreous detachment with subsequent circumferential oral giant retinal tear 
formation.  
 
Knowing this predisposition to anterior oral giant retinal tears, it is conceivable that 
applying primary 360° prophylactic cryotherapy to the junction of the post-oral retina 
with the pars plana in patients with type 1 Stickler syndrome would result in a 
chorioretinal adhesion between the anterior neurosensory retina and the retinal 
pigment epithelium before the development of a retinal break at that position, and 
thereby reduce the likelihood of retinal tears forming and progressing to retinal 
detachment. 
 
Furthermore, a second outcome measure assessing the long-term side effect profile 
of primary 360° prophylactic cryotherapy would be essential to determine if the 
benefit of prophylactic intervention outweighed any associated adverse side effects. 
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2.3 Material and methods 
 
 
2.3.1 Ethical approval 
 
Following local Research Governance Coordinator and Cambridge Research and 
Ethics Committee review, it was decided the project would be registered as a 
Service Evaluation under the Cambridge University Hospitals NHS Foundation 
Trust’s Audit Department. 
 
 
2.3.2 Patients and study design  
 
To assess the efficacy and safety of primary 360° prophylactic cryotherapy in 
preventing retinal detachment in Stickler syndrome, a retrospective observational 
analysis was conducted. Type 1 Stickler syndrome patients (OMIM#108300) were 
selected as they are the most common subgroup of the disorder and have the 
highest risk of retinal detachment, typically arising from oral giant retinal tears 
(Snead and Yates, 1999). Study patients were identified from the Vitreoretinal 
Research Unit electronic database at Addenbrooke’s Hospital (nationally 
commissioned Multidisciplinary Stickler Diagnostic Service). Retrospective data from 
clinical records and research pedigree files were collected and anonymised before 
analysis.  
 
The clinical diagnosis of type 1 Stickler syndrome was made according to published 
criteria (Snead and Yates, 1999); this required the presence of the congenital 
vitreous membranous anomaly, pathognomonic of type 1 Stickler syndrome, in 
addition to any three of the following clinical features: 
 
1. Myopia, with onset before six years of age. 
2. Rhegmatogenous retinal detachment and/or paravascular pigmented 
lattice degeneration. 
3. Joint hypermobility with an abnormal Beighton score, with or without 
radiological evidence of joint degeneration. 
4. Audiometric confirmation of a sensorineural hearing defect. 
5. Midline clefting (including high-arched palate, bifid uvula, submucosal 
cleft or cleft palate). 
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Mutational analysis was performed in the majority of cases and in every case where 
vitreous phenotyping was not possible due to previous bilateral vitrectomy surgery.  
 
 
2.3.3 Exclusion criteria 
 
All eyes that received any form of non-standard prophylaxis were excluded; this 
included any previous focal laser or cryotherapy to identified retinal breaks or areas 
of lattice degeneration, previous 360° prophylactic laser retinopexy, previous 
prophylactic scleral buckling, and previous 360° prophylactic cryotherapy applied 
equatorially or posteriorly to the oral retina (undertaken in other eye units). In 
addition, all eyes without the required study details available in the clinical notes and 
research pedigree files were excluded from analysis.  
 
 
2.3.4 Primary outcome measures 
 
1. Time to retinal detachment (this included any post prophylactic cryotherapy 
case requiring further retinopexy, even those without formal retinal 
detachment repair in the treatment group). 
 
2. Side effects resulting from prophylactic treatment. 
 
 
2.3.5 The Cambridge Prophylactic Cryotherapy Protocol 
 
The Cambridge Prophylactic Cryotherapy Protocol is performed under general 
anaesthesia following informed patient consent. The consent process reiterates that 
the rationale of the procedure is to reduce the risk of retinal detachment arising from 
giant retinal tears, but is not intended or expected to prevent rhegmatogenous 
retinal detachments occurring from more posteriorly located horseshoe tears.  
 
The protocol begins with bilateral indirect indentation ophthalmoscopic examination 
under anaesthetic. Previously unidentified retinal breaks or detachments are treated 
accordingly, either by inclusion into the planned 360° cryotherapy treatment or by 
formal retinal detachment repair, depending on their location and extent.  
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Under direct visualisation, carefully monitored 360° transconjunctival prophylactic 
cryotherapy is applied in a contiguous ribbon at the junction of the post-oral retina 
with the pars plana; the cryotherapy applications are deployed so they touch 
shoulder to shoulder, ensuring no gaps are left in the prophylactic treatment, whilst 
at the same time avoiding any areas of retreatment. The final application connects 
the penultimate cryotherapy application with the first to ensure a continuous barrier 
at the far anterior limit of the retina (Figure 2-7 Video Appendix 1.1). 
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Figure 2-7 Fundal photograph illustrating the positioning of cryotherapy 
application in the Cambridge Prophylactic Cryotherapy protocol.  
Noncontact, high resolution ultrawide-field colour fundal photograph annotated to 
demonstrate the standardised anterior positioning of retinal cryopexy applied during 
the Cambridge Prophylactic Cryotherapy protocol. Individual cryotherapy 
applications (white dotted circles) touch shoulder to shoulder and include the ora 
serrata (dotted red line). Note classic paravascular lattice degeneration inferior to 
optic disc.  
Original photograph courtesy of Mr C.K. Patel and the Oxford Eye Hospital Imaging 
Department.  
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2.3.6 Statistical analysis 
 
No single statistical method could unequivocally address the complex, 
heterogeneous dataset, which included patients of different ages, who had 
prophylactic interventions at different times, with the possibility of multiple events 
(retinal detachment in both eyes), and then compare the differences in primary 
outcome to an appropriate control.  
 
To ensure a robust systematic approach, a network of several analytical methods 
was devised to be performed on multiple data-subsets, with the hypothesis that 
should prophylactic intervention be efficacious, there would be consistency of the 
results between various methods. 
 
The devised analytical methodology was validated by independent external 
methodologists and statisticians. These individuals included: Dr Christopher Carroll, 
School of Health and Related Research, University of Sheffield (primary investigator 
of the commissioned Health Technology Assessment report (Carroll et al., 2011)); 
Professor Alan Hackshaw, Department of Epidemiology and Medical Statistics, 
Cancer Research UK and UCL Cancer Trial Centre; Professor Richard Samworth, 
Department of Pure Mathematics and Mathematical Statistics, University of 
Cambridge; Professor Douglas Easton, Department of Oncology, Public Health and 
Primary Care, University of Cambridge and Dr Christopher, Centre for Applied 
Medical Statistics, University of Cambridge. 
 
All statistical analysis was completed by an independent external statistician (Laura 
Pasea, Centre for Applied Medical Statistics, University of Cambridge). All statistical 
tests were two-sided and used a 5% significance level; analyses were completed 
using SPSS software version 21.0 (IBM Corp., Armonk, NY). 
 
Collected data were analysed separately as patient and single eye datasets. 
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2.3.7 Patient dataset analysis 
 
Patient dataset analysis included only those participants who had both eyes 
available for study. Patients were divided into the following groups for comparison: 
 
1. Bilateral prophylaxis group. Patients who had suffered no previous retinal 
detachment and had undergone the Cambridge Prophylactic Cryotherapy 
protocol in both eyes. 
 
2. Bilateral control group. Patients who had not undergone the prophylactic 
protocol (patients may have suffered unilateral, bilateral or no previous 
retinal detachment).  
 
3. Unilateral prophylaxis group. Patients who had undergone the Cambridge 
Prophylactic Cryotherapy protocol to one eye following retinal detachment in 
their fellow eye. 
 
4. Unilateral control group. Patients who had not undergone the prophylactic 
protocol and suffered previous unilateral or bilateral retinal detachment (a 
subgroup of the bilateral control group). 
 
Outcomes between groups receiving the Cambridge Prophylactic Cryotherapy 
protocol and their respective controls were compared. A risk ratio was estimated 
from patients having a retinal detachment event in at least one eye for the bilateral 
prophylaxis and bilateral control groups, and for a second eye retinal detachment 
event for the unilateral prophylaxis and unilateral control groups. Survival analysis 
was then made to compare the time to event outcomes amongst the groups. For the 
bilateral prophylaxis and control group, this was time from birth until first retinal 
detachment or the end of follow-up; for the unilateral prophylaxis and control groups, 
this was time from first to second eye retinal detachment or the end of follow-up. 
Survival analysis was completed using Kaplan Meier plots, log rank tests and a Cox 
regression model to estimate hazard ratios and 95% confidence intervals. Covariate 
analysis using Cox proportional hazards models was performed to adjust for gender.  
 
To specifically address previous concerns regarding differences in age and follow-
up duration between controls and patients receiving prophylaxis, and to ensure 
control patients did not sustain a retinal detachment event prior to the prophylaxis 
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group receiving cryotherapy, a novel individual patient matching protocol was 
developed to compare the bilateral prophylaxis and bilateral control groups, and the 
unilateral prophylaxis and unilateral control groups. To facilitate equal age at last 
review between matched pairs, a control group follow-up ‘cropping’ step was 
implemented; any retinal detachment that occurred during this ‘cropped’ period was 
discarded, as it did not occur during the matched follow-up time. After matching and 
control group ‘cropping’, comparison groups were exactly equal in number, age and 
follow-up duration, and patients who received prophylaxis did so prior to any retinal 
detachment event in their individually matched control. 
 
Outcomes between individually matched groups receiving prophylaxis and their 
respective matched controls were then compared. The matched data were analysed 
using paired tables, and the Mantel-Haenszel method for stratified data (that takes 
matching into account) was used to estimate the risk ratio. McNemar’s test was 
used to test the association between prophylaxis groups and retinal detachment 
events. Survival analysis was completed using Kaplan Meier plots and log rank tests 
to investigate and compare time to event outcomes between the matched groups. 
Since the pairs were matched to ensure that neither the prophylaxis case nor the 
control in a pair had had a retinal detachment event before the prophylaxis case 
subject had cryotherapy, a Cox proportional hazards model was used to estimate an 
adjusted hazard ratio at a 95% confidence interval. The time of origin for the 
matched bilateral prophylaxis and control group was the time from prophylaxis (or 
the corresponding time point in the matched control) to first retinal detachment or 
the end of follow-up, and for the matched unilateral prophylaxis and control groups 
was the time from prophylaxis (or the corresponding time point in the matched 
control) to second eye retinal detachment or the end of follow-up. The proportional 
hazards assumption of the Cox models was verified using residual and log-log plots. 
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2.3.8 Patient dataset matching protocols  
 
 
See video appendix 1.2 for matching protocol explanation. 
 
Bilateral prophylaxis group versus bilateral control group 
 
1. All bilateral prophylaxis group patients with both eyes available for analysis were 
included for matching.  
2. Observers were blinded to prophylactic cryotherapy failure status.  
3. All bilateral prophylaxis group patients were arranged in descending order of 
length of follow-up after prophylactic cryotherapy. Those patients with less than 
one year of post-prophylactic cryotherapy follow-up were excluded from further 
analysis.  
4. The individual bilateral prophylaxis group patient with the longest follow-up after 
prophylactic cryotherapy was selected for matching. The age at which this 
patient underwent prophylactic cryotherapy and their age at last review were 
noted for subsequent control matching. 
5. All bilateral control group patients with both eyes available for analysis were 
included for matching. 
6. From the bilateral control group, all patients who had their first retinal 
detachment at an age equal to or less than the age at which the selected 
bilateral prophylaxis group patient had their prophylactic cryotherapy were 
excluded from the current round of matching (but returned to the bilateral control 
group for subsequent rounds of matching).  
7. Observers were blinded to the retinal detachment status in the selected 
subgroup of bilateral control group patients available for the current round of 
matching. 
8. From this subgroup, the patient with an equal or next closest (but older) age at 
last review was selected to be matched to the selected bilateral prophylaxis 
group patient (if no control group patient had an equal or older age at last 
review, the selected prophylaxis group patient was considered unmatched and 
excluded from further matching analysis; analysis would then restart from step 
4). 
9. Once matched, these patients were removed from their respective bilateral 
prophylaxis and bilateral control groups and made unavailable for further 
matching. 
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10. Steps 4 through 9 were repeated, using the bilateral prophylaxis group patient 
with the next longest follow-up after prophylactic cryotherapy as the next 
selected case for matching. 
11. Matching continued until all bilateral prophylaxis group patients had been 
matched to an appropriate bilateral control or were excluded from matching.  
12. The matched bilateral prophylaxis and bilateral control group patients were 
unmasked with regards to prophylactic cryotherapy failure and retinal 
detachment status respectively. 
13. Individual patient ages at last review in the matched bilateral control group 
(purposely selected to be equal or older) were compared with the individual 
patient ages at last review in the corresponding matched bilateral prophylaxis 
group and ‘cropped’ accordingly to equal the age at last review of their match. 
Any retinal detachment events that occurred in the matched bilateral control 
group patients during this ‘cropped’ period were excluded from further analysis. 
14. Prevalence of retinal detachment was then compared between the matched 
bilateral prophylaxis and ‘cropped’ matched bilateral control groups. 
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Unilateral prophylaxis group versus unilateral control group 
 
1. All unilateral prophylaxis group patients with both eyes available for analysis 
were included for matching.  
2. Observers were blinded to prophylactic cryotherapy failure status.  
3. All unilateral prophylaxis group patients were arranged in descending order of 
length of follow-up after prophylactic cryotherapy. Those patients with less than 
one year of post-prophylactic cryotherapy follow-up were excluded from further 
analysis.   
4. The unilateral prophylaxis group patient with the longest follow-up after 
prophylactic cryotherapy was selected for matching. The age at which this 
patient suffered their first retinal detachment (untreated eye), the age at which 
they underwent prophylactic cryotherapy (treated eye), and their age at last 
review were noted for subsequent control matching. 
5. All unilateral control group patients with both eyes available for analysis were 
included for matching. 
6. Observers were blinded to the retinal detachment status in the second eye. 
7. The unilateral control group patient with an age of first retinal detachment 
closest to that of the selected unilateral prophylaxis group patient’s age of first 
retinal detachment was selected for further matching (if there was a difference of 
more than three years, the selected unilateral prophylaxis group patient was 
considered unmatched and excluded from further matching analysis; analysis 
would then restart from step 4). 
8. If the selected unilateral control group patient’s age at last review was equal or 
older than the selected unilateral prophylaxis group patient’s age at last review, 
they were considered for the final matching step (if the age at final review was 
less than the selected unilateral control group patient’s age at last review, the 
matching process returned to step 7, selecting the unilateral control group 
patient with the next closest age of first retinal detachment).  
9. The final matching step involved unmasking the retinal detachment status of the 
selected unilateral control group patient’s second eye. If the selected unilateral 
control group patient did not have a second retinal detachment event or the age 
at which they had their second retinal detachment was older than the age at 
which the selected unilateral prophylaxis group patient had their prophylactic 
cryotherapy, they were considered an appropriate match. If the age of the 
selected unilateral control group patient at the time of their second retinal 
detachment was the same or younger than the age at which the selected 
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unilateral prophylaxis group patient had their cryotherapy, the match was 
considered inappropriate; the matching process then returned to step 7 
(selecting the unilateral control group patient with the next closest age of first 
retinal detachment). 
10. Once matched, these patients were removed from their respective unilateral 
prophylaxis and unilateral control groups and made unavailable for further 
matching. 
11. Steps 4 through 10 were repeated using the unilateral prophylaxis group patient 
with the next longest follow-up after prophylactic cryotherapy as the next 
selected case for matching.  
12. Matching continued until all unilateral prophylaxis group patients had been 
matched to an appropriate control or were excluded from matching. 
13. The matched unilateral prophylaxis group patients were unmasked with regards 
to prophylactic cryotherapy failure. 
14. Individual patient ages at last review in the matched unilateral control group 
(purposely selected to be equal or older) were compared to the individual patient 
ages at last review in the corresponding matched unilateral prophylaxis group 
and ‘cropped’ accordingly to equal the age at last review of their match. Any 
retinal detachment events that occurred in the matched unilateral control group 
patients during this ‘cropped’ period were excluded from further analysis. 
15. Prevalence of retinal detachment was then compared between the matched 
unilateral prophylaxis and ‘cropped’ matched unilateral control groups. 
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2.3.9 Single eye dataset analysis 
 
Single eye dataset analysis included all available study eyes; these datasets 
included eyes from patients that only had one eye that met study inclusion criteria 
(thereby being excluded from patient matching datasets). Single eyes were divided 
into the following groups for comparison: 
 
1. Prophylaxis eye group. All eyes that underwent the Cambridge 
Prophylactic Cryotherapy protocol were included. This group was comprised 
of both eyes of all patients in the bilateral prophylaxis group, the eye that 
received prophylaxis in all patients in the unilateral prophylaxis group, and all 
eyes that received prophylaxis in those patients who had only one eye 
available to study (fellow eye did not meet study inclusion criteria). 
 
2. Control eye group. All eyes that did not undergo the Cambridge 
Prophylactic Cryotherapy protocol were included. This group was comprised 
of both eyes of all patients in the bilateral control group, the eye that did not 
receive prophylaxis in all patients in the unilateral prophylaxis group, and all 
eyes that did not receive prophylaxis in those patients who had only one eye 
available to study (fellow eye did not meet study inclusion criteria). 
 
3. Excluded prophylaxis eye group. All eyes that received prophylaxis in the 
unilateral prophylaxis group and all eyes that received prophylaxis in those 
patients who had only one eye available to study were excluded. This group 
was only comprised of both eyes of all patients in the bilateral prophylaxis 
group. 
 
4. Excluded control eye group. All eyes that did not receive prophylaxis in the 
unilateral prophylaxis group and all eyes that did not receive prophylaxis in 
those patients who had only one eye available to study were excluded. This 
group was only comprised of both eyes of all patients in the bilateral control 
group. 
 
Retinal detachment outcomes were compared between the prophylaxis eye group 
and the control eye group. In order to account for potential sampling bias weighting 
in favour of the effectiveness of prophylaxis, the excluded prophylaxis eye group 
and excluded control eye group comparison omitted all eyes that did not come from 
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patients in the bilateral prophylaxis and bilateral control groups; this included all 
eyes from patients with only single eyes available to study and every untreated eye 
with retinal detachment from the unilateral prophylaxis group (by definition this group 
required 100% first eye retinal detachment rates); this group was selected as it 
excluded patients deemed to be at highest risk of retinal detachment, and therefore 
reduced the prevalence of retinal detachment in the control group, effectively 
weighting selection bias against the effectiveness of treatment. 
 
To eliminate the possibility that eyes belonging to the same patient were correlated, 
random single eye datasets were generated, in which one eye was randomly 
selected from each patient for further analysis (random prophylaxis eye group 
versus random control eye group and random excluded prophylaxis eye group 
versus random excluded control eye group). Random eye selection was made using 
a computerised random sampler and analysis was repeated three times in each 
comparison group to ensure no sampling bias was introduced through the 
randomised selection process; the outcomes deliberately report the smallest 
difference between groups to weigh against the effectiveness of prophylaxis and 
thereby providing the most rigorous test of any benefit in receiving prophylactic 
cryotherapy. 
 
A risk ratio was estimated for having a retinal detachment event between the 
compared single eye groups receiving prophylaxis and their appropriate controls. 
Survival analysis was then made to compare time from birth to retinal detachment 
between the groups and their controls. Survival analysis was completed using 
Kaplan Meier plots, log rank tests and a Cox regression model to estimate hazard 
ratios and 95% confidence intervals. Covariate analysis using Cox proportional 
hazards models was performed to adjust for gender. 
 
 
2.3.10 Side effects 
 
The occurrence of the following prophylaxis side effects was assessed: lid and 
conjunctival inflammation, accommodation insufficiency, discomfort, photophobia, 
macular pucker and any reported perioperative surgical complication; anaesthetic 
recovery records were reviewed for episodes of nausea or vomiting.   
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Converted LogMar preoperative visual acuity (measured during admission on the 
day of surgery) was compared to converted LogMar postoperative visual acuity 
(measured at the four week postoperative outpatient review). Visual acuity 
documented at subsequent clinic reviews was noted in all cases with visual 
reduction until preoperative visual acuity levels were attained, or until the last clinic 
review. 
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Results 
 
 
2.3.11 Demographic details 
 
From the Vitreoretinal Research Unit electronic database, 976 patients with type 1 
Stickler syndrome were identified; 551 patients from 256 family pedigrees met 
inclusion criteria, with 487 patients having both eyes and 64 patients with a single 
eye available to study. 
 
COL2A1 mutations were formally tested in 87.7% of the participants (n=483); the 
mutation detection rate, using the Cambridge two-stage diagnostic screening 
strategy (Richards et al., 2006), was 96.9% at the time of study completion. The 
majority of patients who did not have molecular confirmation of a COL2A1 mutation, 
tended to be historical cases that no longer attended clinic review; the remainder 
were cases in which molecular testing was incomplete at the time of the study 
conclusion. 
 
 
2.3.12 Patient dataset results 
 
The prevalence of prophylaxis failure in patients who received bilateral or unilateral 
(following fellow eye retinal detachment) cryotherapy was compared to the 
prevalence of retinal detachment in appropriate control groups with both eyes 
available to study, before and after individual patient matching. 
 
Patient demographic details are given in Table 2-2. 
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Table 2-2 Demographic details for patient datasets (both eyes available) 
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Bilateral prophylaxis 
- no retinal detachment 
- unilateral retinal detachment 
- bilateral retinal detachment 
 
229 
210 
18 
1 
 
104:125 
92:118 
11:7 
1:0 
 
20.8 (16.9) 
19.6 (16.6) 
34.6 (19.6) 
10.9  
 
- 
- 
29.3 (19.4) 
4.2  
 
- 
- 
- 
4.2  
 
14.5 (15.9) 
13.7 (15.3) 
24.1 (20.4) 
4.0 
 
6.3 (6.4) 
5.9 (6.0) 
10.6 (9.0) 
6.8 
 
Bilateral control 
- no retinal detachment 
- unilateral retinal detachment 
- bilateral retinal detachment 
 
194 
90 
20 
84 
 
95:99 
38:52 
9:11 
48:36 
 
31.3 (21.6) 
18.6 (18.6) 
37.0 (24.6) 
43.4 (15.7) 
 
- 
- 
24.8 (20.4) 
15.2 (10.4) 
 
- 
- 
- 
22.0 (13.8) 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
 
Matched bilateral prophylaxis 
- no retinal detachment 
- unilateral retinal detachment 
- bilateral retinal detachment 
 
165 
150 
14 
1 
 
78:87 
68:82 
9:5 
1:0 
 
19.8 (15.0) 
18.8 (14.3) 
31.9 (17.5) 
10.9 
 
- 
- 
25.5 (16.8) 
4.2  
 
- 
- 
- 
4.2 
 
11.6 (12.9) 
10.9 (12.3) 
19.1 (17.0) 
4.0  
 
7.7 (6.2) 
7.8 (6.0) 
12.8 (9.0) 
6.8  
 
Matched bilateral control 
- no retinal detachment 
- unilateral retinal detachment 
- bilateral retinal detachment 
 
165 
104 
34 
27 
 
83:82 
48:56 
17:10 
18:16 
 
19.8 (15.0) 
19.5 (15.8) 
18.4 (13.2) 
22.0 (14.1) 
 
- 
- 
15.2 (13.1) 
14.8 (12.1) 
 
- 
- 
- 
16.9 (12.0) 
 
- 
- 
- 
- 
 
- 
- 
- 
- 
 
Unilateral prophylaxis 
- unilateral retinal detachment 
- bilateral retinal detachment 
 
64 
56 
8 
 
37:27 
31:25 
6:2 
 
33.2 (18.0) 
32.2 (18.3) 
40.1 (14.2) 
 
16.9 (13.5) 
17.4 (13.9) 
13.1 (10.2) 
 
- 
- 
27.8 (15.8)  
 
22.9 (15.7) 
23.3 (15.6) 
40.1 (14.2) 
 
10.1 (10.4) 
9.0 (9.7) 
19.2 (11.8) 
 
Unilateral control 
- unilateral retinal detachment 
- bilateral retinal detachment 
 
104 
20 
84 
 
57:47 
9:11 
48:36 
 
42.2 (17.8) 
37.0 (24.6) 
43.4 (15.7) 
 
17.0 (13.4) 
24.8 (20.4) 
15.2 (10.4) 
 
- 
- 
22.0 (13.8) 
 
- 
- 
- 
 
- 
- 
- 
 
Matched unilateral prophylaxis 
- unilateral retinal detachment 
- bilateral retinal detachment 
 
39 
33 
6 
 
23:16 
19:14 
4:2 
 
31.4 (16.3) 
30.7 (17.0) 
35.5 (12.4) 
 
14.2 (11.8) 
14.9 (12.6) 
10.6 (5.7) 
 
- 
- 
21.0 (9.6) 
 
17.8 (13.3) 
19.0 (14.0) 
11.1 (5.9) 
 
13.7 (11.1) 
11.7 (10.2) 
24.6 (9.8) 
 
Matched unilateral control 
- unilateral retinal detachment 
- bilateral retinal detachment 
 
39 
12 
27 
 
27:12 
9:3 
18:9 
 
31.4 (16.3) 
28.8 (16.7) 
32.6 (16.3) 
 
14.4 (11.6) 
13.8 (13.2) 
14.7 (11.1) 
 
- 
- 
23.4 (14.1) 
 
- 
- 
- 
 
- 
- 
- 
 
*SD denotes standard deviation        
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Bilateral prophylaxis group versus bilateral control group 
 
Four hundred and twenty three patients were available for the bilateral prophylaxis 
and bilateral control group comparison; 229 patients received prophylactic 
cryotherapy in both eyes and 194 control patients received no prophylactic 
intervention in either eye.  
 
The prevalence of retinal detachment in the bilateral prophylaxis group was 8.3% 
(19/229), of which 7.9% (18/229) were unilateral and 0.4% (1/229) bilateral. The 
prevalence of retinal detachment in the bilateral control group was 53.6% (104/194), 
of which 10.3% (20/194) were unilateral and 43.3% (84/194) bilateral (Figure 2-8). 
Of the 20 retinal detachment events occurring after prophylaxis, 12 required formal 
surgical repair and eight were managed with additional retinopexy alone; all 188 
control group retinal detachments required formal surgical repair.  
 
Although the mean age at final review was younger for the bilateral prophylaxis 
group (20.8 years) compared to the bilateral control group (31.3 years), the mean 
age at first retinal detachment occurred later in the bilateral prophylaxis group (28.4 
years) compared to the bilateral control group (17.0 years). 
 
The relative risk of retinal detachment in at least one eye was six and a half times 
greater for the bilateral control group compared to the bilateral prophylaxis group 
(relative risk, 6.46; 95% confidence interval: 4.12 to 10.13; p<0.001). 
 
Kaplan-Meier survival plots were generated to compare time from birth until first eye 
retinal detachment or the end of follow up in both groups (Figure 2-9). Time from 
birth was selected, as type 1 Stickler syndrome is an inherited congenital disorder 
and patients are at risk of retinal detachment from birth; the plots do not distinguish 
time points at which each prophylaxis group patient underwent cryotherapy. 
 
The log-rank test statistic (𝜒1
2 = 87.23; p<0.001) rejects the null hypothesis that the 
two groups have identical survival and hazard functions, suggesting the survival 
times between the bilateral prophylaxis and control groups are not the same. 
 
The median survival time to first eye retinal detachment was 18.28 years (95% 
confidence interval, 14.92 to 21.63) in the bilateral control group, but a median 
survival time was not reached in the bilateral prophylaxis group (Figure 2-9). A Cox 
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proportional hazards model estimated a hazard ratio of 7.27 (95% confidence 
interval, 4.47 to 11.87; p<0.001), suggesting the bilateral control group was over 
seven times more likely to suffer from a retinal detachment in at least one eye 
compared to the bilateral prophylaxis group. 
 
Covariate analysis using the Cox proportional hazards model to adjust for gender 
estimated a hazard ratio of 7.40 (95% confidence interval, 4.53 to 12.08; p<0.001), 
suggesting the bilateral control group was almost seven and a half times more likely 
to suffer from a retinal detachment in at least one eye compared to the bilateral 
prophylaxis group after accounting for gender. Males had more than double the risk 
of having at least one retinal detachment compared to females in the same 
treatment group (hazard ratio, 2.13; 95% confidence interval, 1.48 to 3.07; p<0.001). 
  
56  
 
 
Figure 2-8 Prevalence of retinal detachment: bilateral prophylaxis group vs. 
bilateral control group 
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Figure 2-9 Kaplan-Meier survival plot: bilateral prophylaxis group vs. bilateral 
control group 
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 ___
 Bilateral prophylaxis group 
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Matched bilateral prophylaxis group versus matched bilateral control group 
 
Three hundred and thirty patients were available for matched bilateral prophylaxis 
and matched bilateral control group comparison; 165 patients received prophylactic 
cryotherapy to both eyes and 165 control patients received no prophylactic 
intervention to either eye.  
 
The prevalence of retinal detachment in the matched bilateral prophylaxis group was 
9.1% (15/165), of which 8.5% (14/165) were unilateral and 0.6% (1/165) bilateral. 
The prevalence of retinal detachment in the matched bilateral control group was 
37.0% (61/165), of which 16.4% (27/165) were unilateral and 20.6% (34/165) 
bilateral (Figure 2-10). Of the 16 retinal detachment events occurring after 
prophylaxis, 12 required formal surgical repair and four were managed with 
additional retinopexy alone; all 95 control group retinal detachments required formal 
surgical repair. Prior to the ‘cropping’ step in the matching protocol, the prevalence 
of retinal detachment in the matched bilateral control group was 61.8% (102/165); 
89 retinal detachments were ‘cropped’ and omitted from final analysis. 
 
 After matching, the mean age at final review was 19.8 years in both the prophylaxis 
and control groups; the mean age at first retinal detachment occurred later in the 
matched bilateral prophylaxis group (23.5 years) compared to the matched bilateral 
control group (14.9 years). 
 
The relative risk of retinal detachment in at least one eye was four times greater for 
the matched bilateral control group compared to the matched bilateral prophylaxis 
group (relative risk, 4.07; 95% confidence interval: 2.38 to 6.94; p<0.001). 
 
McNemar’s test (𝝌𝟏
𝟐 = 31.12; p<0.001) rejected the null hypothesis that there is no 
association between having prophylaxis and having a retinal detachment. 
 
The matching protocol ensured matched pairs were event-free until the time at 
which the prophylaxis case underwent cryotherapy. Therefore, Kaplan-Meier 
survival plots were generated to compare time from cryotherapy prophylaxis (or the 
corresponding time point in the matched control) until first eye retinal detachment or 
the end of follow up, in both groups (Figure 2-11).  
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The log-rank test statistic (𝝌𝟏
𝟐 = 35.65; p<0.001) rejects the null hypothesis that the 
two groups have identical survival and hazard functions, suggesting the survival 
times between the matched bilateral prophylaxis and matched bilateral control 
groups are not the same. 
 
The median survival time to first eye retinal detachment was 16.41 years (95% 
confidence interval, 5.31 to 27.51) in the matched bilateral control group, but a 
median survival time was not reached in the matched bilateral prophylaxis group 
(Figure 2-11). A Cox proportional hazards model estimated a hazard ratio of 4.77 
(95% confidence interval, 2.71 to 8.40; p<0.001), suggesting the matched bilateral 
control group was almost five times more likely to suffer from a retinal detachment in 
at least one eye compared to the matched bilateral prophylaxis group. 
 
Covariate analysis using the Cox proportional hazards model to adjust for gender 
estimated a hazard ratio of 4.97 (95% confidence interval, 2.82 to 8.78; p<0.001), 
suggesting the matched bilateral control group was five times more likely to suffer 
from a retinal detachment in at least one eye compared to the matched bilateral 
prophylaxis group after accounting for gender. Males had almost double the risk of 
having at least one retinal detachment compared to females in the same treatment 
group (hazard ratio, 1.93; 95% confidence interval, 1.21 to 3.07; p=0.006). 
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Figure 2-10 Prevalence of retinal detachment: matched bilateral prophylaxis 
group vs. matched bilateral control group 
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Figure 2-11 Kaplan-Meier survival plot: matched bilateral prophylaxis group 
vs. matched bilateral control group 
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Unilateral prophylaxis group versus unilateral control group 
  
One hundred and sixty eight patients were available for the unilateral prophylaxis 
and unilateral control group comparison; 64 patients received unilateral prophylaxis 
to the contralateral eye following previous fellow eye retinal detachment, and 104 
unilateral control patients received no prophylactic intervention following previous 
eye retinal detachment.  
 
The prevalence of second eye retinal detachment in the unilateral prophylaxis group 
was 12.5% (8/64) compared to 80.8% (84/104) in the unilateral control group (Figure 
2-12). Of the eight second eye retinal detachment events occurring after 
prophylaxis, six required formal surgical repair and two were managed with 
additional retinopexy alone; all 84 unilateral control group second eye retinal 
detachments required formal surgical repair.  
 
Although the mean age at final review was younger for the unilateral prophylaxis 
group (33.2 years) compared to the unilateral control group (42.2 years), the mean 
age of second eye retinal detachment occurred later in the unilateral prophylaxis 
group (27.8 years) compared to the unilateral control group (22.0 years). The mean 
age at the time of first eye retinal detachment was similar between the groups (16.9 
years in the unilateral prophylaxis group and 17.0 years in the unilateral control 
group). 
 
The relative risk of second eye retinal detachment was six and a half times greater 
for the unilateral control group compared to the unilateral prophylaxis group (relative 
risk, 6.46; 95% confidence interval: 3.36 to 12.44; p<0.001). 
 
Kaplan-Meier survival plots were generated to compare time from first eye retinal 
detachment until second eye retinal detachment or end of follow up, in both groups 
(Figure 2-13). However, these plots do not distinguish time points at which each 
unilateral prophylaxis group patient underwent cryotherapy. 
 
The log-rank test statistic (𝝌𝟏
𝟐 = 60.27, p<0.001) rejects the null hypothesis that the 
two groups have identical survival and hazard functions, suggesting the survival 
times between the unilateral prophylaxis and control groups are not the same. 
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The median survival time to second eye retinal detachment was 4.00 years (95% 
confidence interval, 2.17 to 5.83) in the unilateral control group compared to 51.60 
years (95% confidence interval, 13.29 to 88.83) in the unilateral prophylaxis group. 
A Cox proportional hazards model estimated a hazard ratio of 10.06 (95% 
confidence interval, 4.86 to 20.84; p<0.001), suggesting the unilateral control group 
was ten times more likely to suffer from a second eye retinal detachment event 
compared to the unilateral prophylaxis group. 
 
Covariate analysis using the Cox proportional hazards model to adjust for gender 
estimated a hazard ratio of 10.29 (95% confidence interval, 4.96 to 21.36; p<0.001), 
suggesting the unilateral control group was more than ten times more likely to suffer 
from a second eye retinal detachment compared to the unilateral prophylaxis group 
after accounting for gender. Males had a 17% reduced risk of having a second 
retinal detachment compared to females in the same treatment group (hazard ratio, 
0.83; 95% confidence interval, 0.55 to 1.27; p=0.396); the effect of gender was not 
statistically significant in this analysis (possibly due to a reduced sample number). 
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Figure 2-12 Prevalence of second eye retinal detachment: unilateral 
prophylaxis group vs. unilateral control group 
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Figure 2-13 Kaplan-Meier survival plot: unilateral prophylaxis group vs. 
unilateral control group 
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Matched unilateral prophylaxis group versus matched unilateral control group 
 
Seventy-eight patients were available for matched unilateral prophylaxis and 
matched unilateral control group comparison; 39 patients received unilateral 
prophylactic cryotherapy to their contralateral eye following previous fellow eye 
retinal detachment and 39 control patients received no prophylactic intervention 
following previous fellow eye retinal detachment.  
 
The prevalence of second eye retinal detachment in the matched unilateral 
prophylaxis group was 15.4% (6/39) compared to 69.2% (27/39) in the matched 
unilateral control group (Figure 2-14). Of the six second eye retinal detachment 
events occurring after prophylaxis, five required formal surgical repair and one was 
managed with additional retinopexy alone; all 27 matched control group second eye 
retinal detachments required formal surgical repair. Prior to the ‘cropping’ step in the 
matching protocol, the prevalence of second eye retinal detachment in the matched 
unilateral control group was 87.2% (34/39); seven second eye retinal detachments 
were ‘cropped’ and omitted from final analysis. 
 
After matching, the mean age at final review was 31.4 years in both the prophylaxis 
and control groups; the mean age of second eye retinal detachment was 21.0 years 
in the matched unilateral prophylaxis group compared to 23.4 years in the matched 
unilateral control group. 
 
The relative risk of second eye retinal detachment was four and a half times greater 
for the matched unilateral control group compared to the matched unilateral 
prophylaxis group (relative risk, 4.50; 95% confidence interval: 2.02 to 10.02; 
p<0.001). 
 
McNemar’s test (𝝌𝟏
𝟐 = 16.33; p<0.001) rejected the null hypothesis that there is no 
association between having unilateral prophylaxis and having a second retinal 
detachment. 
 
The matching protocol ensured matched pairs were event-free until the time at 
which the prophylaxis case underwent cryotherapy. Therefore, Kaplan-Meier 
survival plots were generated to compare time from cryotherapy prophylaxis (or the 
corresponding time point in the matched control) until second eye retinal 
detachment or the end of follow up, in both groups (Figure 2-15).  
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The log-rank test statistic (𝝌𝟏
𝟐 = 23.59; p<0.001) rejects the null hypothesis that the 
two groups have identical survival and hazard functions, suggesting the survival 
times between the matched unilateral prophylaxis and matched unilateral control 
groups are not the same. 
 
The median survival time to second eye retinal detachment was 5.93 years (95% 
confidence interval, 0.00 to 13.66) in the matched unilateral control group, but a 
median survival time was not reached in the matched unilateral prophylaxis group 
(Figure 2-15). A Cox proportional hazards model estimated a hazard ratio of 6.85 
(95% confidence interval, 2.80 to 16.75; p<0.001), suggesting the matched 
unilateral control group was almost seven times more likely to suffer a second retinal 
detachment compared to the matched unilateral prophylaxis group. 
 
Covariate analysis using the Cox proportional hazards model to adjust for gender 
estimated a hazard ratio of 8.36 (95% confidence interval, 3.24 to 21.57; p<0.001), 
suggesting the matched unilateral control group was over eight times more likely to 
suffer a second eye retinal detachment compared to the matched unilateral 
prophylaxis group after accounting for gender. Males had a 44% reduced risk of 
having a second retinal detachment compared to females in the same treatment 
group (hazard ratio, 0.56; 95% confidence interval, 0.26 to 1.22; p=0.561); the effect 
of gender was not statistically significant in this analysis and likely due to a reduced 
sample number. 
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Figure 2-14 Prevalence of retinal detachment: matched unilateral prophylaxis 
group vs. matched unilateral control group 
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Figure 2-15 Kaplan-Meier survival plot: matched unilateral prophylaxis group 
vs. matched unilateral control group 
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2.3.13 Single eye dataset results 
 
The prevalence of prophylaxis failure in eyes that received cryotherapy was 
compared to the prevalence of retinal detachment in appropriate control eyes that 
received no prophylaxis for all eyes available to study and in a data subset of 
excluded single eyes; analysis was repeated after randomly selecting one eye from 
each patient. 
 
Demographic details are available in Table 2-3.  
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Table 2-3 Demographic details for single eye datasets 
Group 
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Prophylaxis eye 
- no retinal detachment 
- retinal detachment 
 
 
528 
500 
28 
 
 
249:279 
230:270 
19:9 
 
 
22.5 (17.6) 
21.9 (17.3) 
34.5 (18.5) 
 
 
- 
- 
27.1 (18.5) 
 
 
15.9 (16.4) 
15.6 (16.2) 
21.5 (19.2) 
 
 
6.7 (7.1) 
6.4 (6.7) 
13.1 (10.4) 
 
Control eye 
- no retinal detachment 
- retinal detachment 
 
510 
205 
305 
 
258:252 
85:120 
173:132 
 
32.6 (20.9) 
20.8 (19.9) 
40.5 (17.5) 
 
- 
- 
19.2 (13.9) 
 
- 
- 
- 
 
- 
- 
- 
 
Random prophylaxis eye 
- no retinal detachment 
- retinal detachment 
 
263 
253 
10 
 
121:142 
113:240 
8:2 
 
22.7 (17.5) 
22.5 (17.5) 
26.8 (18.5) 
 
- 
- 
17.9 (16.0) 
 
16.0 (16.5) 
16.1 (16.7) 
13.7 (13.2) 
 
6.7 (7.2) 
6.5 (6.9) 
13.1 (10.9) 
 
Random control eye 
- no retinal detachment 
- retinal detachment 
 
288 
106 
182 
 
150:138 
43:63 
107:75 
 
33.4 (20.8) 
22.4 (21.2) 
39.8 (17.6) 
 
- 
- 
19.4 (13.9) 
 
- 
- 
- 
 
- 
- 
- 
 
Excluded prophylaxis eye  
- no retinal detachment 
- retinal detachment 
 
458 
438 
20 
 
208:250 
195:243 
13:7 
 
20.8 (16.9) 
20.2 (16.5) 
32.3 (19.9) 
 
- 
- 
26.8 (19.9) 
 
14.5 (15.9) 
14.2 (15.6) 
22.1 (20.3) 
 
6.3 (6.4) 
6.1 (6.2) 
10.2 (8.6) 
 
Excluded control eye 
- no retinal detachment 
- retinal detachment 
 
388 
200 
188 
 
190:198 
85:115 
105:83 
 
31.3 (21.6) 
20.5 (20.0) 
42.8 (16.9) 
 
- 
- 
19.2 (13.7) 
 
- 
- 
- 
 
- 
- 
- 
 
Random excluded prophylaxis eye 
- no retinal detachment 
- retinal detachment 
 
229 
222 
7 
 
104:125 
99:123 
5:2 
 
20.8 (16.9) 
20.6 (16.7) 
26.5 (21.5) 
 
- 
- 
19.7 (18.8) 
 
14.5 (15.9) 
14.5 (16.0) 
15.7 (15.2) 
 
6.3 (6.4) 
6.1 (6.2) 
10.8 (10.8) 
 
Random excluded control eye 
- no retinal detachment 
- retinal detachment 
 
194 
101 
93 
 
95:99 
43:58 
52:41 
 
31.3 (21.6) 
21.7 (21.4) 
41.6 (16.6) 
 
- 
- 
18.7 (13.2) 
 
- 
- 
- 
 
- 
- 
- 
 
*SD denotes standard deviation       
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Prophylaxis eye group versus control eye group 
 
One thousand and thirty eight eyes from 551 patients (487 patients with both eyes 
and 64 patients with one eye) were available for analysis; 528 eyes received 
prophylactic cryotherapy and 510 control eyes received no prophylactic intervention. 
 
The prevalence of retinal detachment in the eyes receiving prophylaxis was 5.3% 
(28/528) compared to 59.8% (305/510) in the control eyes (Figure 2-16). Of the 28 
retinal detachment events occurring after prophylaxis, 18 required formal surgical 
repair and ten were managed with additional retinopexy alone; all 305 control eye 
retinal detachments required formal surgical repair.  
 
Although the mean age at final review was younger for the eyes receiving 
prophylaxis (22.5 years) compared to the control eyes (32.6 years), the mean age at 
retinal detachment occurred later in the prophylaxis eyes (27.1 years) compared to 
the control eyes (19.2 years), suggesting a delay in the age of retinal detachment in 
those patients who underwent prophylactic cryotherapy. 
 
The relative risk of retinal detachment was over 11 times greater for the control eyes 
compared to those receiving prophylaxis (relative risk, 11.28; 95% confidence 
interval: 7.81 to 16.28; p<0.001). 
 
Kaplan-Meier survival plots were generated to compare time from birth until retinal 
detachment or the end of follow up in both groups (Figure 2-17). As mentioned 
above, time from birth was selected, as type 1 Stickler syndrome is an inherited 
congenital disorder and patients are at risk of retinal detachment from birth; the plots 
do not distinguish time points at which each prophylaxis group patient underwent 
cryotherapy. 
 
The log-rank test statistic (𝝌𝟏
𝟐 = 275.69; p<0.001) rejects the null hypothesis that the 
two groups have identical survival and hazard functions, suggesting the survival 
times between the prophylaxis and control groups are not the same. 
 
The median survival time to retinal detachment was 20.00 years (95% confidence 
interval, 17.02 to 22.98) in the control eye group, but a median survival time was not 
reached in the prophylaxis eye group (Figure 2-17). A Cox regression model 
estimated a hazard ratio of 12.70 (95% confidence interval, 8.62 to 18.71; p<0.001), 
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suggesting the control eyes were over twelve and a half times more likely to suffer 
from a retinal detachment compared to the eyes receiving prophylaxis. 
 
Multivariate analysis using the Cox proportional hazards model to adjust for gender 
estimated a hazard ratio of 12.70 (95% confidence interval, 8.62 to 18.71; p<0.001) 
suggesting that the control eyes were over twelve and a half times more likely to 
suffer from a retinal detachment compared to the eyes receiving prophylaxis group 
after accounting for gender. Males had an almost double the risk of having a retinal 
detachment compared to females in the same group (hazard ratio, 1.93; 95% 
confidence interval, 1.55 to 2.40; p<0.001). The fact that adjusting for gender does 
not alter the hazard ratio to two decimal places, suggests the effect of prophylactic 
cryotherapy on reducing the risk of retinal detachment is independent of gender.  
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Figure 2-16 Prevalence of retinal detachment: prophylaxis eye group vs. 
control eye group 
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Figure 2-17 Kaplan-Meier survival plot: prophylaxis eye group vs. control eye 
group 
  
---  Control eye group 
 ___
 Prophylaxis eye group 
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Random prophylaxis eye group versus random control eye group 
 
From the 487 patients with both eyes available for analysis, one eye was randomly 
selected and pooled with the 64 eyes from the patients with only one eye available 
to study. Of the resulting 551 single eyes, 263 received prophylactic cryotherapy 
and 288 received no prophylactic intervention. Randomly selected single eye 
analysis was used to exclude any correlation that may exist between eyes from the 
same patient. 
 
The prevalence of retinal detachment in the randomly selected eyes receiving 
prophylaxis was 3.8% (10/263) compared to 63.2% (182/288) in the randomly 
selected control eyes (Figure 2-18). Of the ten retinal detachment events occurring 
after prophylaxis, eight required formal surgical repair and two were managed with 
additional retinopexy alone; all 182 control eye retinal detachments required formal 
surgical repair.  
 
The mean age at final review was 22.7 years for the random prophylaxis eye group 
and 33.4 years for the random control eye group; the mean age at retinal 
detachment was 17.9 years in the eyes receiving prophylaxis and 19.4 years in the 
control eyes. 
 
The relative risk of retinal detachment for the control eyes was over sixteen and a 
half times compared to those receiving prophylaxis (relative risk, 16.62; 95% 
confidence interval: 8.99 to 30.72; p<0.001). 
 
Kaplan-Meier survival plots were generated to compare time from birth until retinal 
detachment or the end of follow up in both groups (Figure 2-19).  
 
The log-rank test statistic (𝝌𝟏
𝟐 = 155.64; p<0.001) rejects the null hypothesis that the 
two groups have identical survival and hazard functions, suggesting the survival 
times between the randomly selected prophylaxis and control eye groups are not the 
same. 
 
The median survival time to retinal detachment was 19.20 years (95% confidence 
interval, 14.58 to 23.81) in the randomly selected control eye group, but a median 
survival time was not reached in the randomly selected prophylaxis eye group 
(Figure 2-19). A Cox regression model estimated a hazard ratio of 18.27 (95% 
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confidence interval, 9.66 to 34.54; p<0.001), suggesting the control eyes were over 
eighteen times more likely to suffer from a retinal detachment compared to the eyes 
receiving prophylaxis. 
 
Covariate analysis using the Cox proportional hazards model to adjust for gender 
estimated a hazard ratio of 17.91 (95% confidence interval, 9.47 to 33.86; p<0.001), 
suggesting the control eyes were nearly eighteen times more likely to suffer from a 
retinal detachment compared to the eyes receiving prophylaxis group after 
accounting for gender. Males had twice the risk of having a retinal detachment 
compared to females in the same group (hazard ratio, 2.02; 95% confidence 
interval, 1.51 to 2.70; p<0.001). 
  
78  
 
 
Figure 2-18 Retinal detachment prevalence: random prophylaxis eye group vs. 
random control eye group 
 
 
 
 
 
  
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Random prophylaxis
eye group
Random control           eye
group
No retinal detachment
Retinal detachment
  n=263   n=288 
79  
 
 
Figure 2-19 Kaplan-Meier survival plot: random prophylaxis eye group vs. 
random control eye group 
---  Random control eye group 
 ___
 Random prophylaxis eye group 
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Excluded prophylaxis eye group versus excluded control eye group 
 
Eight hundred and forty six eyes from 423 patients were available for analysis; 458 
eyes received prophylactic cryotherapy and 388 control eyes received no 
prophylactic intervention. This analysis excluded those sub-groups of patients 
deemed to be at greatest risk of retinal detachment (previous retinal detachment in 
their fellow eye) in order to investigate the potential effectiveness of prophylaxis in 
those patients who had not experienced a previous retinal detachment. 
 
The prevalence of retinal detachment in the eyes receiving prophylaxis was 4.4% 
(20/458) compared to 48.5% (188/388) in the control eyes (Figure 2-20). Of the 20 
retinal detachment events occurring after prophylaxis, 15 required formal surgical 
repair and five were managed with additional retinopexy alone; all 188 control eye 
retinal detachments required formal surgical repair.  
 
Although the mean age at final review was younger for the eyes receiving 
prophylaxis (20.8 years) compared to the control eyes (31.3 years), the mean age at 
retinal detachment occurred later in the excluded prophylaxis eyes (26.8 years) than 
the excluded control eyes (19.2 years). 
 
The relative risk of retinal detachment for the control eyes was over eleven times 
compared to those receiving prophylaxis (relative risk, 11.10; 95% confidence 
interval: 7.14 to 17.24; p<0.001). 
 
Kaplan-Meier survival plots were generated to compare time from birth until retinal 
detachment or the end of follow up in both groups (Figure 2-21).  
 
The log-rank test statistic (𝝌𝟏
𝟐 = 168.91; p<0.001) rejects the null hypothesis that the 
two groups have identical survival and hazard functions, suggesting the survival 
times between the eyes receiving prophylaxis and control eyes are not the same. 
 
The median survival time to retinal detachment was 25.00 years (95% confidence 
interval, 20.67 to 29.33) in the excluded control eye group, but a median survival 
time was not reached in the excluded prophylaxis eye group (Figure 2-21). A Cox 
regression model estimated a hazard ratio of 11.21 (95% confidence interval, 7.07 
to 17.79; p<0.001), suggesting the control eyes were over eleven times more likely 
to suffer from a retinal detachment compared to the eyes receiving prophylaxis. 
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Covariate analysis using the Cox proportional hazards model to adjust for gender 
estimated a hazard ratio of 11.03 (95% confidence interval, 6.95 to 17.49; p<0.001), 
suggesting that control eyes were over eleven times more likely to suffer from a 
retinal detachment compared to the eyes receiving prophylaxis group after 
accounting for gender. Males had an increased risk of having a retinal detachment 
compared to females in the same group (hazard ratio, 1.86; 95% confidence 
interval, 1.41 to 2.45; p<0.001). 
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Figure 2-20 Prevalence of retinal detachment: excluded prophylaxis eye group 
vs. excluded control eye group 
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Figure 2-21 Kaplan-Meier survival plot: excluded prophylaxis eye group vs. 
excluded control eye group  
---  Excluded control eye group 
 ___
 Excluded prophylaxis eye group 
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Random excluded prophylaxis eye group versus random excluded control eye 
group 
 
Of the 423 patients with both eyes available for analysis, one eye was randomly 
selected from each patient; 229 eyes received prophylactic cryotherapy and 194 
received no prophylactic intervention. This analysis excluded those sub-groups of 
patients deemed to be at greatest risk of retinal detachment (previous retinal 
detachment in their fellow eye) in order to investigate the potential effectiveness of 
prophylaxis in those patients who had not experienced a previous retinal 
detachment. Furthermore, randomly selected single eye analysis was used to 
exclude any correlation that may exist between eyes from the same patient. 
 
The prevalence of retinal detachment in the randomly selected eyes receiving 
prophylaxis was 3.1% (7/229) compared to 47.9% (93/194) in the randomly selected 
control eyes (Figure 2-22). Of the seven retinal detachment events occurring after 
prophylaxis, six required formal surgical repair and one was managed with 
additional retinopexy alone; all 182 control eye retinal detachments required formal 
surgical repair.  
 
Although the mean age at final review was older for those eyes receiving 
prophylaxis (20.8 years) compared control eyes (31.3 years), the mean age at 
retinal detachment occurred later in the prophylaxis eyes (19.7 years) compared to 
the control eyes (18.7 years). 
 
The relative risk of retinal detachment was over fifteen and a half times greater for 
the control eyes compared to those receiving prophylaxis (relative risk, 15.68; 95% 
confidence interval: 7.45 to 33.00; p<0.001). 
 
Kaplan-Meier survival plots were generated to compare time from birth until retinal 
detachment or the end of follow up in both groups (Figure 2-23).  
 
The log-rank test statistic (𝝌𝟏
𝟐 = 91.96; p<0.001) rejects the null hypothesis that the 
two groups have identical survival and hazard functions, suggesting the survival 
times between the randomly selected prophylaxis and control eye groups are not the 
same. 
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The median survival time to retinal detachment was 26.11 years (95% confidence 
interval, 20.21 to 32.01) in the randomly selected excluded control eye group, but a 
median survival time was not reached in the randomly selected excluded 
prophylaxis eye group (Figure 2-23). A Cox regression model estimated a hazard 
ratio of 15.82 (95% confidence interval, 7.34 to 34.11; p<0.001), suggesting the 
control eyes were over fifteen and half times more likely to suffer from a retinal 
detachment compared to the eyes receiving prophylaxis. 
 
Covariate analysis using the Cox proportional hazards model to adjust for gender 
estimated a hazard ratio of 15.43 (95% confidence interval, 7.16 to 33.28; p<0.001), 
suggesting the control eyes were over fifteen times more likely to suffer from a 
retinal detachment compared to the eyes receiving prophylaxis after accounting for 
gender. Males had an increased risk of having a retinal detachment compared to 
females in the same group (hazard ratio, 1.75; 95% confidence interval, 1.18 to 
2.60; p<0.001). 
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Figure 2-22 Retinal detachment prevalence: excluded random prophylaxis eye 
group vs. excluded random control eye group 
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Figure 2-23 Kaplan-Meier survival plot: random excluded prophylaxis eye 
group vs. random excluded control eye group 
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2.3.14 Results summary 
 
The results of all conducted analyses are summarised in Table 2-4 and Table 2-5. 
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Table 2-4 Results summary table: the prevalence of retinal detachment in 
prophylaxis vs. control groups  
    
Group Prevalence of retinal 
detachment  
Unilateral retinal 
detachment 
Bilateral retinal 
detachment 
    
 
   
Bilateral prophylaxis 8.3% (19/229) 7.9% (18/229) 0.4% (1/229) 
Bilateral control 53.6% (104/194) 10.3% (20/194) 43.3% (84/194) 
    
Matched bilateral prophylaxis 9.1% (15/165) 8.5% (14/165) 0.6% (1/165) 
Matched bilateral control 37.0% (61/165) 16.4% (27/165) 20.6% (34/165) 
    
Unilateral prophylaxis 100% (64/64) 100% (64/64) 12.5% (8/64) 
Unilateral control 100% (104/104) 100% (104/104) 80.8% (84/104) 
    
Matched unilateral prophylaxis 100% (39/39) 100% (39/39) 15.4% (6/39) 
Matched unilateral control 100% (39/39) 100% (39/39) 69.2% (27/39) 
    
Prophylaxis eye 5.3% (28/528) - - 
Control eye 59.8% (305/510) - - 
    
Random prophylaxis eye 3.8% (10/263) - - 
Random control eye 63.2% (182/288) - - 
    
Excluded prophylaxis eye 4.4% (20/458) - - 
Excluded control eye 48.5% (188/388) - - 
    
Random excluded prophylaxis eye 3.1% (7/229) - - 
Random excluded control eye 47.9% (93/194) - - 
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Table 2-5 Results summary table: risk ratios and hazard ratios for prophylaxis 
vs. control groups 
      
Group Analysis Total number  
(prophylaxis: 
control) 
Risk ratio  
(95% CI*) 
Hazard 
ratio  
(95% CI*) 
Gender adjusted 
hazard ratio  
(95% CI*) 
      
      
 
Bilateral prophylaxis vs.  
Bilateral control  
Unmatched 
patients 
423  
(229:194) 
6.46  
(4.12, 10.13) 
7.27  
(4.47, 11.87) 
7.40  
(4.53, 12.08) 
Matched 
patients 
330  
(165:165) 
4.07  
(2.38, 6.94) 
4.77  
(2.71, 8.40) 
4.97  
(2.82, 8.78) 
      
      
 
Unilateral prophylaxis vs.  
Unilateral control  
Unmatched 
patients 
168  
(64:104) 
6.46  
(3.36, 12.44) 
10.06  
(4.86, 20.84) 
10.29  
(4.96, 21.36) 
Matched 
patients 
78  
(39:39) 
4.50  
(2.02, 10.02) 
6.85  
(2.80, 16.75) 
8.36  
(3.24, 21.57) 
      
      
 
Prophylaxis eye vs.  
Control eye  
All available 
eyes 
1038 
(528:510) 
11.28  
(7.81, 16.28) 
12.70  
(8.62, 18.71) 
12.70  
(8.62, 18.71) 
Randomly 
selected eyes 
551  
(263:288) 
16.62  
(8.99, 30.72) 
18.27  
(9.66, 34.54) 
17.91  
(9.47, 33.86) 
      
      
 
Excluded prophylaxis eye 
vs. Excluded control eye 
All excluded 
eyes 
846  
(458:388) 
11.10  
(7.14, 17.24) 
11.21  
(7.07, 17.79) 
11.03  
(6.95, 17.49) 
Randomly 
selected eyes  
423  
(229:194) 
15.68  
(7.45, 33.00) 
15.82  
(7.34, 34.11) 
15.43  
(7.16, 33.28) 
      
 
*CI denotes confidence interval 
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2.3.15 Prophylactic cryotherapy failure 
 
Failure of retinal cryotherapy prophylaxis occurred in 9.0% (27/299) of patients 
(5.3% (28/528) of eyes receiving treatment). The mean age at the time of 
cryotherapy in the failed cases was 21.5 years (range, 2.4 to 59.6; standard 
deviation, 19.2) and the mean time from treatment to prophylaxis failure was 5.6 
years (range, 0.1 to 22.4; standard deviation, 7.2).  
 
Eighteen eyes (from 17 patients) required formal surgical retinal detachment repair. 
Six of these cases were due to retinal breaks identified posterior to the cryotherapy 
treatment barrier, five cases were attributed to treated breaks being lifted off or 
extending through the cryotherapy treatment barrier and one case was for a break 
that developed at the junction of the posterior edge of the cryotherapy treatment 
barrier and untreated retina. No aetiological break was reported in six cases 
requiring surgical retinal detachment repair, two of which presented with associated 
proliferative vitreoretinopathy due to delayed presentation following retinal 
detachment.  
 
Of the ten cases classed as prophylaxis failure, but managed with additional 
retinopexy alone, seven cases were for retinal breaks occurring posterior to the 
cryotherapy treatment barrier (three of which had associated sub-retinal fluid), two 
cases were for localised retinal detachments within the prophylaxis barrier that were 
being held by the cryotherapy treatment (but a further retinopexy barrier was applied 
for additional security), and one case was for a suspected break at the junction of 
the posterior edge of the cryotherapy treatment barrier and untreated retina. 
 
All failure cases were unilateral except one bilateral case, which developed in a four 
year old child with a co-existing diagnosis of Down syndrome; the operation record 
documented concerns regarding the appearance of the peripheral retina at the time 
of cryotherapy. Bilateral prophylactic cryotherapy failure was diagnosed 51 days 
following treatment; the right retinal detachment had associated proliferative 
vitreoretinopathy and the left retinal detachment was secondary to an inferior 
horseshoe tear posterior to the cryotherapy treatment barrier.   
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2.3.16 Side effects 
 
The Cambridge Prophylactic Cryotherapy protocol caused no long-term side effects 
in any of the 528 eyes (299 patients) that underwent prophylactic intervention; in 
particular, no cases of unexplained visual loss, macular pucker or intraoperative 
choroidal haemorrhage occurred. 
 
The mean pre and postoperative converted LogMar visual acuity recorded in 419 
eyes (237 patients) was 0.29 (range, -0.18 to -1.80; standard deviation, 0.29) and 
0.25 (range, -0.18 to -1.30; standard deviation, 0.24) respectively. Vision remained 
unaltered in 45.1% (189/419), improved in 32.2% (135/419) and deteriorated in 
22.7% (95/419) of eyes at the four week postoperative review. Of those eyes that 
experienced a visual acuity reduction, only five eyes had a reduction of more than 
one line of Snellen acuity equivalent; four eyes were from patients who were less 
than four years of age. Subsequent clinical review revealed any visual acuity decline 
returned to, or was better than, preoperative visual acuity levels. The only eye that 
did not regain preoperative visual acuity levels was from a 38.4-year-old patient who 
was documented to have a Foster Fuch’s spot and progressive macular atrophy 
accounting for the continued reduction in their central vision.  
 
Reported side effects are listed in Table 2-6. 
  
93  
 
Table 2-6 Reported patient side effect 
Side effect Number of patients 
affected  
(percentage) 
Mean patient age 
(years) (SD*)  
Mean time to 
resolution 
(weeks) (SD*) 
Lid/conjunctival inflammation (mild) 76/299 (25.4%) 10.7 (9.9) <4 
Lid/conjunctival inflammation (moderate) 42/299 (14.1%) 17.5 (18.4) <4 
Lid/conjunctival inflammation (marked) 20/299 (6.7%) 14.8 (16.0) <4 
Nausea and/or vomiting 37/299 (12.3%) 16.0 (12.6) <1 
Accommodation insufficiency 28/299 (9.4%) 25.8 (14.2) 5.3 (2.5) 
Ocular discomfort 7/299 (2.3%) 21.2 (18.0) <1  
Anisocoria/mydriasis 6/299 (2.0%) 30.2 (23.1)  6.8 (2.9) 
Photophobia 3/299 (1.0%) 25.1 (24.6) 2.7 (1.2)  
Itchy eyes 2/299 (0.7%) 9.2 (2.5) <1 
New floaters 1/299 (0.3%) 18.3 6 
*SD denotes standard deviation    
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2.4 Discussion 
 
 
2.4.1 The natural history of retinal detachment in type 1 Stickler syndrome 
 
Despite an increasing understanding of the molecular genetic aetiology of the 
Stickler syndromes (Table 2-1), the rate of retinal detachment and subsequent 
visual loss in the disorder remains high (Ang et al., 2008; Donoso et al., 2002; 
Parma et al., 2002; Stickler et al., 2001).  
 
In the largest global cohort of type 1 Stickler patients (reported above), the bilateral 
control group median survival time to first retinal detachment was 18.3 years (Figure 
2-9) and the unilateral control group median survival time from first to second eye 
retinal detachment was 4.0 years (Figure 2-13). These conservative survival time 
statistics characterise for the first time the natural history of the disorder, illustrating 
that half of all untreated type 1 Stickler syndrome patients will have their first retinal 
detachment within the first two decades of life, and half of all patients who suffer a 
retinal detachment are likely to suffer a second eye retinal detachment within four 
years of the first.  
 
Although type 1 Stickler syndrome is an inherited congenital disorder and present 
from birth, the risk of retinal detachment appears to be life-long; the oldest patient in 
the current series to suffer their first eye retinal detachment was 78.5 years old. 
However, the most disturbing cases are the late presentations of preverbal children 
with inoperable, bilateral retinal detachments. Severe visual impairment, 
compounded by hearing, speech and mobility problems associated with this 
disorder, result in a significant lifelong impact on the future of these young people. 
Although rare before the age of one and a half years of age, the youngest child seen 
in the current series with retinal detachments was six weeks of age.  
 
 
2.4.2 The Cambridge Prophylactic Cryotherapy protocol 
 
Historically, the Cambridge Prophylactic Cryotherapy protocol was offered to 
children from approximately five years of age. This was the typical age when they 
were old enough to cooperate with accurate vitreous phenotyping on slit lamp 
biomicroscopic examination, required to clinically confirm the presence of the type 1 
membranous anomaly and type 1 Stickler syndrome. Recent development and 
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provision of two-stage diagnostic screening (Richards et al., 2006) means that type 
1 Stickler syndrome can now be accurately identified and confirmed in over 90% of 
cases (Richards et al., 2010). Further refinement with specialised minigene and 
multiplex ligation-dependent probe amplification analysis has resulted in a mutation 
detection rate of 96.9% at the time of completion of this study. Early and accurate 
molecular diagnosis now makes it possible to offer prophylaxis at any age before 
potential retinal detachments occur; the youngest patient to receive prophylaxis in 
our series was 10.8 months. 
 
Since 1975, the Vitreoretinal Research Clinic at Addenbrooke’s Hospital (nationally 
commissioned Stickler Syndrome Diagnostic Service since 2011) has been offering 
type 1 Stickler syndrome patients the Cambridge Prophylactic Cryopexy protocol; for 
37 years this standardised prophylactic retinal intervention has been delivered 
according to a consistent rationale and protocol. The rationale of the prophylaxis 
strategy is to prevent retinal detachment secondary to giant retinal tears. Prevention 
of “conventional” posterior breaks would not be expected or intended and this 
limitation is clarified with patients consenting to treatment; the expectation is to 
substantially reduce (but not eliminate) the risk of retinal detachment.  
 
Cryotherapy rather than prophylactic laser retinopexy was used for every treated 
patient in this series as past experience has shown it to be safe when deployed 
according to this specific protocol (Ang et al., 2008), and using a single standardised 
intervention avoids introducing a further confounding variable of a different treatment 
modality. The results provide the first benchmark against which future treatment 
modalities or strategies could be compared. 
 
 
2.4.3 Validation of study design 
 
It is accepted that any retrospective analysis should be interpreted with caution as 
they may be more prone to bias; previous studies of prophylaxis in Stickler 
syndrome are no exception (Ang et al., 2008; Leiba et al., 1996; Monin et al., 1994). 
Although all patients were reviewed on the first postoperative day and one month 
after prophylaxis to evaluate individual responses to treatment and side effects, it is 
accepted that the retrospective nature of the current study may have underreported 
short-term side effects. However, when thoughtfully designed, retrospective studies, 
such as Lane-Claypon's 1926 seminal investigations into breast cancer risk factors 
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(Lane-Claypon, 1926), can contribute vital information that is impossible, impractical 
or unethical to ascertain prospectively (Mann, 2003). Given the inevitable 
constraints when studying rare genetic disorders, and the results of the current 
study, it is unlikely that a prospective randomised trial could ever be commissioned 
to assess the efficacy of retinal prophylaxis in Stickler syndrome on practical or 
ethical grounds. 
 
The significant treatment effects of prophylaxis in the current retrospective study are 
so large it is highly unlikely to be all due to bias and confounding factors. In fact, the 
study has been deliberately designed to weight against the benefit of treatment to 
ensure true treatment effect is underestimated.  
 
For example, the primary outcome measure of retinal detachment in the prophylaxis 
groups was defined to include all cases of prophylaxis failure requiring formal retinal 
detachment surgery, in addition to any post-prophylactic retinopexy without surgical 
repair (even if the retinopexy was indicated for posteriorly located tears that were 
never intended to be prevented by the anterior cryotherapy barrier). In contrast only 
retinal detachment requiring formal surgical repair was included in the control 
groups (all control patients receiving previous retinopexy were excluded from 
analysis). When reviewing the causes of retinal prophylaxis failure in the 28 eyes 
(18 of which required formal surgical retinal detachment repair and ten cases which 
were managed with retinopexy alone), it is apparent that expanding the study end 
point of retinal detachment to include cases managed without formal surgical repair 
in the treatment group could be considered to overestimate the failure rate by more 
than one third. In addition, it could be argued that all cases of failure caused by 
retinal breaks posterior to the cryotherapy treatment barrier (six of which required 
formal retinal detachment repair and seven required retinopexy alone) are not a 
cause of primary prophylaxis failure as the treatment protocol is explicitly designed 
not to prevent retinal detachments from these breaks.     
 
Furthermore, matching protocols between the bilateral and unilateral patient groups 
also permitted all retinal detachment events (including post-prophylaxis retinopexy) 
and follow-up time to be included for prophylaxis patients, but ‘cropped’ follow-up 
time resulted in lost retinal detachment events in the control groups. These 
measures intentionally weight bias against the efficacy of treatment, thereby 
reinforcing any demonstrated protective result. 
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A criticism of previous studies has been the inclusion of inappropriate controls with 
the suggestion that the majority of patients without retinal detachment receive 
prophylaxis, leaving the major source of control patients as those who have already 
suffered a retinal detachment and incurred the outcome event (Aylward et al., 2008).  
 
The best available estimate of the prevalence of retinal detachment  in Stickler 
syndrome comes from the Stickler syndrome support group surveys (59.8% 
[189/316], of which not all patients were type 1 and many had undergone previous 
cryotherapy) (Stickler et al., 2001), large family pedigree studies (57.6% [95/165] to 
65.2% [43/66]) (Donoso et al., 2002; Parma et al., 2002) and hospital eye service 
studies (73.0% [81/111]) (Ang et al., 2008). Given the rate of retinal detachment in 
the bilateral control group (53.6% [104/194]) is lower than the published prevalence 
data, it is unconvincing that this criticism would be appropriate to the current study. 
Our conservative estimate is due to the Vitreoretinal Research Unit’s algorithm of 
tracing undiagnosed family members through family pedigrees from presenting 
probands and the study exclusion criteria. In addition, this potential bias has been 
addressed in the current study by creating comparable intervention and control 
groups; individual patient matching protocols ensured that patients receiving 
prophylaxis did so prior to any potential retinal detachment event in their individually 
matched control. 
 
Although there may be some uncertainty over the precise estimate of treatment 
effect, all outcomes show a clear benefit of the Cambridge Prophylactic Cryotherapy 
protocol in reducing the risk of retinal detachment in type 1 Stickler syndrome (Table 
2-4 and Table 2-5) and current findings support the previous study conducted on a 
sample of the current cohort population (Ang et al., 2008). 
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2.4.4 Summary 
 
This study compares 299 patients and 528 eyes receiving prophylaxis with up to 
36.1 years of follow up, with 252 control patients and 510 control eyes respectively. 
It is the largest type 1 Stickler syndrome case controlled cohort, with the longest 
post interventional follow up published to date. All analyses, despite being 
deliberately weighted against treatment effect, consistently demonstrated that 
prophylaxis is safe and definitively reduces the risk of retinal detachment.  
 
The results suggest that the Cambridge Prophylactic Cryotherapy protocol should 
be offered to all type 1 Stickler syndrome patients to reduce their risk of retinal 
detachment that is so high in this subgroup of the disorder. 
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3 Pathogenesis: The posterior hyaloid membrane and its associated 
laminocytes 
 
 
 
“Few subjects in histology have been the occasion of so much difference of opinion 
as the structure of the vitreous humour of the eye. The tissue is so transparent, its 
structural elements so delicate and difficult to observe under the microscope, that so 
much variance in opinion is scarcely surprising.” (Younan, 1884) 
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3.1 Background 
 
 
Having established that retinal detachment can be prevented or reduced in a 
defined high-risk population, investigations now focus on the pathogenesis of retinal 
detachment in the wider population. 
 
The nature of the vitreoretinal junction is a fundamental starting point in the process 
of posterior vitreous detachment, the most common precursor to rhegmatogenous 
retinal detachment. Understanding this relationship between the vitreous and the 
internal limiting membrane is essential to understanding the aetiology of retinal 
detachment, and potential future prophylactic and treatment strategies. 
 
 
3.1.1 Basement membranes 
 
The hallmark in the evolution of multicellular organisms, some six hundred million 
years ago, was the development of extracellular matrices. These supporting 
molecular configurations, which include basement membranes, have evolved into a 
variety of specialised structures that perform tissue specific functions. Basement 
membranes have intimate cellular associations that appear to be central in 
determining their biological purpose, the significance of which is reiterated by the 
observation that, except for a few sponges, basement membranes are found in all 
members of the animal kingdom (Rohrbach and Timpl, 1993). The evolutionary 
importance of basement membranes to the basic nature of multicellular organisms is 
perhaps best demonstrated by the fact that basement membrane components are 
already present at the two-cell stage of development (Timpl and Dziadek, 1986). 
 
Since the seminal description of basal lamina as discrete morphological structures 
forming continuous sheet interfaces around tissues by Todd and Bowman in the 
1850s (Todd and Bowman, 1850), improvements in histological staining practices, 
such as the use of periodic acid-Schiff reagent to detect complex carbohydrates 
(Hotchkiss, 1948), have facilitated visualisation of this ‘anhistous membrane’ that 
does not stain with conventional haematoxylin and eosin. Furthermore, the 
advancements in imaging technology, such as the introduction of electron 
microscopy, has enabled ultrastructural interrogation (Pease and Baker, 1950); the 
International Anatomical Nomenclature Committee recommend the terms ‘lamina 
lucida’ (the pale layer of the basement membrane adjacent to the cell membrane), 
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‘lamina densa’ (the darker layer below the lamina lucida) and ‘lamina fibroreticularis’ 
(the outer region which is in continuity with the adjacent extracellular matrix) (Laurie 
and Leblond, 1985). 
 
With the expansion of biological analytical techniques, there has been an 
exponential increase in the molecular characterisation of connective tissue. Despite 
the discovery of the type I collagen triple helix (Ramachandran and Kartha, 1954), 
the outline of its molecular structure (Cowan et al., 1955; Ramachandran and 
Kartha, 1955; Rich and Crick, 1955) and the fundamentals of molecular packing 
(Hodge and Schmitt, 1960; Schmitt et al., 1955) between the 1950s and 1960s, it 
soon became apparent that, although type I collagen was the most abundant 
collagen, it was only one of many proteins in the collagen family, with the discovery 
of type II and type III fibrillar collagens (Miller and Matukas, 1969; Miller et al., 1971) 
in the early 1970s.  
 
Following pepsin digestion of anterior lens capsules, Kefalides reported a solubilised 
collagenous protein formed by three identical α-like chains; he proposed that 
basement membranes contained this unique non-fibrillar collagen, which he called 
type IV collagen (Kefalides, 1971). Further evaluation of type IV collagen has 
revealed an ability for spontaneous self-assembly into sheets of spidery branching 
nets (Duncan et al., 1983), analogous to a ‘chicken wire’ meshwork. This stable but 
flexible three-dimensional network functions as a scaffold for non-collagenous 
glycoprotein rich components (such as laminin, fibronectin, nidogen and heparin 
sulphate proteoglycans) to be incorporated through specific collagenous binding 
sites (Fox et al., 1991; Leblond and Inoue, 1989; Timpl, 1989). 
 
Our insights into basement membrane structure and function have expanded to 
appreciate that these structures have complex molecular components organised into 
three-dimensional functional matrices. These matrices perform important roles in 
cellular-extracellular matrix interactions and differentiation, influencing development 
and maintenance of phenotype (Merker, 1994). Basement membranes are not static 
matrices for tissue support, but rather dynamic in their interaction of specific peptide 
domains with cell surface receptors. In addition, basement membranes serve as 
selective semipermeable membranes to molecular traffic between tissue 
compartments (Farquhar et al., 1961), reservoirs that modulate local concentrations 
of growth factors and cytokines (Hynes, 2009; Schlötzer-Schrehardt et al., 2007) 
and have proposed roles in calcium homeostasis (Carafoli, 1987). Basement 
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membranes are also able to regulate cell polarity (Raftopoulou and Hall, 2004; 
Rizzolo, 1991; Russell et al., 2003), adhesion, spreading and migration via their 
cytoskeletal effects (Hamelers et al., 2005; Hamill et al., 2009; Sehgal et al., 2006) 
and influence wound healing (Torricelli et al., 2013). 
 
Testament to the physiological importance of basement membranes are the 
functional changes observed in certain acquired inflammatory and metabolic 
disorders such as Goodpasture’s syndrome (Butkowski et al., 1987; Weber et al., 
1990) and diabetes (Engerman and Colquhoun, 1982; Farquhar et al., 1961; 
Johnson et al., 1981; Kanwar and Farquhar, 1979), and the dramatic pathology 
observed in basement membrane hereditary conditions such as Alport syndrome 
(Knebelmann et al., 1996; Spear, 1973; Yoshikawa et al., 1982) and epidermolysis 
bullosa (Anton-Lamprecht, 1978; Christiano et al., 1996; Davison, 1965). 
 
 
3.1.2 The internal limiting membrane 
 
There are several well characterised basement membranes in the human eye. 
These include the eponymously named Bowman’s membrane (located between the 
corneal epithelium and corneal stroma) (Wilson and Hong, 2000), Descemet’s 
membrane (located between the corneal stroma and corneal endothelium) (Johnson 
et al., 1982) and Bruch’s membrane (located between the retinal pigment epithelium 
and choriocapillaris) (Booij et al., 2010), in addition to the lens capsule (located 
between crystalline lens epithelial cells and the aqueous humour/anterior hyaloid) 
(Danysh and Duncan, 2009). Excluding the basement membranes of the 
choriocapillaris and retinal vasculature, arguably, the largest ocular basement 
membrane is the internal limiting membrane at the vitreoretinal interface.  
 
The earliest anatomical references to the vitreoretinal interface comes from 
Gottsche in 1836, who identified a lamellar tissue in close relationship to the inner 
nervous elements of the retina, and Michaelis in 1837, who described a serous inner 
layer of the retina; the term internal limiting membrane, however, is attributed to 
Pacini in 1845, who referred to the homologous structure on the vitreous surface of 
the retina as the ‘membrana limitante’ (Pedler, 1961). In 1871, using a silver 
impregnation technique for light microscopy, Retzius detailed the morphology of the 
‘membrana limitans retinae interna’ of human and animal retinae and categorically 
concluded that the membranous structure was not a true plasma membrane but 
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rather formed by the flat vitrad ends of radial fibres (Retzius, 1871). The concept 
that the internal limiting membrane is made of the expanded vitreal foot processes 
of Müller glia became widely accepted (Menner, 1930; Polyak, 1941). Retzuis’ 
original observations, however, have been debated and further refined, with modern 
consensus seeming to consider the internal limiting membrane to be a distinct 
extracellular basement membrane between the inner surface of the retina and the 
extracellular matrix of the vitreous; investigators have now concluded that the 
internal limiting membrane is a separate structure from the plasma membrane of 
Müller glia, which are likely to form, develop and insert into it, but do not comprise it 
(Wolff, 1937, 1961; Pedler, 1961; Cohen, 1961; Heegaard et al., 1986; Uga and 
Smelser, 1973; Seiler et al., 1995).  
 
In addition to its anatomical location, further supporting evidence that the internal 
limiting membrane is a basement membrane comes from interrogation of its 
molecular composition. Studies have demonstrated that the internal limiting 
membrane to be composed of collagen IV (Jerdan et al., 1986; Kleppel and Michael, 
1990), laminin and fibronectin (Kohno et al., 1987) and carbohydrate residues 
(Rhodes, 1982). 
 
The ultrastructure of the internal limiting membrane has been well characterised by 
electron microscopy. The descriptions from the original studies conducted by Fine 
(Fine, 1961) and Fine and Tousimis (Fine and Tousimis, 1961), have been 
confirmed and reiterated in several subsequent studies (Daicker et al., 1977; 
Gärtner, 1965; Hogan et al., 1971; Malecaze et al., 1985; Masutani-Noda and 
Yamada, 1983) and further expanded by Foos (Foos, 1972a). Foos described 
variations of the internal limiting membrane in three distinct topographical zones 
within the eye; in the basal zone the internal limiting membrane was uniformly thin, 
but reported it to be progressively and irregularly thickened in the equatorial and 
posterior zones, in addition to loss of the anteriorly observed Müller vitreal surface 
attachment plaques in the posterior zone (Figure 3-1).   
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Figure 3-1 Topographical variations of the internal limiting membrane 
Transmission electron micrograph of the vitreoretinal interface demonstrating: (P) 
posterior zone with markedly thickened internal limiting membrane (37-fold increase 
in thickness compared to the basal zone), note the characteristically smooth vitreal 
aspect and irregular retinal aspect following the contour of underlying Müller glia, in 
addition to the conspicuous loss of Müller vitreal surface attachment plaques, (E) 
equatorial zone with progressive loss of internal limiting membrane thickness and 
retinal aspect irregularity (six-fold increase in thickness compared to the basal 
zone), note the presence of Müller vitreal surface attachment plaques, (B) basal 
zone with uniformly thin internal limiting membrane following undulations of the 
retinal surface, note presence of Müller vitreal surface attachment plaques (x11850). 
Reproduced with permission from Investigative Ophthalmology (Foos, 1972a).  
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Seeking to investigate if the internal limiting membrane thickened with age in a 
fashion consistent with other ocular basement membranes (Murphy et al., 1984; 
Danysh and Duncan, 2009), Heegaard reported on a series of adult eyes from the 
third to tenth decade of life and compared them with foetal eyes (Heegaard, 1994). 
The internal limiting membrane of foetal eyes was found to be uniformly thin in all 
regions and followed the surface contour of Müller glia compared to the internal 
limiting membrane of adult eyes that reiterated similar topographical variance 
findings of progressive thickening and irregularity posteriorly (with a characteristic 
smooth inner vitreal surface and undulating outer cellular surface), as described by 
Foos (Foos, 1972a). Although the internal limiting membrane was found to be 
markedly thicker in adult eyes compared to foetal eyes at 24 weeks gestation, there 
was no reported statistical correlation of increasing thickness with increasing age; 
the author attributed the lack of trend to small study numbers (a pair of eyes from 
two adults from each of the third through to the tenth decades, except for the sixth 
decade where only one pair of eyes was obtained), in addition to technical issues of 
averaging median thickness values of a structure with complex external folds, and 
using different examination techniques.  
 
Reappraising Heegaard’s original data, it is apparent that the maximum thickness of 
the internal limiting membrane at the posterior pole appeared to peak at between 
the ages of 30 to 50 years (median thickness: 3230nm) in specimens examined by 
transmission electron microscopy, and between the ages of 60 to 80 years (median 
thickness: 1336nm) for specimens examined by scanning electron microscopy. A 
conceivable explanation may be that the thickness of the internal limiting membrane 
peaked between the ages of 40 to 70 and declined thereafter (especially plausible 
as no reference was made to posterior vitreous detachment status in the examined 
eyes), and this would confound any attempts at correlating increasing thickness with 
increasing age.  
 
The aetiological importance of the internal limiting membrane and its associated cell 
population in the context of the vitreoretinal interface disorders (such as retinal 
detachment, proliferative vitreoretinopathy, macular pucker, cellophane 
maculopathy, macular holes and the vitreomacular adhesion disorders) has been 
the subject of much research (Cherfan et al., 1988; Gandorfer et al., 2002; Green et 
al., 1979; Guérin et al., 1990; Hiscott et al., 1984; Kampik et al., 1980; Morino et al., 
1990; Smiddy et al., 1990). However, despite belonging to a spectrum, the 
heterogeneity of these individual conditions has made comparisons difficult between 
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studies and correlation of the findings problematic. In an attempt to address these 
concerns, Snead and co-workers (Snead et al., 2004) immunohistochemically 
examined surgical specimens from four clinically distinct vitreomaculopathy 
subgroups; internal limiting membrane samples from patients in these subgroups 
(who had no previous intraocular surgery or retinopexy) were compared with post-
mortem eyes (with and without uncomplicated posterior vitreous detachment). 
Basement membrane from the surgical internal limiting membrane specimens was 
the principle component identified in all four subgroups, with prominent 
hyperconvolution and reduplication of the internal limiting membrane apparent in the 
macular pucker and cellophane maculopathy subgroups (Figure 3-2). Although not 
discussed in this study, control light micrographs of post-mortem eyes with 
uncomplicated senile posterior vitreous detachment appeared to show similar but 
less extensive duplication, thickening, contracture and even schisis of the posterior 
hyaloid membrane (Figure 3-3).  
 
This is perhaps unsurprising since systemic reduplication or lamellation of basement 
membranes is frequently found around capillaries in patients with diabetic micro- 
angiopathy (Fischer et al., 1982; Vracko, 1974) and increasing basement membrane 
production is a well characterised cellular response to sublethal injury (Martinez-
Hernandez and Amenta, 1983). 
 
107  
 
 
Figure 3-2 Hyperconvolution of the internal limiting membrane 
Light micrographs demonstrating internal limiting membrane surgical specimens 
from: (a) and (b) macular pucker cases stained with anti-collagen IV antibody, note 
rounded nodules representing remodelling of duplicated basement membrane in (a) 
and hyperconvoluted segments with basement membrane duplications in (b) (x400), 
(c) and (d) cellophane maculopathy cases illustrating hyperconvolution and 
duplication of the internal limiting membrane, note haematoxylin and eosin staining 
in (c) and anti-collagen IV antibody staining in (d) (x400). 
Images courtesy of Dr David Snead (Snead et al., 2004).  
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Figure 3-3 Duplications of the posterior hyaloid membrane 
Light micrographs demonstrating focal duplication, thickening, contracture and 
schisis of the posterior hyaloid membrane in cadaveric globes which had ante-
mortem clinical confirmation of uncomplicated senile posterior vitreous detachment, 
note laminocyte cells closely associated to membrane. Focal positive staining for (a) 
anti-collagen IV antibody and (b) anti-glial fibrillary acidic protein (GFAP) antibody 
(x400). 
Images courtesy of Dr David Snead (Snead et al., 2004). 
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3.1.3 Posterior vitreous detachment and the posterior hyaloid membrane 
 
The vitreous humour is the largest anatomical structure in the eye; it fills the 
posterior segment of the eye, occupying over three quarters of the total ocular 
volume. In common with connective tissues in the rest of the body, the vitreous is a 
collection of extracellular matrix components with a paucity of resident cells. Unlike 
other parts of the body, the vitreous has evolved to maintain an optically clear media 
given its critical position in the visual pathway (between the crystalline lens anteriorly 
and retina posteriorly). 
 
Most mammals have a solid vitreous throughout life, however, there are a few 
primate species, such as the owl monkey (Douroucoulis aotus trivirgatus) and bush 
baby (Galagidae), that undergo physiological vitreous liquefaction as a 
developmental phenomenon before they reach adulthood (Balazs, 1973). Uniquely 
in humans, the vitreous undergoes a progressive morphological remodelling with an 
increase in fluid-filled lacunae (synchisis) (Foos and Wheeler, 1982) and an 
increase in collagenous condensations (syneresis) (Sebag, 1987) as part of the 
aging process. The vitreous, that is firmly adherent to the retina in youth, may 
undergo vitreoretinal dehiscence and detach from the surface of the retina during 
the process of posterior vitreous detachment. 
 
Posterior vitreous detachment may be an asymptomatic finding in many patients, 
however, in those patients who are symptomatic, separation of the vitreous from the 
retina is associated with an acute onset of ‘flashes and floaters’; flashes refer to the 
pathognomonic features of temporal photopsia, described as a momentary arc of 
light in the lateral field of vision, whilst floaters refer to the subjective perception of 
the shadows cast onto the retina by vitreal opacities (Murakami et al., 1983; Snead 
et al., 2008).  
 
Despite posterior vitreous detachment being a common ocular event that will affect 
the majority of individuals in an aging population (Akiba, 1993; Snead et al., 1994b; 
Weber-Krause and Eckardt, 1997), there is still little consensus regarding its precise 
definition. Review of the literature reveals two main theories:  
 
1. Currently the predominantly accepted theory defines posterior vitreous 
detachment as the separation of the dense outer layer of type II collagen 
fibrils of the vitreous, known as the posterior vitreous cortex, from the internal 
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limiting membrane of the retina (American Academy of Ophthalmology 
Retina Panel, 2008; Kuhn and Aylward, 2014; Sebag, 1989; Stalmans et al., 
2012; Steel and Lotery, 2013). Proponents of this concept advocate the term 
posterior hyaloid face to describe the outermost cortical layer of the vitreous. 
Clinical diagnosis of a suspected posterior vitreous detachment is based 
upon the classic patient history of reported new onset ‘flashes and floaters’, 
with or without the identification of epipapillary glial tissue torn form the optic 
nerve head (Weiss ring) noted in the posterior vitreous cortex on slit lamp 
biomicroscopy. 
 
2. The less prevalent theory of posterior vitreous detachment defines the 
process as the separation of the vitreous and its enveloping posterior hyaloid 
membrane from the surface of the retina (Ang et al., 2005; Kakehashi et al., 
2014; Snead et al., 2008). Proponents of this concept advocate the term 
posterior hyaloid membrane to describe the membranous structure encasing 
the detached vitreous (Figure 3-3, Figure 3-4 and Figure 3-5). Clinical 
diagnosis of a suspected posterior vitreous detachment is based upon the 
classic patient history of reported new onset ‘flashes and floaters’, in addition 
to the identification of a continuous, discrete, highly creased and refractile 
membranous sheet observed by slit lamp dynamic vitreous biomicroscopy 
with a wide illumination-observation angle (Figure 3-7 and Video Appendix 
1.3). This theory considers the Weiss ring to be a defect in the posterior 
hyaloid membrane, surrounded by a cellular cuff of laminocyte cells that 
delineate the recent position of attachment to the optic nerve head (Figure 
3-6). The posterior hyaloid membrane, which was not present prior to the 
posterior vitreous detachment (but apparent after) is considered by definition 
to arise from part of the internal limiting membrane on the surface of the 
retina in its attached state. 
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Figure 3-4 The posterior hyaloid membrane 
Light micrographs presented by Zimmerman and Straatsma at the second 
conference of the Retina Foundation in 1958 to illustrate the concept of the posterior 
hyaloid membrane as a distinct and separate histological structure of the 
vitreoretinal interface; the presence of associated cells are noted, but no detailed 
account is given: (a) and (b) Rinehart-Abul-Haj stain (x305). 
Reproduced with permission from Elsevier (Upminster Local History Group., 1960). 
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Figure 3-5 Electron microscopy of the posterior hyaloid membrane and 
associated laminocytes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please turn over for figure legend 
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Figure 3-5 Electron microscopy of the posterior hyaloid membrane and 
associated laminocytes 
Electron micrographs of posterior hyaloid membranes from donors with ante-mortem 
clinical confirmation of posterior vitreous detachment: (a) low magnification scanning 
electron micrograph of the posterior aspect of a detached Weiss ring, note the 
irregular coarse appearance of the retinal aspect of the posterior hyaloid membrane, 
in addition to cortical gel spilling over into the retrohyaloid space, (b) low 
magnification scanning electron micrograph demonstrating the smooth vitreal aspect 
of the posterior hyaloid membrane adjacent to areas of fibrillar cortical gel (* denotes 
a laminocyte cell), (c) high magnification transmission electron micrograph 
demonstrating a cross-section through extensively convoluted posterior hyaloid 
membrane (* denotes areas of membrane in tangential section and the arrows 
depict collagen fibrils on the vitreal aspect of the posterior hyaloid membrane), (d) 
high magnification transmission electron micrograph demonstrating laminocyte 
cellular component association with the posterior hyaloid membrane (* denotes the 
relationship of collagen fibrils to the posterior hyaloid membrane and the arrows 
denote hemi-desmosome attachment plaques). 
Images courtesy of Mr Martin Snead (Snead et al., 2002). 
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Figure 3-6 Histology of the Weiss ring 
Light micrographs demonstrating a Weiss ring defect in flat mounted posterior 
hyaloid membranes: (a) and (b) stained with haematoxylin and eosin (x100, x200 
respectively).  
Images courtesy of Mr Martin Snead (Snead et al., 2002). 
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Figure 3-7 The clinical appearance of the posterior hyaloid membrane 
Slit lamp biomicroscopy images demonstrating the clinical appearance of the 
posterior hyaloid membrane following posterior vitreous detachment, note the 
classic creased and crinkled topographical appearance, in addition to the vitreous 
fibrils anterior to the membrane in (j), (k) and (l) and the associated cells studded 
onto the surface of the membrane in (i). 
Photographs courtesy of Dr Paul Meyer.  
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3.1.4 Laminocytes 
 
Although the presence of cells intimately associated with the posterior hyaloid 
membrane has been apparent in published histological reports of the vitreoretinal 
interface for decades, little attention has been paid to their presence; this is 
surprising given their potentially important location with respect to the process of 
posterior vitreous detachment (Figure 3-4). 
 
In 2002, Snead and colleagues proposed the term ‘laminocyte’ to be designated to 
the cell population integral to the posterior hyaloid membrane (Snead et al., 2002). 
The term was suggested to classify this distinct cellular population, emphasising 
their association with the basal lamina of the posterior hyaloid membrane, in 
addition to the laminar array pattern of distribution. 
 
Light microscopy has demonstrated laminocytes to be spindle shaped cells with 
indistinct cytoplasm and oval or round nuclei. They are only seen abutting the 
posterior hyaloid membrane (Figure 3-3 and Figure 3-4) and have a classic 
distribution pattern, being most densely populated around the Weiss ring, becoming 
less densely populated peripherally (Figure 3-6). Electron microscopic investigations 
have confirmed the intimate relationship of laminocytes to the vitreal aspect of the 
posterior hyaloid membrane (Figure 3-5b and Figure 3-5d) (Snead et al., 2004, 
2002, 2008). 
 
Close inspection of the clinically detached posterior hyaloid membrane in vivo using 
slit lamp dynamic vitreous biomicroscopy with a wide illumination-observation angle, 
reveals the membrane to be studded with laminocyte cells that correlate to light 
microscopy findings in vitro (Figure 3-7i) (Snead et al., 2008).  
 
Limited immunohistochemical interrogations of laminocytes in cadaveric globes 
(from donors with ante-mortem clinical confirmation of posterior vitreous 
detachment) have demonstrated focal and patchy staining of laminocytes with anti-
glial fibrillary acidic protein (GFAP) antibodies that was reported to be variable in 
nature (Figure 3-3b); similarly, anti-collagen IV antibodies demonstrated focal and 
patchy staining to the associated posterior hyaloid membrane (Figure 3-3a). 
Evaluation of cadaveric globes without posterior vitreous detachment demonstrated 
weak positivity of the retinal internal limiting membrane for type IV collagen and a 
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monolayer of GFAP positive cells lining the vitreal aspect of the internal limiting 
membrane (Snead et al., 2004, 2002, 2008). 
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3.2 Hypothesis 
 
 
The posterior hyaloid membrane may not be a condensation of posterior vitreous 
cortex commonly referred to as the posterior hyaloid face, but rather a true 
basement membrane or separately distinct structure that encases the extracellular 
matrix of the vitreous body. This basal lamina may separate from the surface of the 
retina during the process of posterior vitreous detachment and form as a result of 
dehiscence of the retinal internal limiting membrane.  
 
Accounting for those elderly patients who never undergo posterior vitreous 
detachment and those young patients with intraocular inflammation who do (in 
addition to potentially explaining the reported acute onset of ‘flashes and floaters’ 
symptomatology), it is conceivable that posterior vitreous detachment may not be an 
entirely age related syneretic and synchitic process, but possibly a violent, biological 
event occurring in predisposed individuals. The laminocyte cell population integral to 
the posterior hyaloid membrane may contribute actively to posterior vitreous 
detachment and knowledge of their phenotypic lineage may add insight into the 
process. 
 
In order to investigate the pathogenesis of retinal detachment, it is necessary to 
investigate the pathogenesis of posterior vitreous detachment; the primary 
objectives of this study are to investigate the histological correlate of the posterior 
hyaloid membrane observed clinically in patients presenting with a posterior vitreous 
detachment, in addition to interrogating the associated resident laminocyte cell 
population. 
 
  
119  
 
3.3 Material and methods 
 
 
3.3.1 Ethical approval 
 
This project was conducted following National Research Ethics Service approval 
(NRES 05/Q2802/77) and all investigations were conducted in accordance with the 
principles of the Declaration of Helsinki with regards to research on human tissue.  
 
 
3.3.2 Globe tissue 
 
Human eye globe tissue was supplied by the Corneal Transplant Service Eye Bank, 
University of Bristol, under a Material Transfer Agreement.  
 
Following enucleation from consented organ donors, an 18mm corneoscleral button 
was trephined and the anterior chamber of the anterior segment removed for 
subsequent corneal transplantation surgery. The remaining globe tissue, comprised 
of all structures internal to and including the scleral coat posteriorly and iris 
anteriorly (Figure 3-8a), was fixed in 4% paraformaldehyde at 4°C for up to the five 
days during collection periods.  
 
Globe tissues were transported by cold chain courier and upon receipt, repeatedly 
rinsed in cold phosphate buffered saline, cryoprotected in a 30% sucrose/phosphate 
buffered saline solution and frozen in acetone chilled in liquid nitrogen; frozen 
globes were stored at -80°C prior to being thawed on ice for dissection at room 
temperature. 
 
 
3.3.3 Dissection protocol 
 
Knowing previous studies have demonstrated that the cadaveric posterior vitreous 
detachment is consistent with, and a true representation of antemortem posterior 
vitreous detachment (Snead et al., 1994b, 2002), a dissection technique was 
developed in order to isolate posterior hyaloid membranes from donated eye globe 
tissue for immunological investigations. 
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Dissection technique 
 
Dissection commenced with a circumferential, full thickness scleral coat incision into 
the suprachoroidal space; the incision was placed posteriorly around the optic nerve 
stalk (Figure 3-8b). Anteriorly, the iris was removed circumferentially at its root 
(Figure 3-8c) and the prolapsing anterior vitreous trimmed to remove retrolenticular 
membranes. The suprachoroidal spaced was entered anteriorly and blunt-dissected 
posteriorly towards the initial peripapillary scleral incision. Radial full thickness 
scleral incisions (connecting the anterior scleral edge to the posterior peripapillary 
incision) facilitated removal of the scleral coat from the remaining eviscerated 
vitreous body, covered by retina and choroid, and attached posteriorly to the optic 
nerve stalk and surrounding rim of scleral tissue (Figure 3-8d).  
 
 
Posterior vitreous detachment status evaluation 
 
To evaluate posterior vitreous detachment status, a modification to the ‘suspended-
in-air examination’, originally described by Foos (Foos, 1972b) was employed. 
Instead of sectioning a globe by longitudinal section into two halves that were 
suspended in air, the modified air suspension technique assessed the shape of the 
eviscerated contents whilst suspended in air from the optic nerve stalk remnant; this 
was done before and after removal of the choroid (Figure 3-9a, Figure 3-9b and 
Figure 3-9c, Figure 3-9d respectively). 
 
Air-suspended eviscerated globe tissue with a posterior vitreous detachment formed 
a ‘long-necked conical flask’ configuration (Figure 3-9a and Figure 3-9c) compared 
to a rounded ‘bell jar’ configuration (Figure 3-9b and Figure 3-9d) observed in those 
without posterior vitreous detachment.  
 
 
Posterior hyaloid membrane isolation 
 
Eviscerated globe tissue deemed to have a posterior vitreous detachment was 
selected for further dissection.  
 
In these cases the posterior circumferential attachment of the retina to the detached 
vitreous was frequently observed to be unable to support the weight of the vitreous 
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body when re-suspended and would spontaneously tear along this region of 
attachment (the junction of the ‘neck’ and ‘body’ in the ‘long-necked flask’ analogy, 
Figure 3-10a). Cases where the retina was able to support the weight of the vitreous 
body were incised at this junction.  
 
The final configuration of the dissected globe tissue before isolation of the posterior 
hyaloid membrane comprised the vitreous body, surrounded by an annulus of 
adherent retina anteriorly and with the transparent posterior pole of the vitreous 
body exposed posteriorly (Figure 3-10b). Posterior to anterior 18mm trephination 
through the vitreous body allowed removal of the anterior annulus of retinal tissue 
and peripheral anterior vitreous gel (Figure 3-10c), resulting in a core of clear 
vitreous gel with its associated posterior hyaloid membrane lining the posterior 
vitreous face (Figure 3-10d).  
 
The trephined gel core was examined using a Zeiss Primo Vert phase contrast light 
microscope to identify the posterior hyaloid membrane; posterior hyaloid 
membranes were readily identified as distinct creased and crinkled refractile sheets 
on the posterior surface of the trephined gel core. 
 
Under direct phase visualisation, the vitreous body was debulked and the posterior 
hyaloid membrane divided to facilitate later slide mounting. Isolated posterior hyaloid 
membranes fragments were stored in phosphate buffered saline at 4°C prior to 
immunohistochemical staining.  
 
 
3.3.4 Retinal internal limiting membrane isolation 
 
In order to interrogate the surface of the retina following posterior vitreous 
detachment, posterior pole retinal tissue collected from globe tissue evaluated to 
have undergone posterior vitreous detachment (Figure 3-9c and Figure 3-10a) was 
collected and stored in phosphate buffered saline (PBS) at 4°C prior to 
immunohistochemical staining and flat mount preparation for examination. 
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Figure 3-8 Dissection technique 
Colour photographs demonstrating: (a) globe tissue as received from the Corneal 
Transplant Service Eye Bank prior to dissection, (b) peripapillary full thickness 
scleral incision entering suprachoroidal space, (c) circumferential iris root incision, 
(d) radial scleral incisions facilitating removal of scleral coat from the eviscerated 
vitreous body (enveloped by retina and choroid but remaining attached to the optic 
nerve stalk posteriorly).    
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Figure 3-9 Posterior vitreous detachment evaluation 
Colour photographs demonstrating the modified air suspension technique: (a) 
eviscerated globe tissue with surrounding choroidal coat demonstrating the ‘long-
necked conical flask’ configuration (detached posterior hyaloid membrane), (b) 
eviscerated globe tissue with surrounding choroidal coat demonstrating the ‘bell jar’ 
configuration (attached posterior hyaloid membrane), (c) eviscerated globe tissue 
following choroidal coat removal confirming the ‘long-necked conical flask’ 
configuration (detached posterior hyaloid membrane), (d) eviscerated globe tissue 
following choroidal coat removal confirming the ‘bell jar’ configuration (attached 
posterior hyaloid membrane). 
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Figure 3-10 Posterior hyaloid membrane isolation 
Colour photographs demonstrating: (a) the inability of the enveloping retina to 
support the weight of the vitreous body when re-suspended in air; (b) the vitreous 
body surrounded by an annulus of adherent retina anteriorly and the transparent 
posterior pole of the vitreous body exposed posteriorly; (c) 18mm trephination 
through the central vitreous body; (d) clear vitreous gel core with associated 
posterior hyaloid membrane lining the posterior vitreous face.  
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3.3.5 Control tissue 
 
Control tissues were obtained from human kidney, tonsil, brain, skin, and hyaline 
cartilage, and supplied by the Arden Tissue Bank, University Hospital Coventry, 
under a Material Transfer Agreement. Optic nerve and retinal control tissues were 
obtained from randomly selected human globe tissue prior to dissection (Section 
3.3.1). 
 
Mirroring globe tissue fixation and processing, control tissues were fixed in 4% 
paraformaldehyde at 4°C, repeatedly washed in PBS and cryoprotected in a 30% 
sucrose/PBS prior to freezing in acetone chilled in liquid nitrogen. 
 
Cryosections were cut using a Leica CM-1850 Cryostat at -20°C after embedding in 
OCTTM (Tissue-Tek®) and then mounted on positively charged Leica X-tra™ 
Adhesive slides. Frozen tissue sections were cut at 10µm, except for retina, which 
was cut from a central calotte of frozen globe tissue as 40µm sagittal sections 
through the optic nerve head to preserve architecture. Cut sections were stored at -
80°C prior to being thawed at 4°C for immunohistochemical staining. 
 
 
3.3.6 Immunohistochemistry 
 
Isolated posterior hyaloid membranes were stained free floating in 24 well plates; 
positive control tissues were stained on slides using conventional 
immunofluorescent techniques.  
 
 
Staining protocol 
 
Prior to staining, all tissues were blocked and permeablised overnight at 4°C in PBS 
with 1:20 donkey serum, 0.5% bovine serum albumin and 0.1% TritonTM X-100, 
which was also used for all washes and to dilute antibodies. Primary and secondary 
antibodies were sequentially incubated over consecutive nights at 4°C; three 
blocking solution washes were performed before and after secondary antibody 
incubation. 6.25mg/ml 4’,6-diamidino-2-phenylindole (DAPI) was used to stain nuclei 
before tissues were mounted in a prepared water-based mounting medium (6g 
glycerol, 2.4g Moviol 4-88, 6ml nuclease-free water and 12ml 
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tris(hydroxymethyl)aminomethane buffer) and covered with Leica Surgipath® 
coverslips.  
 
 
Antibodies for immunophenotyping 
 
Primary antibodies raised against collagen IV, laminin and fibronectin were selected 
to immunophenotype basement membranes. Primary antibodies raised against 
opticin were selected to immunophenotype vitreous gel.  
 
To investigate laminocyte immunophenotype, primary antibodies raised against 
cluster of differentiation (CD) 11 (leucocyte marker), CD68 (monocyte/macrophage 
marker), cellular retinaldehyde-binding protein (CRALBP) (Müller glia marker), pan-
cytokeratin (epithelial marker), ezrin (retinal pigment epithelium marker), ionized 
calcium-binding adapter molecule 1 (Iba1) (macrophage/microglial marker), GFAP 
(astrocyte/Müller glia marker), major histocompatibility complex (MHC) class II 
(macrophage/antigen presenting cell marker), S100 calcium binding protein B 
(S100B) (astrocyte/Müller glia marker) and vimentin 
(mesenchymal/fibroblast/astrocyte/Müller glia marker) were selected.   
 
Antibody concentrations were based on the recommended dilutions reported in 
similar immunofluorescent applications; concentrations were optimised using serial 
dilutions. 
 
Details of primary and secondary antibody sources and dilutions are shown in Table 
3-1 and Table 3-2. 
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Table 3-1 Primary antibodies 
Primary antibody Manufacturer Catalog # Species Dilution 
     
Basement membrane markers    
Anti-collagen IV Abcam ab6586 Rabbit polyclonal 1:100                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
Anti-fibronectin Abcam ab26245 Mouse monoclonal [A17] 1:100 
Anti-laminin Abcam ab11575 Rabbit polyclonal 1:200 
     
Vitreous gel markers    
Anti-opticin Abcam ab170886 Rabbit monoclonal [EPR11980(B)] 1:250 
    
Cell phenotype markers    
Anti-CD11b Abcam ab63317 Mouse monoclonal [2Q902] 1:200 
Anti-CD68 DAKO M0718 Mouse monoclonal [EBM11] 1:200 
Anti-CRALBP Abcam ab15051 Mouse monoclonal [B2] 1:200 
Anti-cytokeratin DAKO M3515 Mouse monoclonal [AE1/AE3] 1:50 
Anti-ezrin Sigma-Aldrich E8897 Mouse monoclonal [3C12] 1:10000 
Anti-GFAP DAKO Z0334 Rabbit polyclonal 1:500 
Anti-Iba1 Abcam ab5076 Goat polyclonal 1:100 
Anti-MHC class II Abcam ab55152 Mouse monoclonal [6C6] 10ug/ml 
Anti-S100B  Abcam ab11178 Mouse monoclonal [SH-B1] 1:1000 
Anti-vimentin 
 
DAKO M7020 Mouse monoclonal [Vim3B4] 1:500 
CD denotes cluster of differentiation 
CRALBP  denotes cellular retinaldehyde-binding protein 
GFAP denotes glial fibrillary acidic protein 
Iba1 denotes ionized calcium-binding adapter molecule 1 
MHC denotes major histocompatibility complex 
S100B denotes S100 calcium binding protein B 
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Table 3-2 Secondary antibodies 
Secondary antibody Manufacturer Catalog # Species Dilution 
     
Alexa Fluor® 488 Life Technologies A21202 Donkey anti-Mouse 1:500 
Alexa Fluor® 568 Life Technologies A10042 Donkey anti-Rabbit 1:500 
Alexa Fluor® 647 Life Technologies A21447 Donkey anti-Goat 
 
1:250 
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3.3.7 Confocal microscopy 
 
Digital confocal micrograph images were acquired on a Zeiss Observer Z1 inverted 
LSM 700 Confocal Laser Scanning Microscope. Separation of fluorescence signals 
by sequential laser frequency excitation at 400nm, 440nm, 470nm and 535nm 
prevented multi-channel crosstalk. Generated .lsm data files were processed with 
Carl Zeiss ZEN 2012 SP1 (black edition) software.   
 
Scanning protocols included phase and confocal low magnification (EC Plan-
Neofluar® 10x0.30 Ph1 M27 Objective) composite tile scans to ascertain global 
topography of posterior hyaloid membrane specimens, in addition to phase and 
confocal high magnification (EC Plan-Apochromat® 63x1.40 Oil Ph3 M27 Objective) 
z-stack imaging to identify laminocyte cell candidates.  
 
In order to categorise an eligible subpopulation of cells as laminocytes, efforts were 
made to identify cells that occupied an expected and intrinsically associated relation 
to the posterior hyaloid membrane.  
 
Posterior hyaloid membranes, vitreous gel and identified laminocyte cells were 
immunologically phenotyped using the selected panel of primary antibodies detailed 
in Table 3-1. 
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3.4 Results 
 
 
In all reported confocal micrograph images primary antibodies raised in mice, rabbit 
and goat species are pseudocoloured green, red and magenta respectively; DAPI 
nuclear staining is pseudocoloured blue.  
 
Positive and negative antibody control figures are cross-referenced to Appendix 6.1 
and Appendix 6.2 respectively. 
 
  
3.4.1 Phase contrast microscopy of the posterior hyaloid membrane 
 
Isolated posterior hyaloid membranes were consistently identified as distinct, 
creased and crinkled glassy sheets on phase contrast microscopy (Figure 3-11a). 
Residual attached vitreous gel had a rucked and undulating appearance (Figure 
3-11b and Figure 3-11c) but was readily distinguishable from the adjacent posterior 
hyaloid membrane which was phase dense with definitive sharp cut edges (Figure 
3-11d).  
 
Physically manipulating samplings under direct phase contrast microscopy 
visualisation further demonstrated differences between the posterior hyaloid 
membrane and the vitreous gel; the membrane component was relatively inflexible 
and reluctant to unfold, preferring to remain in a crumpled orientation, whilst the gel 
component had a pliable and elastic nature, returning to its original orientation after 
being handled.  
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Figure 3-11 Posterior hyaloid membrane phase contrast microscopy 
Phase contrast micrograph series demonstrating: (a) glassy, phase-dense 
appearance of the posterior hyaloid membrane (x5), (b) rippled vitreous gel 
appearance (upper right corner) adjacent to the posterior hyaloid membrane (lower 
half of image) (x5), (c) distinct boundary between vitreous gel (upper right corner) 
and posterior hyaloid membrane (lower right corner) (x5), (d) high power view 
illustrating a definitive cut edge of the posterior hyaloid membrane (x10). 
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3.4.2 Basement membrane immunohistochemistry 
 
 
Posterior hyaloid membrane immunostaining for collagen IV  
 
Isolated posterior hyaloid membrane specimens consistently demonstrated positive 
immunofluorescence with rabbit polyclonal anti-collagen IV antibodies. 
Immunofluorescent images characterised membranous sheets with definitive sharp 
cut edges (Figure 3-12a and Figure 3-12b). Surface topography micrographs 
revealed the membrane to have a highly creased and crinkled appearance (Figure 
3-12c). 
 
Z-stack cross-section confocal analysis (Figure 3-12d) and three-dimensional image 
reconstructions demonstrated a smooth configuration to the vitreal aspect (Figure 
3-12e) and an irregular coarse configuration to the retinal aspect (Figure 3-12f) of 
the posterior hyaloid membrane. 
 
See Appendix Figure 6-1 for anti-collagen IV antibody positive controls and 
Appendix Figure 6-15c and Figure 6-15d for posterior hyaloid membrane negative 
controls. 
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Figure 3-12 Posterior hyaloid membrane immunohistochemistry: collagen IV 
 
 
Please turn over for figure legend 
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Figure 3-12 Posterior hyaloid membrane immunohistochemistry: collagen IV 
Posterior hyaloid membrane confocal micrograph series stained with antibodies to 
collagen IV (red fluorescence, Alexa Fluor® 568) demonstrating: (a) 10x10 tile scan 
(x5), (b) 3x3 tile scan (x5), (c) surface topography (x63), (d) z-stack cross-section 
through membrane fold (x63), (e) and (f) z-stack three-dimensional image 
reconstructions illustrating smooth vitreal aspect and coarse retinal aspect of the 
posterior hyaloid membrane respectively. 
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Posterior hyaloid membrane immunostaining for laminin 
 
Isolated posterior hyaloid membrane specimens consistently demonstrated positive 
immunofluorescence with rabbit polyclonal anti-laminin antibodies. 
Immunofluorescent images characterised membranous sheets with definitive sharp 
cut edges (Figure 3-13a and Figure 3-13b). Surface topography micrographs 
revealed the membrane to have a highly creased and crinkled appearance (Figure 
3-13c). 
 
Z-stack cross-section confocal analysis (Figure 3-13d) and three-dimensional image 
reconstructions demonstrated a smooth configuration to the vitreal aspect (Figure 
3-13e) and an irregular coarse configuration to the retinal aspect (Figure 3-13f) of 
the posterior hyaloid membrane. 
 
See Appendix Figure 6-2 for anti-laminin antibody positive controls and Appendix 
Figure 6-15c and Figure 6-15d for posterior hyaloid membrane negative controls. 
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Figure 3-13 Posterior hyaloid membrane immunohistochemistry: laminin 
 
 
Please turn over for figure legend 
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Figure 3-13 Posterior hyaloid membrane immunohistochemistry: laminin 
Posterior hyaloid membrane confocal micrograph series stained with antibodies to 
laminin (red fluorescence, Alexa Fluor® 568) demonstrating: (a) 5x5 tile scan (x5), 
(b) 3x3 tile scan (x5), (c) surface topography (x63), (d) z-stack cross-section through 
membrane fold (x63), (e) and (f) z-stack three-dimensional image reconstructions 
illustrating smooth vitreal aspect and coarse retinal aspect of the posterior hyaloid 
membrane respectively. 
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Posterior hyaloid membrane immunostaining for fibronectin 
 
Isolated posterior hyaloid membrane specimens consistently demonstrated positive 
immunofluorescence with mouse monoclonal anti-fibronectin antibodies. Staining 
was not restricted to membranes with immunofluorescent images characterising 
membranous sheets with definitive sharp cut edges, in addition to non-specific 
delineation of residually attached vitreous gel (Figure 3-14a and Figure 3-14b).  
 
Z-stack cross-section confocal analysis reiterated the anti-fibronectin antibody 
binding pattern to the posterior hyaloid membrane and vitreous gel (Figure 3-14c 
and Figure 3-14d), however, both aspects of the membrane appeared smooth with 
no observed irregular coarse configuration to the retinal aspect as delineated with 
anti-collagen IV and anti-laminin antibodies (Figure 3-12d and Figure 3-13d 
respectively). Three-dimensional image reconstructions confirmed a smooth 
configuration to the retinal aspect (Figure 3-14e) and a granular non-specific gel 
staining to the vitreal aspect (Figure 3-14f) of the posterior hyaloid membrane. 
 
See Appendix Figure 6-3 for anti-fibronectin antibody positive controls and Appendix 
Figure 6-15a and Figure 6-15b for posterior hyaloid membrane negative controls. 
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Figure 3-14 Posterior hyaloid membrane immunohistochemistry: fibronectin 
 
 
Please turn over for figure legend  
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Figure 3-14 Posterior hyaloid membrane immunohistochemistry: fibronectin 
Posterior hyaloid membrane confocal micrograph series stained with antibodies to 
fibronectin (green fluorescence, Alexa Fluor® 488) demonstrating: (a) 6x6 tile scan 
(x5), (b) 7x7 tile scan (x5), (c) z-stack cross-section through membrane fold and 
vitreous gel (x81.9), (d)  z-stack cross-section through membrane fold and vitreous 
gel (x308.7), (e) and (f) z-stack three-dimensional image reconstructions illustrating 
smooth retinal aspect of the posterior hyaloid membrane and a non-specific gel 
staining on the vitreal aspect respectively.  
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3.4.3 Vitreous gel immunohistochemistry 
 
 
Vitreous gel immunostaining for opticin  
 
Vitreous gel consistently demonstrated positive immunofluorescence with rabbit 
monoclonal anti-opticin antibodies. Staining delineated individual vitreous gel fibrils 
(Figure 3-15a and Figure 3-15b).  
 
Z-stack cross-section confocal analysis reiterated the anti-opticin antibody binding 
pattern to the posterior hyaloid membrane and vitreous gel with a distinct 
condensation of vitreal fibres observed at the gel-membrane interface (Figure 3-15c 
and Figure 3-15d). Three-dimensional image reconstructions demonstrated a 
smooth configuration to the vitreal and retinal aspect of the gel-membrane interface 
that mirrored the folds and convolutions of the underlying posterior hyaloid 
membrane (Figure 3-15e and Figure 3-15f respectively). There was no irregular 
coarse configuration to the retinal aspect of this interface as observed with anti-
collagen IV and anti-laminin antibodies (Figure 3-12d and Figure 3-13d 
respectively). 
 
See Appendix Figure 6-4 for anti-opticin antibody positive controls and Appendix 
Figure 6-15c and Figure 6-15d for posterior hyaloid membrane negative controls. 
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Figure 3-15 Posterior hyaloid membrane and vitreous gel 
immunohistochemistry: opticin 
 
Please turn over for figure legend 
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Figure 3-15 Posterior hyaloid membrane and vitreous gel 
immunohistochemistry: opticin 
Posterior hyaloid membrane and vitreous gel confocal micrograph series 
micrographs stained with antibodies to opticin (red fluorescence, Alexa Fluor® 568) 
demonstrating: (a) 5x5 tile scan (x5), (b) vitreous fibres (x31.5), (c) z-stack cross-
section through membrane fold and vitreous gel (x63), (d) z-stack surface 
topography of retinal aspect of membrane (left panel) with corresponding gel-
membrane interface cross-section (right panel) (x10), (e) and (f) z-stack three-
dimensional image reconstructions illustrating smooth vitreal and retinal aspects of 
the gel interface and posterior hyaloid membrane respectively. 
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3.4.4 Posterior hyaloid membrane and associated retinal macroglia marker 
immunohistochemistry 
 
 
Posterior hyaloid membrane immunostaining for CRALBP 
 
Isolated posterior hyaloid membrane specimens demonstrated discrete areas of 
positive immunofluorescence with mouse monoclonal anti-CRALBP antibodies. 
Although staining varied in intensity, z-stack cross-sectional analysis (Figure 3-16a, 
Figure 3-16b) and three-dimensional reconstruction images (Figure 3-16c, Figure 
3-16d) consistently demonstrated the immunofluorescence to be associated with the 
retinal aspect of the posterior hyaloid membrane. 
 
See Appendix Figure 6-5 for anti-CRALBP antibody positive controls and Appendix 
Figure 6-15a and Figure 6-15b for posterior hyaloid membrane negative controls. 
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Figure 3-16 Posterior hyaloid membrane and associated retinal macroglia 
immunohistochemistry: CRALBP 
Posterior hyaloid membrane confocal micrograph series stained with antibodies to 
CRALBP (green fluorescence, Alexa Fluor® 488) and collagen IV (red fluorescence, 
Alexa Fluor® 488) demonstrating: (a) and (b) z-stack cross-sections demonstrating 
discrete areas of variable CRALBP staining consistently localised to the retinal 
aspect of the membrane (x31.5, x182.7 respectively), (c) and (d) z-stack three-
dimensional image reconstructions reiterating distribution of CRALBP staining to the 
retinal aspect of the membrane. 
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Posterior hyaloid membrane immunostaining for S100B 
 
Isolated posterior hyaloid membrane specimens demonstrated scanty discrete areas 
of positive immunofluorescence with mouse monoclonal anti-S100B antibodies. 
Although staining was minimal compared to that seen with anti-CRALBP antibodies 
(Figure 3-16), z-stack cross-sectional analysis (Figure 3-17, Figure 3-16a) and 
three-dimensional reconstruction images (Figure 3-17b, Figure 3-17c, Figure 3-17d) 
consistently demonstrated this borderline immunofluorescence to be associated with 
the retinal aspect of the posterior hyaloid membrane. 
 
See Appendix Figure 6-6 for anti-S100B antibody positive controls and Appendix 
Figure 6-15a and Figure 6-15b for posterior hyaloid membrane negative controls. 
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Figure 3-17 Posterior hyaloid membrane and associated retinal macroglia 
immunohistochemistry: S100B 
Posterior hyaloid membrane confocal micrograph series stained with antibodies to 
S100B (green fluorescence, Alexa Fluor® 488) and collagen IV (red fluorescence, 
Alexa Fluor® 568) demonstrating: (a) z-stack cross-section demonstrating discrete 
areas of S100B staining consistently localised to the retinal aspect of the membrane 
(note laminocyte cell nucleus stained with DAPI (blue fluorescence) on vitreal aspect 
of the membrane) (x63), (b) z-stack three-dimensional surface shadow 
reconstruction demonstrating association of S100B to retinal aspect of the 
membrane (x63), (c) and (d) z-stack three-dimensional image reconstructions 
reiterating distribution of S100b staining to retinal aspect of the membrane. 
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Posterior hyaloid membrane immunostaining for vimentin 
 
Isolated posterior hyaloid membrane specimens demonstrated scanty discrete areas 
of positive immunofluorescence with mouse monoclonal anti-vimentin antibodies. 
Although the extent of staining was less than that seen with anti-CRALBP antibodies 
(Figure 3-16), z-stack cross-sectional analysis (Figure 3-18, Figure 3-16a, Figure 
3-18b) and three-dimensional reconstruction images (Figure 3-18c, Figure 3-18d) 
consistently demonstrated the immunofluorescence to be associated with the retinal 
aspect of the posterior hyaloid membrane. 
 
See Appendix Figure 6-7 for anti-vimentin antibody positive controls and Appendix 
Figure 6-15a and Figure 6-15b for posterior hyaloid membrane negative controls. 
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Figure 3-18 Posterior hyaloid membrane and associated retinal macroglia 
immunohistochemistry: vimentin 
Posterior hyaloid membrane confocal micrograph series stained with antibodies to 
vimentin (green fluorescence, Alexa Fluor® 488) and collagen IV (red fluorescence, 
Alexa Fluor® 568) demonstrating: (a) and (b) z-stack cross-sections demonstrating 
discrete areas of vimentin staining consistently localised to the retinal aspect of the 
membrane (note laminocyte cell nucleus stained with DAPI (blue fluorescence) on 
vitreal aspect of the membrane in (a)) (x31.5), (c) and (d) z-stack three-dimensional 
image reconstructions reiterating distribution of vimentin staining to retinal aspect of 
the membrane.  
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3.4.5 Retinal internal limiting membrane immunohistochemistry following 
posterior vitreous detachment 
 
Internal limiting membrane specimens from retinal fragments attached to the 
periphery of detached posterior hyaloid membranes (Figure 3-19) and posterior pole 
retinal flat mounts from of eyes with posterior vitreous detachment (Figure 3-20) 
were evaluated with anti-collagen IV antibodies. 
 
Immunofluorescent images demonstrated the anticipated vascular branching pattern 
of superficial retinal blood vessels, delineated by their endothelial basement 
membranes; the vascular net appeared to be associated with the surrounding 
internal limiting membrane.  
 
The internal limiting membrane formed a continuous, less intensely fluorescent 
sheet, best demonstrated at its edges (Figure 3-19b, Figure 3-19c, Figure 3-20a, 
Figure 3-20b).  
 
See Appendix Figure 6-1 for anti-collagen IV antibody positive controls; note 
Appendix Figure 6-1c demonstrates positive anti-collagen IV staining for the internal 
limiting membrane and associated retinal blood vessel. See Appendix Figure 6-16 
for the retinal flat mount negative controls.  
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Figure 3-19 Internal limiting membrane immunohistochemistry: collagen IV 
Please turn over for figure legend  
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Figure 3-19 Internal limiting membrane immunohistochemistry: collagen IV 
Confocal micrograph stained with antibodies to collagen IV (red fluorescence, Alexa 
Fluor® 568) demonstrating: (a) 10x10 tile scan of the posterior hyaloid membrane 
centrally with peripherally attached retinal fragments, identified by their surface 
vascular markings (x5), (b) and (c) magnified windows of retinal fragments in (a) 
demonstrating the internal limiting membrane (most apparent at its edges) with the 
associated microvascular network delineated by its endothelial basement membrane 
(x21.6, x16 respectively). 
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Figure 3-20 Internal limiting membrane immunohistochemistry: collagen IV 
Confocal micrograph series stained with antibodies to collagen IV (red fluorescence, 
Alexa Fluor® 568) demonstrating: (a) 3x3 tile scan of retinal posterior pole flat 
mount following posterior vitreous detachment (note greater internal limiting 
membrane immunofluorescence in the upper right corner compared to bottom left 
due to retinal undulation altering focal plane) (x5), (b) magnified view of artifactual 
retinal break in (a) demonstrating internal limiting membrane edge (x5), (c) and (d) 
z-stack three-dimensional reconstructions of the illustrating the relationship of the 
internal limiting membrane to the retinal microvascular network (retinal and vitreal 
aspect respectively). 
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3.4.6 Laminocyte phenotype  
 
 
A phenotypically distinct cell population, recognised by their large ‘cashew’ shaped 
nuclei (frequently appearing binucleated in cross-section) and branched, extensive 
dendritic morphology, were the only subpopulation of vitreal cells identified to be 
adherent to the posterior hyaloid membrane (Figure 3-21, Figure 3-22). These 
readily identifiable cells were always apparent on the vitreal aspect of the posterior 
hyaloid membrane and were found in all specimens examined. 
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Figure 3-21 Laminocyte phenotype 
Confocal micrograph series with phase contrast overlay demonstrating cells 
adherent to the posterior hyaloid membrane with: (a) elongated pseudopodia, scanty 
somatic cytoplasm and large nucleus (appearing binucleate in cross-section) 
(x44.1), (b) extensive dendritic morphology (x63), (c) large ‘cashew’ shaped nucleus 
(x100.8), (d) phagocytic terminal bulb with associated nuclear material and positive 
CD68 cytoplasmic granule staining (220.5x). Tissue stained with DAPI (blue 
fluorescence) to identify nuclei and nuclear material. 
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Figure 3-22 Laminocyte phenotype 
Confocal micrograph series of a posterior hyaloid membrane specimen stained with 
antibodies to collagen IV (red fluorescence, Alexa Fluor® 568) and DAPI (blue 
fluorescence); scanning microscope detector gain setting maximised to produce a 
non-specific fluorescent signal in order to delineate cellular morphology: (a) and (b) 
demonstrate elongated pseudopodia and extensive dendritic morphology, note non-
specificity indicated by loss of nuclear void (x63), (c) large nucleus (appearing 
binucleate in cross-section) (x63), (d) integrally adherent to the underlying posterior 
hyaloid membrane (x110.8).  
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3.4.7 Laminocyte immunohistochemical phenotyping 
 
 
Laminocyte immunostaining for GFAP 
 
All examined laminocyte cells, identified to be adherent to the posterior hyaloid 
membrane on phase contrast microscopy, demonstrated positive staining with rabbit 
polyclonal anti-GFAP antibodies. Immunofluorescence appeared localised to the cell 
body and cytoplasmic extensions along branching pseudopodia. In addition, the vast 
majority of laminocyte cells demonstrated nuclear staining (Figure 3-23), whilst a 
minority (all from a single posterior hyaloid membrane specimen) did not (Figure 
3-24).  
 
See Appendix Figure 6-12 for rabbit polyclonal anti-GFAP antibody positive controls 
and Appendix Figure 6-17c and Figure 6-17d for laminocyte negative controls. 
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Figure 3-23 Laminocyte immunohistochemistry: GFAP 
Confocal micrograph series stained with GFAP (red fluorescence, Alexa Fluor® 
568) and DAPI (blue fluorescence) demonstrating: (a) and (b) with and without 
phase contrast overlay respectively (x107.1), (c) and (d) with and without phase 
contrast overlay respectively (x126). Note cytosolic and nuclear staining. 
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Figure 3-24 Laminocyte immunohistochemistry: GFAP 
Confocal micrograph series stained with GFAP (red fluorescence, Alexa Fluor® 
568) and DAPI (blue fluorescence) demonstrating: (a) and (b) with and without 
phase contrast overlay respectively (x63), (c) and (d) with and without phase 
contrast overlay respectively (x94.5). Note cytosolic but no nuclear staining. 
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Laminocyte immunostaining for MHC Class II 
 
Laminocyte cells, identified to be adherent to the posterior hyaloid membrane on 
phase contrast microscopy, consistently demonstrated positive immunofluorescence 
with mouse monoclonal anti-MHC Class II antibodies. Staining was specific and 
localised along the extent of their branching pseudopodia (Figure 3-25and Figure 
3-26).  
 
Staining intensity was strong, with immunofluorescence strength sufficient to readily 
and reliably detect the cells by xenon arc lamp (Leistungselektronik Jena Gmbh 
HXP-120C) epifluorescent microscopy. 
 
See Figure 3-27 for co-staining of anti-MHC Class II and anti-GFAP antibody. 
 
See Appendix Figure 6-8 for anti-MHC Class II antibody positive controls and 
Appendix Figure 6-17a and Figure 6-17b for laminocyte negative controls. 
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Figure 3-25 Laminocyte immunohistochemistry: MHC Class II 
 
Please turn over for figure legend
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Figure 3-25 Laminocyte immunohistochemistry: MHC Class II 
Confocal micrograph series stained with antibodies to MHC Class II (green 
fluorescence, Alexa Fluor® 488), collagen IV (red fluorescence, Alexa Fluor® 568) 
and DAPI (blue fluorescence) demonstrating: (a) and (b) multiple laminocytes 
positive for MHC Class II antigens (x31.5), (c) to (f) MHC Class II 
immunofluorescence delineating cell morphology, note (c) perinuclear staining, (d) 
z-stack maximum image projection, (e) z-stack three-dimensional surface shadow 
reconstruction image, (f) z-stack three-dimensional image reconstruction illustrating 
intrinsic relationship of MHC Class II positive laminocyte to posterior hyaloid 
membrane. (x113.4)  
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Figure 3-26 Laminocyte immunohistochemistry: MHC Class II 
 
 
Please turn over for figure legend  
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Figure 3-26 Laminocyte immunohistochemistry: MHC Class II 
 
Confocal micrograph series stained with antibodies to MHC Class II (green 
fluorescence, Alexa Fluor® 488), collagen IV (red fluorescence, Alexa Fluor® 568) 
and DAPI (blue fluorescence) demonstrating consistent MHC Class II 
immunofluorescence for six consecutively imaged laminocytes tabulated in rows (a) 
to (f): column (1) and (2) represent immunofluorescent images with and without 
phase contrast overlay respectively, note perinuclear staining in column (2), column 
(3) represents z-stack maximum image projection reconstructions to summate the 
distribution of MHC Class II along pseudopodia, column (4) represents z-stack 
three-dimensional image reconstructions illustrating the intimate relationship of cells 
to the posterior hyaloid membrane. 
Magnification: (a) x100.8, (b) x88.2, (c) x113.4, (d) x63, (e) x88.2, (f) x37.8. 
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Figure 3-27 Laminocyte immunohistochemistry: GFAP and MHC class II co-
staining 
Confocal micrograph series stained with antibodies to MHC Class II (green 
fluorescence, Alexa Fluor® 488), GFAP (red fluorescence, Alexa Fluor® 568) and 
DAPI (blue fluorescence) demonstrating co-staining of four consecutively imaged 
laminocytes tabulated in rows (a) to (d): column (1) represents immunofluorescent 
images with phase contrast overlay, column (2) and (3) represent single channel 
GFAP and MHC class II immunofluorescence respectively (note GFAP nuclear 
staining and MHC Class II perinuclear staining patterns), column (4) represents co-
staining of GFAP and MHC class II immunofluorescence depicted in yellow. 
Magnification: (a) x233, (b) x63, (c) x170.1, (d) x107.1  
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Laminocyte immunostaining for CD68  
 
Laminocyte cells, identified to be adherent to the posterior hyaloid membrane on 
phase contrast microscopy, consistently demonstrated positive immunofluorescence 
with mouse monoclonal anti-CD68 antibodies. Staining was specific and localised to 
cytoplasmic granules along the extent of their branching pseudopodia (Figure 3-28 
and Figure 3-29).  
 
Although staining intensity was granular and mild to moderate in intensity, it was 
apparent in every laminocyte identified by phase contrast microscopy and 
immunofluorescence was of sufficient strength to readily and reliably detect the cells 
by xenon arc lamp (Leistungselektronik Jena Gmbh HXP-120C) epifluorescent 
microscopy. 
 
Furthermore, CD68 immunofluorescence was association with DAPI 
immunofluorescence in the phagocytic terminal bulbs of the branching dendritic 
pseudopodia (Figure 3-21b).    
 
See Figure 3-30 for co-staining of anti-CD68 and anti-GFAP antibody.  
 
See Appendix Figure 6-9 for anti-CD68 antibody positive controls and Appendix 
Figure 6-17a and Figure 6-17b for laminocyte negative controls. 
 
 
 
 
 
 
 
 
  
167  
 
 
Figure 3-28 Laminocyte immunohistochemistry: CD68 
 
 
 
Please turn over for figure reference 
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Figure 3-28 Laminocyte immunohistochemistry: CD68 
Confocal micrograph series stained with antibodies to CD68 (green fluorescence, 
Alexa Fluor® 488), collagen IV (red fluorescence, Alexa Fluor® 568) and DAPI (blue 
fluorescence) demonstrating: (a) and (b) laminocyte with positive CD68 
immunofluorescence localised to granules along branching pseudopodia, with and 
without phase contrast overlay respectively (x63), (c) and (d)  scanning microscope 
detector gain setting maximised to produce non-specific autofluorescent signal in 
order to delineate cellular morphology (demonstrated by loss of nuclear void in (c)), 
without and with CD68 and DAPI immunofluorescence respectively (x63), (e) z-
stack three-dimensional surface shadow reconstruction (x63), (f) z-stack three-
dimensional image reconstruction illustrating intrinsic relationship of CD68 positive 
laminocyte to posterior hyaloid membrane.     
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Figure 3-29 Laminocyte immunohistochemistry: CD68 
 
 
Please turn over for figure reference 
170  
 
Figure 3-29 Laminocyte immunohistochemistry: CD68 
Confocal micrograph series stained with antibodies to CD68 (green fluorescence, 
Alexa Fluor® 488), collagen IV (red fluorescence, Alexa Fluor® 568) and DAPI (blue 
fluorescence) demonstrating immunofluorescence for six consecutively imaged 
laminocytes tabulated in rows (a) to (f): column (1) and (2) represent 
immunofluorescent images with and without phase contrast overlay respectively, 
column (3) represents maximum image projection reconstructions to summate the 
distribution of CD68 along pseudopodia, in addition to scanning microscope detector 
gain setting maximised to produce non-specific autofluorescent signal in order to 
delineate cellular morphology (posterior hyaloid membrane stained with rabbit 
polyclonal anti-collagen IV antibody), column (4) represents a three-dimensional 
surface shadow reconstruction. 
Magnification: (a) x81.9, (b) x50.4, (c) x63, (d) x100.8, (e) x44.1, (f) x100.8. 
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Figure 3-30 Laminocyte immunohistochemistry: GFAP and CD68 co-staining 
Confocal micrograph series stained with antibodies to CD68 (green fluorescence, 
Alexa Fluor® 488), GFAP (red fluorescence, Alexa Fluor® 568) and DAPI (blue 
fluorescence) demonstrating co-staining of four consecutively imaged laminocytes 
tabulated in rows (a) to (d): column (1) represents immunofluorescent images with 
phase contrast overlay, column (2) and (3) represent single channel GFAP and 
CD68 immunofluorescence respectively (note GFAP nuclear staining and CD68 
perinuclear staining patterns), column (4) represents co-staining of GFAP and MHC 
class II immunofluorescence depicted in yellow. 
Magnification: (a) x132, (b) x132, (c) x94.5, (d) x119.7  
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Laminocyte immunostaining for CD11  
 
Laminocyte cells, identified to be adherent to the posterior hyaloid membrane on 
phase contrast microscopy, consistently demonstrated no detectable 
immunofluorescence with mouse monoclonal anti-CD11 antibodies (Figure 3-31).  
 
See Appendix Figure 6-10 for anti-CD11 antibody positive controls and Appendix 
Figure 6-17a and Figure 6-17b for laminocyte negative controls. 
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Figure 3-31 Laminocyte immunohistochemistry: CD11 
Confocal micrograph series stained with antibodies to CD11 (green fluorescence, 
Alexa Fluor® 488) and DAPI (blue fluorescence) demonstrating negative CD11 
immunofluorescence: (a) and (b) with and without phase contrast overlay 
respectively (x63), (c) and (d) with and without phase contrast overlay respectively 
(x63).  
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Laminocyte immunostaining for Iba1 
 
Laminocyte cells, identified to be adherent to the posterior hyaloid membrane on 
phase contrast microscopy, consistently demonstrated no detectable 
immunofluorescence with goat polyclonal anti-Iba1 antibodies (Figure 3-32).  
 
See Appendix Figure 6-11 for anti-Iba1 antibody positive controls and Appendix 
Figure 6-17e and Figure 6-17f for laminocyte negative controls. 
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Figure 3-32 Laminocyte immunohistochemistry: Iba1 
Confocal micrograph series stained with antibodies to Iba1 (magenta fluorescence, 
Alexa Fluor® 647) and DAPI (blue fluorescence) demonstrating laminocytes with 
negative Iba1 immunofluorescence: (a) and (b) with and without phase contrast 
overlay respectively (x63), (c) and (d) with and without phase contrast overlay 
respectively (x63).   
176  
 
CRALBP 
 
Laminocyte cells, identified to be adherent to the posterior hyaloid membrane on 
phase contrast microscopy, consistently demonstrated no detectable 
immunofluorescence with mouse monoclonal anti-CRALBP antibodies (Figure 3-33).  
 
See Appendix Figure 6-5 for anti-CRALBP antibody positive controls and Appendix 
Figure 6-17a and Figure 6-17b for laminocyte negative controls. 
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Figure 3-33 Laminocyte immunohistochemistry: CRALBP 
Confocal micrograph series stained with antibodies to CRALBP (green fluorescence, 
Alexa Fluor® 488) and DAPI (blue fluorescence) demonstrating laminocytes with 
negative CRALBP immunofluorescence: (a) and (b) with and without phase contrast 
overlay respectively (x75.6), (c) and (d) with and without phase contrast overlay 
respectively (x63). 
Note: CRALBP immunofluorescence apparent on the retinal side of the posterior 
hyaloid membrane in (a) and (b) but not present in (c) and (d) due to confocal optical 
sectioning through a membrane trough in (a) and (b) and through a membrane peak 
in (c) and (d) (Section 3.4.4 and Figure 3-16 for further details of CRALBP staining 
in relation to the posterior hyaloid membrane).  
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Laminocyte immunostaining for S100B 
 
Laminocyte cells, identified to be adherent to the posterior hyaloid membrane on 
phase contrast microscopy, consistently demonstrated no detectable 
immunofluorescence with mouse monoclonal anti-S100B antibodies (Figure 3-34).  
 
See Appendix Figure 6-6 for anti-S100B antibody positive controls and Appendix 
Figure 6-17a and Figure 6-17b for laminocyte negative controls. 
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Figure 3-34 Laminocyte immunohistochemistry: S100B 
Confocal micrograph series stained with antibodies to S100B (green fluorescence, 
Alexa Fluor® 488) and DAPI (blue fluorescence) demonstrating laminocytes with 
negative S100B immunofluorescence: (a) and (b) with and without phase contrast 
overlay respectively (x81.9), (c) and (d) with and without phase contrast overlay 
respectively (x63). 
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Laminocyte immunostaining for vimentin 
 
Laminocyte cells, identified to be adherent to the posterior hyaloid membrane on 
phase contrast microscopy, consistently demonstrated no detectable 
immunofluorescence with mouse monoclonal anti-vimentin antibodies (Figure 3-35).  
 
See Appendix Figure 6-7 for anti-vimentin antibody positive controls and Appendix 
Figure 6-17a and Figure 6-17b for laminocyte negative controls. 
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Figure 3-35 Laminocyte immunohistochemistry: vimentin 
Confocal micrograph series stained with antibodies to vimentin (green fluorescence, 
Alexa Fluor® 488) and DAPI (blue fluorescence) demonstrating laminocytes with 
negative vimentin immunofluorescence: (a) and (b) with and without phase contrast 
overlay respectively (x63), (c) and (d) with and without phase contrast overlay 
respectively (x63). 
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Laminocyte immunostaining for ezrin 
 
Laminocyte cells, identified to be adherent to the posterior hyaloid membrane on 
phase contrast microscopy, consistently demonstrated no detectable 
immunofluorescence with mouse monoclonal anti-ezrin antibodies (Figure 3-36).  
 
See Appendix Figure 6-13 for anti-ezrin antibody positive controls and Appendix 
Figure 6-17a and Figure 6-17b for laminocyte negative controls. 
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Figure 3-36 Laminocyte immunohistochemistry: ezrin 
Confocal micrograph series stained with antibodies to ezrin (green fluorescence, 
Alexa Fluor® 488) and DAPI (blue fluorescence) demonstrating laminocytes with 
negative ezrin immunofluorescence: (a) and (b) with and without phase contrast 
overlay respectively (x81.9), (c) and (d) with and without phase contrast overlay 
respectively (x63). 
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Laminocyte immunostaining to cytokeratin  
 
Laminocyte cells, identified to be adherent to the posterior hyaloid membrane on 
phase contrast microscopy, consistently demonstrated no detectable 
immunofluorescence with mouse monoclonal anti-cytokeratin antibodies (Figure 
3-37).  
 
See Appendix Figure 6-14 for anti-ezrin antibody positive controls and Appendix 
Figure 6-17a and Figure 6-17b for laminocyte negative controls. 
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Figure 3-37 Laminocyte immunohistochemistry: cytokeratin 
Confocal micrograph series stained with antibodies to cytokeratin (green 
fluorescence, Alexa Fluor® 488) and DAPI (blue fluorescence) demonstrating 
laminocytes with negative cytokeratin immunofluorescence: (a) and (b) with and 
without phase contrast overlay respectively (x75.6), (c) and (d) with and without 
phase contrast overlay respectively (x50.4). 
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3.4.8 Immunohistochemistry results summary 
 
The results for all immunohistochemical investigations are summarised in Table 3.3. 
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Table 3-3 Immunohistochemistry results summary  
Primary anitbody Laminocytes Vitreous Posterior hyaloid membrane 
    
Anti-collagen IV   Positive stain with vitreal/retinal aspect distinction 
Anti-laminin   Positive stain with vitreal/retinal aspect distinction 
Anti-fibronectin  Non-specific stain Stained without vitreal/retinal aspect distinction  
Anti-opticin  Positive fibrillar stain Stained without vitreal/retinal aspect distinction 
Anti-GFAP Positive stain *   
Anti-MHC class II Positive stain   
Anti-CD68 Positive stain   
Anti-CD11b Negative stain   
Anti-Iba1 Negative stain   
Anti-CRALBP Negative stain  Diffuse fragmented stain on retinal aspect 
Anti-S100B  Negative stain  Minimal stain on retinal aspect 
Anti-vimentin Negative stain  Minimal stain on retinal aspect 
Anti-ezrin Negative stain   
Anti-cytokeratin Negative stain   
* Denotes positive staining not as expected for glial cells 
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3.5 Discussion 
 
 
3.5.1 Validation of study design 
 
Globe tissue 
 
For repeatable results that can be dependably extrapolated, histological 
investigations are entirely dependent on the quality of the supplied tissue to be 
examined.  
 
In some respects, the eye is a fortunate organ to investigate histologically, as donor 
globe retrieval can be delayed up to 24 hours post-mortem (Gaum et al., 2012), 
without excessive accumulation of ocular surface microbial load (due to loss of tears 
and blink reflex) and without excessive accumulation of metabolic waste products in 
the aqueous humour (Armitage and Easty, 1997). Furthermore, unlike the heart, 
lung, liver and pancreas, which are perfusion sensitive organs and require 
transplantation within four to twelve hours (Egan, 1992; Reich and Guy, 2012; 
Wheeldon, 1991), organ culture medium allows donor corneas to be stored for up to 
five weeks before transplantation (Pels and Rijneveld, 2009). In the current study, 
globe tissue specimens received from the Corneal Transplant Service Eye Bank 
were fixed in 4% paraformaldehyde at the time viable corneal tissue was harvested 
for storage; given the similar avascular nature of the vitreous and the cornea, in 
addition to continual cold chain storage, it is possible that there was little anoxic 
cellular response in the examined tissue and the presented histological results are 
likely to be a true reflection of the ante-mortem state.  
 
Despite removal of an 18mm corneoscleral button for subsequent corneal 
transplantation, the majority of globe tissue specimens received were found to be 
anatomically intact on gross examination; conservation of the iris architecture and 
apposition of the intraocular crystalline lens to the pupillary aperture anteriorly, in 
arrangement with an intact scleral coat laterally and posteriorly, appeared to provide 
sufficient support to preserve the posterior segment contents. A minority of the globe 
tissue specimens received were not anatomically preserved on gross examination 
and were excluded from further investigation. 
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Dissection protocol 
 
In some respects, the vitreous is an unfortunate structure to examine histologically; 
it is an amorphous, transparent structure that is comprised of 98 to 99% water 
(Graymore, 1970). In the current study, a novel dissection technique was developed 
to address these challenges, in addition to: 
 
1. Reliably determining the posterior vitreous detachment status of globe tissue 
prior to isolation of the posterior hyaloid membrane. 
 
2. Isolating posterior hyaloid membranes in a manner that would facilitate en 
face microscopic examination. 
 
Pivotal to the primary objective of interrogating the histological correlate of the 
posterior hyaloid membrane observed clinically in patients with acute posterior 
vitreous detachment (using off-axis slit lamp biomicroscopy) (Figure 3-7 and Video 
Appendix 1.3), was to ensure that only globe tissue that had sustained a posterior 
vitreous detachment was selected. Posterior vitreous detachment status was 
evaluated using a modification to the ‘suspended-in-air examination’ (Foos, 1972b). 
The modified air suspension technique assessed the shape of the eviscerated 
contents (before and after removal of the choroid whilst suspended in air from the 
optic nerve stalk remnant) as an alternative to examining sectioned globe calottes 
vertically supported by wire hooks, as originally described by Foos. Although Foos’ 
technique was attempted in initial dissections in the current study, it was found to be 
technically challenging to cut globe tissue calottes without distorting the ocular 
anatomy and unreliable in determining posterior vitreous detachment status; this 
may be a result of using posterior segment globe tissue in comparison to whole 
globes used by Foos. 
 
Prospective studies have demonstrated that cadaveric posterior vitreous 
detachment is consistent with, and a true representation of antemortem posterior 
vitreous detachment (Snead et al., 1994b, 2002). These studies validate Foos’ 
‘suspended-in-air examination’ and the current dissection technique, suggesting the 
observed posterior vitreous detachments are not postmortem artifacts. 
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Retrieval of intact sheets of posterior hyaloid membrane, that could be flat mounted 
for en face microscopic examination, was sought to enable a topographical ‘bird’s 
eye view’ of the tissue that would allow direct comparison with the clinical 
appearance of the posterior hyaloid membrane observed on slit lamp 
biomicroscopy. Furthermore, en face examination was sought to facilitate a global 
morphological examination of laminocytes (compared to existing cross-sectional 
views), in addition to their relationship with the posterior hyaloid membrane using 
confocal microscopy z-stack imaging. 
 
 
3.5.2 Phenotypic characteristics of the posterior hyaloid membrane and its 
likely clinical correlate 
 
Topographical appearance 
 
Expectedly, the topographical appearance of isolated posterior hyaloid membranes 
seen on phase (Figure 3-11d) and confocal microscopy (Figure 3-12a, Figure 3-12b, 
Figure 3-12c, Figure 3-13a, Figure 3-13b, Figure 3-13c, Figure 3-14a, Figure 3-14b 
and Figure 3-19a) correlate well. Both imaging modalities demonstrate delineated 
sheets with a consistently creased and crinkled surface appearance. Comparison to 
the biomicroscopic topographical appearance of the posterior hyaloid membrane 
observed clinically in patients presenting with posterior vitreous detachment (Figure 
3-7 and Video Appendix 1.3), highlights and confirms the similarities between these 
structures.   
 
The impression gained when manipulating in vitro posterior hyaloid membrane 
specimens (under phase contrast microscopy) is of a firm but flexible film, 
reminiscent of the impression one gains from observing the movement of the 
posterior hyaloid membrane on dynamic vitreous microscopy in vivo (slit lamp 
biomicroscopic examination of the vitreous between voluntary vertical saccadic eye 
movements utilising a wide illumination-observation angle) (Video Appendix 1.3). 
 
Furthermore, high power slit lamp biomicroscopic in vivo examination demonstrates 
occasional cells studded onto the surface of the posterior hyaloid membrane (Figure 
3-7i and Video Appendix 1.3), an appearance in keeping with the resident 
laminocyte cell population described in the literature (Snead et al., 2004, 2002) and 
identified in the current study. 
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This study demonstrates that the posterior hyaloid membrane specimens isolated 
from human globe tissue in the current study are the in vitro correlates of the 
posterior hyaloid membrane seen in vivo when examining patients with a posterior 
vitreous detachment. 
 
Basement membrane immunohistochemistry 
 
The posterior hyaloid membrane specimens in the current study reliably and 
repeatedly stained with anti-collagen IV antibodies and anti-laminin antibodies 
(Figure 3-12 and Figure 3-13). Staining appeared specific, distinctly delineating 
morphology and demonstrating the characteristic creased and crinkled surface 
topography. As type IV collagen and laminin are recognised as basement 
membrane defining components (Fox et al., 1991; Kefalides, 1971; Kohno et al., 
1987; Leblond and Inoue, 1989; Timpl and Dziadek, 1986; Timpl et al., 1981), it is 
apparent that the isolated posterior hyaloid membranes reported in the current study 
are sheets of true basement membrane. 
 
Fibronectin is a ubiquitous extracellular matrix molecule and a known component of 
basement membranes and the vitreoretinal interface (Chen et al., 2009; Kohno et 
al., 1987; Stalmans et al., 2012; 1993). Anti-fibronectin antibody staining of posterior 
hyaloid membranes confirmed these assertions by demonstrating 
immunofluorescent staining patterns that was specific for, but not restricted to 
membranes (less specific delineation of residually attached vitreous gel) (Figure 
3-14).  
 
 
3.5.3 Origins of the posterior hyaloid membrane 
 
The detached posterior hyaloid membrane specimens isolated in the current study 
have been demonstrated to be true basement membranes that correlate closely to 
the appearance of posterior hyaloid membranes observed on slit lamp 
biomicroscopy (Figure 3-7 and Video Appendix 1.3).  
 
The results of this study suggest that prior to posterior vitreous detachment, the 
posterior hyaloid membrane must form part of the internal limiting membrane of the 
retina. It is conceivable that the vitreous, with its firm attachment to the internal 
limiting membrane, becomes detached from the surface of the retina along a plane 
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of weakness or split in an age thickened (Section 3.1.2) and/or hyperconvoluted 
(Snead et al., 2004) internal limiting membrane during the process of posterior 
vitreous detachment.  
 
The configuration of isolated posterior hyaloid membranes in cross-section and 
three-dimensional reconstructions, when stained with anti-collagen IV and anti-
laminin antibodies in this study, consistently demonstrate a smooth vitreal aspect 
and an irregularly coarse retinal aspect (Figure 3-12d, Figure 3-12e, Figure 3-12f 
and Figure 3-13d, Figure 3-13e, Figure 3-13f respectively). This configuration is 
highly reminiscent of the electron micrograph cross-sections of the internal limiting 
membrane (Figure 3-1P and Figure 3-1E), again supporting the hypothesis that prior 
to separation the posterior hyaloid membrane isolates originate from the internal 
limiting membrane on the surface of the retina. 
 
Furthermore, immunofluorescent investigations in the current study depicting the 
association of retinal macroglia markers to the retinal aspect of isolated posterior 
hyaloid membranes (most notably anti-CRALBP antibodies used to identify Müller 
glia) (Figure 3-16, Figure 3-17 and Figure 3-18), appear to confirm a retinal origin 
and further evidence these membranes are derived from the internal limiting 
membrane. 
 
To discount an important argument that agrees with the aforementioned findings, 
but attributes them to an artifactual split of the internal limiting membrane off the 
surface of the retina during vitreous processing, anti-collagen IV 
immunofluorescence was undertaken on retinal specimens from dissected globe 
tissues that were evaluated to have a posterior vitreous detachment (using the 
modified air suspension test, in addition to having the corresponding posterior 
hyaloid membranes isolated). Immunofluorescent images demonstrated the 
anticipated vascular branching pattern of the superficial retinal blood vessels, 
delineated by their endothelial basement membranes, in association with a 
continuous sheet of internal limiting membrane on the retinal surface (Figure 3-19 
and Figure 3-20).  
 
In addition to validating the dissection protocol employed in the current study, the 
present findings suggest that isolated posterior hyaloid membrane specimens are 
not an artifactual split of the internal limiting membrane off the surface of the retina. 
Interpretations of the findings are more likely to indicate that the process of posterior 
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vitreous detachment represents an intramembranous split of the retinal internal 
limiting membrane that results in an anterior lamellar (recognised as the posterior 
hyaloid membrane) that encases and remains attached to the detached vitreous gel 
at the original vitreoretinal interface, and a residual posterior lamella (recognised as 
internal limiting membrane) on the surface of the retina. Alternatively, the results 
may indicate the process of posterior vitreous detachment involves complete 
detachment of the internal limiting membrane into the vitreous cavity, with 
reformation of the internal limiting membrane on the surface of the retina. 
 
 
3.5.4 Vitreous gel immunohistochemistry 
 
Opticin is highly expressed in the adult eye and present throughout the vitreous 
where it is thought to stabilise the vitreous gel structure by associating with collagen 
fibrils (through binding to chondroitin sulphate proteoglycans) (Reardon et al., 2000). 
Furthermore, opticin has been demonstrated to be particularly concentrated at the 
internal limiting membrane, where it binds heparin sulphate proteoglycans, a major 
component of basement membranes (including the internal limiting membrane) 
(Hindson et al., 2005). It has been suggested that opticin, through its binding affinity 
for glycosaminoglycans (including heparin and chondroitin sulphates) could link 
vitreous collagen fibrils to the inner limiting membrane, acting as a “molecular glue” 
at the vitreoretinal interface (Le Goff and Bishop, 2007). 
 
As proof of concept, vitreous gel residually attached to isolated posterior hyaloid 
membrane specimens was immunohistochemically phenotyped using anti-opticin 
antibodies; immunofluorescent images confirm the expected opticin vitreous 
distribution in a fibrillar pattern, in addition to a concentrated “molecular glue” layer 
at the vitreoretinal interface (Figure 3-15).  
 
 
3.5.5 Phenotypical characteristics of laminocytes 
 
Laminocytes, defined as the cell population intimately associated to the posterior 
hyaloid membrane, were identified in all examined specimens in the current study. 
Identified laminocyte cells appeared to be phenotypically distinctive, demonstrating 
constantly recognisable morphological and structural features. These typically 
included characteristically large ‘cashew’ shaped nuclei that occasionally appeared 
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binucleated in cross-section, in addition to somatic cytoplasm that commonly 
extended into two or three main pseudopodia, that in turn often branched heavily, 
resulting in an extensively variable dendritic morphology (Figure 3-21 and Figure 
3-22). The nuclear and somatic appearance was so characteristic that laminocyte 
cells in the current study were readily identifiable on epifluorescent or phase 
contrast microscopy respectively.  
 
Although previous histological studies have reported laminocytes to be spindle 
shaped cells with round or oval nuclei and scanty cytoplasm (Figure 3-3), these 
investigations have been limited by relatively low magnification light microscopy with 
no delineation of cellular morphology on phase contrast microscopy or 
immunofluorescence, in addition to only cross-sectional interpretations of 
morphology. In keeping with previous electron microscopic findings (Figure 3-5), 
laminocytes in the current study were only identified on the vitreal aspect of the 
posterior hyaloid membrane (Snead et al., 2002, 2008). Furthermore, although 
electron microscopy is recognised to be prone to processing artefact, the three-
dimensional laminocyte morphology demonstrated on scanning electron microscopy 
(Figure 3-5b) is more in keeping with a dendritic branching cell with a large central 
nucleus, than the reported spindle shaped cells observed under light microscopy. 
The reported characteristic distribution pattern of laminocytes (densely populated 
around the Weiss ring, becoming less densely populated peripherally) was beyond 
the scope of the current study as isolated posterior hyaloid membranes were 
debulked and dissected into fragments to facilitate processing. 
 
Previous immunohistochemical phenotyping of laminocytes has been limited to anti-
GFAP and anti-collagen IV antibodies. Studies on cadaveric globes, with (Figure 
3-3) and without posterior vitreous detachment, demonstrated focal and patchy 
staining of laminocytes with GFAP, and weak positive staining of the associated 
posterior hyaloid membrane and internal limiting membrane for type IV collagen 
(Snead et al., 2004, 2002, 2008). GFAP positivity was interpreted as to indicate that 
laminocytes were of glial origin, which prompted the comparison to glial cells 
associated with asymptomatic, simple epiretinal membranes originally reported by 
Foos (Foos, 1974).  
 
Foos observed cells of the vitreoretinal interface in eight autopsy eyes, which he 
reported to have long flattened processes he described as exceedingly delicate and 
spreading remarkable distances along the retinal surface; he noted extending cell 
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processes typically branched in two or three chief directions. Abundant cytoskeletal 
filaments and the appearance of an active perikaryon with an abundant granular 
cytoplasmic reticulum and a conspicuous Gogli apparatus were identified by 
electron microscopy. He also noted the cells had no basement membrane apparent 
on their vitreal aspect. These reported characteristics appear to align well with the 
morphological appearance of laminocytes described in the current study. Although 
no staining was employed by Foos, the cells were identified as glial and he 
hypothesised that these cells migrated through self-sealing breaks in the internal 
limiting membrane to form simple epiretinal membranes (Foos, 1974). An alternative 
explanation may be that the cells identified by Foos were in fact laminocytes, and 
the observed breaks in the internal limiting membrane were artifactual.  
 
In the current study, anti-GFAP antibody labelling was detected in all identified 
laminocytes (Figure 3-23). Immunofluorescence was demonstrated within the 
cytoplasmic dendritic extensions, in addition to the cell nucleus (except for a minority 
of cells in one examined posterior hyaloid specimen, where only cytoplasmic 
immunofluorescence was detected (Figure 3-24)). Although loss of the nuclear void 
may indicate non-specific fluorescence and imply non-specific staining of cytosolic 
labelling antibodies (Figure 3-22), the detection of GFAP in the nucleus has been 
demonstrated in previous studies (Danielyan et al., 2007) and is consistent with in 
vitro studies demonstrating the interaction of this type III intermediate filament 
protein with DNA (Tolstonog et al., 2000; Traub, 1995). However, with the exception 
of nuclear laminins, intermediate filaments are not generally found in the nucleus; 
the classically anticipated staining pattern for GFAP would be in a cytoplasmic 
filamentous pattern, with a non-staining nuclear void. The current equivocal GFAP 
findings are therefore not entirely explainable and should be interpreted with 
caution. Further investigations would be required to ascertain if laminocyte 
definitively express GFAP, this could be achived by RNA extraction followed by 
reverse transcription quantitative PCR and/or protein extraction followed by Western 
blotting from isolated laminocytes.  
 
Previous extrapolations that suggest laminocytes are of glial origin due to their 
expression of GFAP (Snead et al., 2004, 2002, 2008) may not necessarily be 
supported by observations in the current study. The antibody panel used, which 
recognised retinal astrocyte and Müller glia epitopes demonstrated no positive 
immunofluorescence in laminocytes utilising anti-CRALB, anti-S100B and anti-
vimentin antibodies (Figure 3-33, Figure 3-34 and Figure 3-35 respectively). In 
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addition, although GFAP was originally considered to be a specific marker protein 
for astrocytes and reactive Müller glia (Brenner, 1994; Brenner et al., 1994), there is 
increasing evidence demonstrating the presence of this intermediate filament protein 
in chondrocytes, fibroblasts, hepatic stellate cells, keratinocytes, kidney glomeruli 
mesangial cells and podocytes, lens epithelial cells, Leydig cells of the testis and 
pancreatic stellate cells (Apte et al., 1998; Buniatian et al., 2002; Danielyan et al., 
2007; Hainfellner et al., 2001; Lu et al., 2001; Riccalton-Banks et al., 2003).  
 
Furthermore, laminocytes demonstrated reliable and repeatable positive 
immunofluorescence with anti-CD68 (monocyte/macrophage marker) and anti-MHC 
class II (antigen presenting cell marker) antibodies (Figure 3-28, Figure 3-29 and 
Figure 3-25, Figure 3-26 respectively, in addition to co-staining with GFAP in Figure 
3-30 and Figure 3-27 respectively), but were negative with anti-Iba1 antibody used 
to identify microglia (Figure 3-32).  
 
These observations would suggest that laminocytes may constitute a macrophage 
subpopulation resident in the vitreous. In addition to a compatible dendritic 
morphology delineated by phase contrast microscopy and autofluorescence (Figure 
3-21 and Figure 3-22 respectively), further evidence of a potential macrophage 
lineage is the presence of phagocytic terminal bulbs at the end of laminocyte 
dendritic processes that showed CD68 positive granules in association with 
endocytosed nuclear material (Figure 3-21d). 
 
Hyalocytes are a well characterised vitreal cell population, with reported 
macrophage features. The term hyalocytes refers to the resident cells of the cortical 
or peripheral vitreous (Balazs et al., 1964; Hamburg, 1959; Szirmai and Balazs, 
1958). These cells have been characterised as having lobulated nuclei, multiple 
cytoplasmic projections and moderate numbers of mitochondria and secretory 
granules, in addition to a well-developed Golgi  apparatus (Balazs et al., 1964; 
Hogan, 1971). They are located at an average of 500µm from the inner retinal 
surface and are concentrated in the anterior vitreous and adjacent to the optic disc 
(the posterior distribution pattern around the optic disc being reminiscent of that 
originally used to describe laminocyte distribution (Snead et al., 2002)).  
 
Recent studies (Matsumoto et al., 2007; Noda et al., 2004; Qiao et al., 2005; Zhu et 
al., 1999) have dispelled the notion that hyalocytes are quiescent resting cells; they 
have been demonstrated to actively maintain the transparent and avascular nature 
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of the vitreous. The effects of hyalocytes on the vitreal environment can be broadly 
classified into three main categories (Sakamoto and Ishibashi, 2011): 
 
1. Extracellular matrix synthesis. Hyalocytes have been reported to produce 
vitreal extracellular matrix components, including collagen, hyaluronic acid 
and glycosaminoglycans (Newsome et al., 1976; Nishitsuka et al., 2007; 
Osterlin and Jacobson, 1968; Rittig et al., 1993; Sommer et al., 2008) 
 
2. Modulation of intraocular immunity. In order to retain transparency of the 
visual pathway whilst maintaining microbial defences, the eye has evolved to 
become an immune-privileged site (Stein-Streilein and Streilein, 2002; 
Streilein, 2003). In a similar fashion to which F4/80 (a macrophage marker) 
positive bone marrow-derived antigen presenting cells (present in the ciliary 
body and iris) are able to induce peripheral immunological tolerance  
(anterior chamber-associated immune deviation) (Stein-Streilein, 2008; 
Streilein et al., 1997), vitreous cavity-associated immune deviation has been 
demonstrated to significantly delay antigen-specific delayed-type 
hypersensitivity responses following injection of an intravitreal antigen; the 
only antigen presenting cell candidates were reported to be hyalocytes, 
which were documented to be F4/80 positive (Sonoda et al., 2005). 
 
3. Modulation of intraocular inflammation. The assertion that hyalocytes have 
characteristics shared with macrophages, including phagocytic activity with 
surface receptors for IgG and complement components (Grabner et al., 
1980), has propagated numerous in vitro investigations on cultured 
hyalocytes in an attempt to understand the complex array of cytokines 
produced by these cells and hypothesised to drive common ocular disorders 
like diabetes and age-related macular degeneration (Hata et al., 2008; Noda 
et al., 2004; Tkachuk et al., 2009). 
 
In addition, hyalocytes have also been demonstrated to have a high binding affinity 
to, and a remarkable contractile ability of extracellular collagenous gel matrices 
(Hirayama et al., 2004; Kita et al., 2008; Schaefer et al., 1996). Matrix contraction is 
a pathophysiological feature implicated in various vitreoretinal disorders, such as 
proliferative vitreoretinopathy, diabetic macular oedema and the formation of 
epiretinal membranes and macular holes (Gandorfer et al., 2009; Matsumoto et al., 
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2007; Ueno et al., 2007), and this could be extrapolated to include posterior vitreous 
detachment. 
  
Morphological studies suggest hyalocytes are derived from a monocyte/macrophage 
lineage (Balazs et al., 1964, 1980; Ogawa, 2002; Salu et al., 1985), although a 
paucity of lysosomes has  highlighted  differences with typical macrophages (Hogan, 
1971). However, under physiological conditions, it has been demonstrated that 
hyalocytes originate from bone marrow (Qiao et al., 2005; Sakamoto, 2003; 
Sakamoto and Ishibashi, 2011).  Immunohistochemical studies have demonstrated 
that hyalocytes express the leucocyte associated antigens CD11a, CD 45, CD64 
and MHC class II antigens. However, they have been shown to conspicuously lack 
CD68, an antigen expressed by virtually all tissue macrophages; in addition, 
hyalocytes express S100, but not GFAP, CRALBP or cytokeratin (Grabner et al., 
1980; Jacobson, 1984; Lazarus and Hageman, 1994; Schönfeld, 1996; Zhu et al., 
1999).  
 
Because there are striking morphological similarities with hyalocytes (Figure 3-38), 
in addition to the close proximity in the shared extracellular matrix environment, it is 
tempting to extrapolate that laminocytes are hyalocytes that have been sequestered 
onto the posterior hyaloid membrane or hyalocytes are laminocytes that that lost 
their attachment to the vitreoretinal interface. However, despite similarities, the 
current study has demonstrated fundamental differences between these distinctly 
different cell types, namely the expression of CD68 and GFAP in laminocytes 
(Figure 3-28, Figure 3-29 and Figure 3-23, Figure 3-24 respectively, in addition to 
Figure 3-30 for co-staining), and the lack of expression of CD11 or S100B as 
reported in hyalocytes (Figure 3-31 and Figure 3-34 respectively).  
 
Additional immunophenotyping with antibodies directed against recognised 
mesenchymal (vimentin, Figure 3-35) and epithelial (ezrin and cytokeratin, Figure 
3-36 and Figure 3-37 respectively) tissue epitopes did not demonstrate positive 
immunofluorescence, suggesting laminocytes are unlikely to be of retinal pigment 
epithelium or fibroblast lineage. 
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Figure 3-38 Hyalocytes 
Phase contrast microscopy of two hyalocytes in peripheral vitreous gel 
demonstrating multiple cytoplasmic projections, in addition to conspicuous 
cytoplasmic granules (x50.4).  
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3.5.6 Potential role of laminocytes 
 
The function of GFAP, a highly conserved intermediate filament protein, in cells 
outside the central nervous system not yet been identified. GFAP has been 
demonstrated to be expressed by perivascular cells of many mammalian organ 
systems, in addition to fibroblasts (including lung alveoli fibroblasts) and cutaneous 
keratinocytes. These specific anatomical sites have demonstrated recurrent co-
staining of metallothionein and MHC class II antigens in association with GFAP  
(Buniatian et al., 2002; Danielyan et al., 2007). The intriguing distribution of a 
common set of antigens at the blood-tissue interfaces of internal organs and the air-
tissue interfaces of the integumentary and respiratory systems has developed the 
concept that these proteins are involved in a universal mechanism controlling tissue 
homeostasis and protection. Furthermore, a simultaneous up-regulation of GFAP 
and MHC class II in nude mice, that was barely detectable in immunodeficient mice, 
suggested a possible role in antigen presenting functions (Danielyan et al., 2007). 
 
The findings presented in the current study would suggest that laminocytes are 
extracellular matrix tissue macrophages, found adherent to the vitreal aspect of the 
posterior hyaloid membrane. The observation that laminocytes may express GFAP 
co-staining with MHC class II, in addition to their anatomical location at a tissue 
interface, is intriguing with regards to a universal theory of tissue homeostasis and 
protection at tissue interfaces.  
 
The suggestion that laminocytes may potentially play a role in antigen presentation 
in the vitreous is a novel and important finding with regards to vitreous cavity 
immunity, a concept classically associated with hyalocyte function and their 
suspected role in vitreous cavity-associated immune deviation (Sonoda et al., 2005). 
The observation that laminocytes express MHC II antigens suggests they are 
unlikely to express F4/80. This assertion would suggest an improbable role in ocular 
immune privilege (Stein-Streilein, 2008; Streilein et al., 1997), but rather an 
important role in pathophysiological vitreal inflammation.  
 
The intimate association of laminocytes to the posterior hyaloid membrane 
potentially make them well placed to be involved in the process of posterior vitreous 
detachment. In view of the structural similarities that exist between laminocytes and 
hyalocytes, it is conceivable that evidence demonstrating the ability of hyalocytes to 
contract three-dimensional extracellular collagenous gel matrices (Hirayama et al., 
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2004; Kita et al., 2008; Schaefer et al., 1996) could potentially be extrapolated to 
include laminocytes; if laminocytes did possess such an ability, they would be prime 
contenders in a cellular hypothesis of posterior vitreous detachment. 
 
 
3.5.7 Summary 
 
The current study developed a novel dissection technique to reliably isolate 
posterior hyaloid membranes and reports a modified air-suspension test developed 
to aid in ascertaining the status of posterior vitreous detachment in donor globe 
tissue.  
 
Isolated posterior hyaloid membranes were immunologically interrogated to reveal 
that they are distinct basement membranes, composed of type IV collagen and 
laminin. In addition, investigations suggest the posterior hyaloid membrane 
originates from the internal limiting membrane of the retina. The membranes 
identified and interrogated in this study correlate with posterior hyaloid membranes 
observed clinically in patients presenting with posterior vitreous detachment. 
 
Furthermore, the laminocyte cell population, adherent to the vitreal aspect of the 
posterior hyaloid membrane, was identified and immunologically phenotyped. The 
results suggest that this population of cells is a distinctly unique subset of 
macrophages that possibly express GFAP. Given their integral anatomical 
association with the posterior hyaloid membrane, laminocytes may play a critical 
role in the process of posterior vitreous detachment.  
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4 Conclusion 
 
 
Designing a research study requires judgments regarding methodology, and when 
there are several different options, any chosen decision results in loss of objectivity. 
Furthermore, clinical and laboratory studies, although imperative to advancing 
scientific understanding and knowledge, are limited to current investigative 
technologies and techniques, in addition to subjective interpretation of the outcomes 
and results. 
 
The current studies have been conducted with an acute awareness of these 
limitations and have been carefully designed to address these potential concerns. 
The methodology employed in the retrospective clinical investigations into the 
efficacy and safety of prophylactic cryotherapy has been especially considered, 
addressing previously highlighted issues with regards to control group comparisons 
(Aylward et al., 2008), in addition to being deliberately weighted against the 
effectiveness of treatment. The results confirm that the Cambridge Prophylactic 
Cryotherapy protocol reduces the risk of retinal detachment in type 1 Stickler 
syndrome and should be offered as a prophylactic treatment option to all patients 
with the disorder as the gold standard of practice.  
 
Understanding the fundamental principles of posterior vitreous detachment in order 
to considerately manage and potentially prevent the complications associated with 
the process is a fundamental strategy for the future success in treating the spectrum 
vitreoretinal interface disorders and retinal detachment. Furthermore, the 
advancement of biotechnological techniques and development of new polymers has 
led to the emergence of innovative intravitreal treatments, including intravitreal 
pharmaceutics and implant devices (Herrero-Vanrell et al., 2014; Lambiase et al., 
2014), in addition to novel gene-mediated interventions delivered by viral vectors 
(Boye, 2014; Lipinski et al., 2013; Rowe-Rendleman et al., 2014) and potential stem 
cell therapies (Uy et al., 2013; Johnson and Martin, 2013; Li et al., 2012; Huang et 
al., 2011). These treatments utilise the immune-privileged character of the vitreous 
cavity as a therapeutic platform; however, a more detailed knowledge of the vitreous 
environment is required in order to understand and predict potential outcomes of 
these and future therapies. 
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6 Appendix 
 
 
6.1 Positive controls 
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Figure 6-1 Positive control: rabbit polyclonal anti-collagen IV antibody 
Confocal micrographs demonstrating: (a) renal glomerular and collecting tubule 
basement membrane (x12), (b) renal collecting tubule basement membrane (x63), 
(c)  internal limiting membrane and intraretinal blood vessel basement membrane 
(x5), (d) intraocular crystalline lens capsule with phase contrast overlay (note ciliary 
body epithelial autofluorescence) (x5). 
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Figure 6-2 Positive control: rabbit polyclonal anti-laminin antibody 
Confocal micrographs demonstrating: (a) renal glomerular and collecting tubule 
basement membrane (x10), (b) renal collecting tubule basement membrane (x31.5), 
(c) internal limiting membrane and intraretinal blood vessel basement membrane 
(x10), (d) internal limiting membrane extending over optic nerve head with retinal 
arcade blood vessel basement membrane (x5). 
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Figure 6-3 Positive control: mouse monoclonal anti-fibronectin antibody 
Confocal micrographs demonstrating: (a) renal glomerular and collecting tubule 
basement membrane (x5), (b) renal collecting tubule basement membrane (x31.5), 
(c) internal limiting membrane and intraretinal blood vessel basement membrane 
(x10), (d) internal limiting membrane (x126). 
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Figure 6-4 Positive control: rabbit monoclonal anti-opticin antibody 
Confocal micrographs demonstrating: (a) hyaline cartilage (x94.5), (b) vitreous gel 
(x31.5), (c) interface between vitreous gel and internal limiting membrane (x15), (d) 
choroidal vasculature (x15). 
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Figure 6-5 Positive control: CRALBP 
Confocal micrographs demonstrating: (a) retinal Müller glia (x10), (b) Müller glia foot 
plates fusing to form internal limiting membrane (x31.5), (c) composite image with 
inner and outer nuclear layer present (left half) and removed (right half) to illustrate 
relationship to Müller glial (x18).  
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Figure 6-6 Positive control: S100B 
Confocal micrographs demonstrating: (a) retinal nerve fibre layer (x20), (b) retinal 
astrocytes (x31.5), (c) optic nerve (x31.5), (d) epidermis (x31.5). 
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Figure 6-7 Positive control: vimentin 
Confocal micrographs demonstrating: (a) retinal astrocytes and their orientation 
towards the internal limiting membrane (x10), (b) maximum image projection of 
retinal astrocytes spanning the inner and outer plexiform layers of the retina (x52), 
(c) and (d) optic nerve fibres (x10, x126 respectively). 
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Figure 6-8 Positive control: mouse monoclonal anti-MHC Class II antibody 
Confocal micrographs demonstrating: (a) and (b) tonsil macrophages (x10, x20 
respectively), (c) and (d) dermal macrophages (x31.5, x189 respectively). 
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Figure 6-9 Positive control: CD68 
Confocal micrographs demonstrating: (a) tonsil macrophages (x100), (b) tonsil 
interdigitating cell (x120), (c) and (d) dermal macrophages represented with and 
without phase contrast overlay respectively (x5). 
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Figure 6-10 Positive control: CD11 
Confocal micrographs demonstrating: (a), (b) and (c) tonsil macrophages (x5, x31.5, 
x100.8 respectively), (d) dermal macrophages (x63). 
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Figure 6-11 Positive control: Iba1 
Confocal micrographs demonstrating: (a) and (b) frontal lobe cortex microglia (x63, 
x189 respectively), (c) and (d) optic nerve microglia (x163.8, x245.7). 
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Figure 6-12 Positive control: GFAP (rabbit polyclonal) 
Confocal micrographs demonstrating: (a) retina (x20), (b) optic nerve (x20), (c) and 
(d) frontal lobe cortex (x20, x63 respectively). 
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Figure 6-13 Positive control: ezrin 
Confocal micrograph demonstrating: (a) and (b) retinal pigment epithelium with and 
without DAPI nuclear staining respectively (note nuclear void in (b) demonstrating 
stain specificity) (x63), (c) and (d) epidermis with and without DAPI nuclear staining 
respectively (note nuclear void in (d) demonstrating stain specificity) (x107.1). 
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Figure 6-14 Positive control: cytokeratin 
Confocal micrograph demonstrating: (a) and (b) retinal pigment epithelium with and 
without DAPI nuclear staining respectively (note nuclear void in (b) demonstrating 
stain specificity) (x37), (c) and (d) epidermis with and without DAPI nuclear staining 
respectively (note nuclear void in (d) demonstrating stain specificity) (x31.5). 
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6.2 Negative controls 
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Figure 6-15 Negative control: posterior hyaloid membrane 
Posterior hyaloid membrane confocal micrographs demonstrating: (a) and (b) 
donkey anti-mouse antibody conjugated to Alexa Fluor® 488, with and without 
phase contrast overlay respectively (x10), (c) and (d) donkey anti-rabbit antibody 
conjugated to Alexa Fluor® 568, with and without phase contrast overlay 
respectively (x10). 
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Figure 6-16 Negative control: retinal flat mount 
Retinal flat mount confocal micrographs demonstrating: (a) and (b) donkey anti-
rabbit antibody conjugated to Alexa Fluor® 568, with and without phase contrast 
overlay respectively (x5). 
Note: retinal microvascular detail lost on phase contrast imaging due to density of 
multi-layered retina. 
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Figure 6-17 Negative control: laminocyte 
 
 
 
Please turn over for figure legend  
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Figure 6-17 Negative control: laminocyte 
Laminocyte confocal micrographs demonstrating: (a) and (b) donkey anti-mouse 
antibody conjugated to Alexa Fluor® 488, with and without phase contrast overlay 
respectively (x126), (c) and (d) donkey anti-rabbit antibody conjugated to Alexa 
Fluor® 568, with and without phase contrast overlay respectively (x126), (e) and (f) 
donkey anti-goat antibody conjugated to Alexa Fluor® 647, with and without phase 
contrast overlay respectively (x126). 
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7 Prizes 
 
 
Prizes awarded for the presentation of: 
 
‘The prevention of retinal detachment in type 1 Stickler syndrome: the 
Cambridge Prophylactic Cryotherapy protocol.’ 
 
 The Oxford Ophthalmological Congress: Ian Fraser Cup winner (July 2013) 
 Royal Society of Medicine, Ophthalmology section: Dermot Pierse Prize 
winner (June 2013) 
 The East of England Deanery specialist registrar meeting: John Cairns 
Memorial Prize (December 2012) 
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